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LAY OVERVIEW 
Sleep disorders occur in 90% of people with depression. In the first chapter of this thesis I 
have reviewed the scientific literature and given a detailed background to the subject of 
sleep in depression and insomnia. 
In the second chapter I wanted to see if one of two types of antidepressants were less 
disruptive to sleep particularly in the first 3 days of treatment when distress about sleep 
may lead to an increaesd risk of suicide. A drug known as nefazodone was shown to be 
less disruptive to objective sleep (measured by overnight sleep EEG, ) than one called 
paroxetine when they were directly compared in this study. 
In the third chapter I investigated the use of nefazodone in people with a history of long- 
term insomnia to see if it could also improve sleep in this group of people even though 
they did not have depression. The numbers were small but compared to placebo there was 
no improvement in sleep objectively or subjectively. 
Psychological therapies, usually based on a cognitive behavioural model, have an 
important role in the treatment of depression and insomnia. Chapter 4 reports the results 
of a cognitive behavioural insomnia goup therapy programme set up to help people with 
insomnia whatever the initial cause. Results showed that although sleep times did not 
improve significantly patients had an improved quality of life having attended the group. 
In particular, participants' quality of life was improved in the domains of mental health, 
energy and vitality and improved perception of their general health. 
ABSTRACT 
This thesis explores the pharmacological and psychological treatment of both primary 
insomnia and insomnia secondary to depression. 
The first study, in a double blind placebo controlled trial, compares the effects of two 
anti-depressants, nefazodone and paroxetine, on the sleep of patients with moderate to 
severe depression. The second study described is a cross over trial that investigates 
whether nefazodone compared to placebo has beneficial effects on sleep in patients with 
primary insomnia. The final chapter explores the treatment of primary insomnia or 
secondary insomnia (e. g. insomnia secondary to depression) using a cognitive behaviour 
therapy group approach. 
In the first study, nefazodone was found, compared to paroxetine, to increase sleep 
efficiency, total sleep time and decrease number of awakenings as measured objectively 
by polysomnography. These effects were evident early in treatment, by day 3. 
In the second study nefazodone was not found, compared to placebo, to increase sleep 
efficiency, total sleep time or decrease number of awakenings in patients with primary 
insomnia. 
In the third study, patients with primary insomnia did report improvements in 
dysfunctional attitudes and beliefs about insomnia and improvements in energy/vitality 
and mental health, as measured by the SF36 quality of life scale, after attending group 
cognitive behavioural therapy (CBT). Sleep parameters were not significantly improved 
when compared pre and post CBT. 
The findings described in this thesis have led to further work to test the efficacy of 
trazodone (nefazodone's sister drug) in a placebo controlled trial for primary insomnia 
and the continued running of the CBT insomnia group with a view to supporting patients 
with chronic insomnia. 
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Chapter 1. 
Background to Sleep in Depression and Insomnia 
1.1 Introduction 
"From nearly all social history and biography, one third of the story is missing a gap 
of about eight hours in every day, hours which need by no means be uneventful or 
without significance. " 
"History of the Bed" Wright 
19621 
There has been much published on the biological and psychological aspects of sleep, 
but it is only recently that sleep has been looked at in a sociological framework. 
Williams and Bendelow2 argue that sleep entitles people to expect certain rights. 
These include: freedom from noise and interference from others, except in 
emergencies; exemption from normal role obligations; and retention of the status and 
authority associated with daytime roles. They also contend that sleep is socially 
patterned, reflecting the social roles, responsibilities and gender relationships inherent 
in our daily lives. 
In 2003 Hislop and Arber 34 carried out the first study of mid life women aged 40-59, 
to address the sleep pattern of women within their social context. At mid life women 
often have multiple roles. They may be the mothers of young children and/or teenage 
or adult children, with each phase of motherhood with its unique demands and 
responsibilities impacting on women's sleep. As well as experiencing the 
physiological symptoms of the menopause, midlife women may be re-entering the 
workforce on a full time basis after parenting, and holding responsible positions with 
increased stress and pressure. They may be supporting partners through periods of 
work place change, redundancy and early retirement, or suffering the effects of 
broken relationships. As daughters of ageing parents they may have increased caring 
responsibilities and the stresses of bereavement. 
Hislop and Arber collected qualitative data from focus groups and audio sleep 
diaries. 3 
Results showed that in sleep, women are first and foremost partners and/or mothers 
and the performance of physical and emotional labour required by these roles often 
curtails their right to a good night's sleep. They see disturbed sleep as a "women's 
lot" but they appear to accept that their partners and children will act as gatekeepers at 
times blocking their access to sleep. Instead of seeing themselves as victims they seek 
pragmatic solutions within the constraints of their social context which balance the 
demands of their responsibilities within the household with their need for sleep. 
Currently there are studies being carried out to address the sociology of men's sleep 
particularly in the context of measuring how couples sleep. 
1.2 Normal sleep 
Sleep is comprised of two distinct physiological states. These are rapid eye movement 
(REM) sleep and non rapid eye movement (non REM) sleep. Rechtshaffen and Kales 
2 
(1968) with the American Government Health Office published a manual produced by 
a committee of experienced health researchers to `stage' human sleep. They are 
known universally as the "Rechtshaffen and Kales criteria", standardise sleep scoring 
and are used worldwide by most sleep researchers .5 There are however limitations of 
the criteria, as they were defined for normal subjects who are not taking medication, 
and so are more difficult to apply to patients with sleep disturbance such as in 
depression and due to psychotrophic medication. For example, depressed patients 
have less well defined sleep spindles and less obvious sleep stages (see below). 
Non REM sleep is made up of four stages: Stage 1 is a light drowsy phase during 
which there is a transition from wakefulness to sleep. The normal rhythms of the 
waking electroencephalogram (EEG), alpha (8-13) Hz and mixed fast activity (14-30) 
Hz are replaced by theta activity (4-7) Hz. Slow rolling lateral eye movements can 
also be picked up on the electro-oculogram (EOG). Stage 2 is the first unequivocal 
stage of sleep with the appearance of sleep spindles (widespread runs of 12 -14 Hz 
activity) and K complexes (large biphasic slow transients) in the EEG and normally 
eye movements are absent. Stages 3 and 4 are known collectively as Slow Wave 
Sleep (SWS) characterized by synchronised delta or slow activity (0-4Hz). If the 
activity is below 2Hz, of an amplitude greater than 75 microvolts and occupies 20%- 
30% of the epoch (conventionally a 30 seconds time period) then it is deemed to be 
stage 3 sleep. If this activity occupies 50% of the epoch it is stage 4 sleep. 
REM sleep has an EEG pattern of low amplitude and mixed frequencies similar to 
waking or stage I sleep with occasional sharp transients interspersed. There is 
3 
complete lack of muscle tone but occasional phasic muscle twitches. It is also 
characterised by frequent jerky conjugate eye movements, which can be lateral or 
vertical (Figure 1.1). 
(d) Stage 3 sleep 
(fl REM, or "paradoxical" sleep 
Figure 1.1: Tracings depicting the different stages of sleep. Top line in each 
trace represents scalp EEG electrode and the bottom line 
represents eye movement. 
As people fall asleep they progress through the non-REM stages. Stage I is the stage 
of drowsiness and together with waking is a measure of poor sleep continuity. People 
who wake when they are asleep usually deny being asleep if it is from stage 1.6 Stage 
2 is light sleep from which it is fairly easy to wake subjects. Myoclonic jerks and 
4 
(e) Stage 4 sleep 
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`falling' arousals occur in this stage and about 50% is spent in this stage. In SWS 
stage 3 and 4 people are pale and still with a slow regular heart rate and breathing. If 
someone is woken from slow wave sleep the person will feel groggy and confused. 
About 90 minutes later than the onset of stage 1 sleep the first episode of REM sleep 
will occur. There is cycling of non-REM and REM sleep through the night and as the 
night progresses the episodes of non-REM become shorter and those of REM become 
longer. Most SWS therefore occurs during the first third of the night and most REM 
in the last third. Each episode of non-REM/REM sleep is called a sleep cycle and a 
hypnogram can be plotted to show the progression of these stages through time 
(Figure 1.2). 
The structure of sleep, i. e. the amount of stages of sleep and timing of them is known 
as "sleep architecture". The sleep architecture of a person's sleep varies from subject 
to subject and night to night. It also varies with age when there is less SWS and 
poorer sleep continuity. There are also variations in sleep architecture that are related 
to disease processes e. g. narcolepsy, Parkinson's Disease, sleep apnoea and 
psychiatric problems e. g. depression and the taking of medication. 7 There are also 





x stage 1 wa 
stage 2 OCF 0) 




Hours of sleep 
Figure 1.2: Hypnogram showing the progression of sleep stages 
through time, with cycles of REM and non-REM sleep. The 
duration of each cycle is approximately one and a half 
hours. Slow wave sleep dominates the early part of sleep 
whereas REM sleep is more predominant in the latter 
stages of the night. 
1.3 Introduction to neurotransmission 
In order to understand what is known at a molecular level about sleep, and the effect 
of drugs on sleep, a basic understanding of the psychopharmacology of 
neurotransmission is important. There are many neurotransmitters in the brain but 
some of the most important are 5-hydroxytryptamine (5HT) or serotonin, 




Neurones send electrical impulses from one part of the cell to another part via their 
axons but neurones communicate with each other at synapses by chemical 
neurotransmission via neurotransmitters. Synapses are specialised sites that connect 
two neurones. 
Neurones are organised so they can send synaptic information by a long axon 
branching into terminal fibres ready to make synaptic contact with other neurones. A 
neurone can also receive synaptic information on its dendrites, cell body and axon 
(Figure 1.3). 
An electrical impulse in the first neuron is converted to a chemical signal at the 
synapse by a process known as excitation-secretion coupling. Once an electrical 
impulse invades the presynaptic axon terminal in the first neuron it causes release of 
the chemical neurotransmitter stored there. This release of neurotransmitter, the first 
messenger, shoots across the synapse and hits target sites on the postsynaptic receptor 
very selective for that neurotransmitter. This opens a process that converts the 
chemical message back to an electrical impulse in the second nerve, or starts other 
biochemical processes within the post synaptic neuron, (via second messengers. ) 
Changes in the rate of receptor synthesis can powerfully modify chemical 
neurotransmission at the synapse. When fewer neurotransmitter receptors are formed 
"down regulation" occurs and when more neurotransmitter receptors are formed "up 
regulation" occurs. 
7 
Figure 1.3: This figure shows how a neuron is organised to receive synaptic 
information. Pre-synaptic input from other neurons can be 
received post-synaptically at many sites, but especially from 
dendrites, often at specialised structures called dendritic spines. 
Other post-synaptic neuronal sites for receiving pre-synaptic input 
from other neurons include the cell body and axon. 
8 
Enzymes involved in neurotransmission can be inhibited by some drugs. This can be 
reversible or irreversible. If it is irreversible enzyme activity cannot be restored unless 
another molecule of enzyme is synthesised by the cell. 
Naturally occurring neurotransmitters stimulate receptors. These are called agonists. 
Some drugs do stimulate receptors just like the natural neurotransmitter and are also 
therefore agonists. Other drugs actually block the actions of the natural 
neurotransmitter at its receptor and are therefore called antagonists. Antagonists only 
exert their actions in the presence of agonists but have no activity of their own in the 
absence of agonists. Other drugs do the opposite of agonists and are called inverse 
agonists. Partial agonists and partial inverse agonists also occur. There is therefore a 
spectrum for drugs acting at a receptor (Figure 1.4). 
Figure 1.4: The Agonist Spectrum 
Agonist Partial Agonist Antagonist Partial Inverse Agonist Inverse Agonist 
In the central nervous system neurones exist specifically for the neurotransmitters 5- 
hydroxytryptamine (5HT), Noradrenaline (NA), Dopamine (DA), Acetylcholine 
(ACh). In the brain NA and 5HT neurones are located in brain stem structures such as 
the raphe nucleus and the locus coeruleus with projections to the frontal cortex. 
There are however also many different receptor subtypes for each of these 
neurotransmitters. The main subtypes are summarised in Table 1.1. 
9 
Transmitter Pre synaptic Post synaptic 
NA alpha2 blocked by alphal 
mianserin, mirtazepine alpha2 
betat 
beta2 
DA DA 1, DA2..... 
5HT 5HT1A, blocked by 5HTIA, 5HTID, 
nefazodone and 5HT2A blocked by 
trazodone 5HT1B nefazodone, trazodone, 







Table 1.1: Subtypes of neurotransmitter receptors in the brain 
1.4 Function of sleep 
The precise function of human sleep is unknown however there have been a number 
of theories proposed. Conservation of energy, and a period of recuperation or 
restoration theories have been postulated! The theories overlap. 
Slow Wave Sleep 
(i) "Conservation of energy theory" 
SWS is probably involved in a homeostatic process. Most people's general activities 
increase during the day compared with the night. The concept of homeostasis may be 
extended to explain that energy that is expended during the day must be balanced by a 
recuperative period. This forms the foundation of one of the theories of the function 
of sleep, that of conservation of energy. Oxygen consumption, heart rate and body 
temperature decline during the first few hours of sleep. Energy expenditure can be 
10 
measured by metabolic rate which is raised by the day and reduced during the night, 
particularly in SWS, by 5-25%. 8 The level of SWS is highest in young individuals 
who are most active. 
(ii) "Restoration of energy theory" 
Sleep is postulated to be a process by which the whole body, including the central 
nervous system can be restored. SWS is linked to anabolic processes. Paradoxically 
anabolism therefore occurs during a period of relatively low oxygen consumption and 
lowered metabolic rate. Growth hormone is released at night particularly in SWS. 9 
When the need for growth is great both the duration of slow wave sleep and the 
overall amount of sleep is increased supporting the restorative function of SWS. Table 
1.2 summarises some of the evidence for the restorative function of SWS. 
Two processes interact in normal sleep. 1° The sleep homeostat "drives" the sleep- 
wake schedule toward a balanced requirement because prolonged wakefulness 
accrues sleep debt and sleep pays off the debt and the circadian timer regulates the 
biological clock in approximation to the 24hr clock. This is hypothesised to be via 
"Process S" which is a substance that accumulates in the brain during the day and 
declines exponentially with sleep and the circadian influence "Process C". 
Also the cycling of non-REM and REM sleep may be fundamental to the restoration 
accomplished during sleep. Each sleep cycle results in partial restoration and after a 
number of cycles recuperation is complete which reduces the need for SWS or "core 
sleep. " This may explain why the duration of SWS reduces during the course of a 
night's sleep as "optional sleep" governed by circadian factors continues. 
11 
At a molecular level in the brain, postsynaptic receptors of the 5HT2 type are thought 
to be involved in the control of SWS. A selective 5HT2A antagonist, ritanserin was 
found to increase SWS in healthy volunteers' 1 and mCPP, an agonist with its highest 
affinity at 5HT2C receptors, decreases it. 12 Sharpley (1994) 13 used ketanserin a 
5HT2A antagonist, with a lower affinity for 5HT2C receptors than ritanserin and 
found ketanserin was much less effective than ritanserin in increasing SWS. They 
suggest that 5HT2C receptors may therefore be more strongly implicated in the 
regulation of SWS than 5HT2A receptors. 
Rapid Eye Movement sleep 
It has been suggested that during REM sleep neuronal connections in the 
catecholamine system are formed and that this activity is necessary to maintain 
cognitive function. Decreasing acetylcholine function generally decreases REM sleep. 
At a molecular level there is evidence that the neurons which initiate the onset of 
REM sleep in the final pathway are actually cholinergic i. e. release ACh but they are 
influenced by noradrenergic neurones. 14-17 The cholinergic neurones appear to initiate 
downward inhibitory impulses that cause atonia during REM sleep and the upward 
processes that stimulate cortical arousal and the phasic events of REM. 
The disruption of sleep e. g. by the many causes of insomnia will therefore interrupt 
the restorative function of sleep and effect the quality of sleep. This may be as 
important as disruption in sleep continuity. 
12 
Raised metabolic activity associated with 
increased TST and SWS: 
Decreased metabolic activity associated with 
decreased SWS 
Pregnancy Blind Patients 




Refeeding of patients with anorexia 
During the mounting of an immune response 
Increased levels of cell division and protein 
synthesis 
Brain restoration as opposed to body restoration 
Table 1.2: Metabolic activity and Slow Wave Sleep 
1.5 Sleep Circuitry 
Sleep wake behaviour is sub-served by a number of brain regions, cell types and 
extracellular messengers making up an elaborate circuit within the brain. The 
ascending reticular activating system (ARAS) which originates in the rostral pontine 
reticular formation and passes through the midbrain reticular formation to the 
thalamus was identified in the 1950's, and associated with arousal. 18 
Different cholinergic and monoaminergic brainstem neurones with projections to the 
cerebral cortex and elsewhere in the brain were identified during the 1970's and 80's 
and as above, cholinergic neurones were associated with REM sleep and 
monoaminergic neurones exhibited their highest activity in NREM sleep and waking 
(Table 1.3). 
13 







Locus coeruleus LC noradrenergic 
ventral periaqueductal grey (vPAG), dopaminergic 
tubermamillary nucleus neurons (TMN) histaminegic and GABA 
(Projections ascend to the thalamus, cerebral cortex, lateral hypothalamus and basal 
forebrain. ) 
Table 1.3 The main brain-stem neurones and their neurotransmitters 
Most recently, attention has focused again on the hypothalamus and the ventrolateral 
pre-optic nucleus (VLPO) being proposed as a "sleep centre" and the 
hypocretin/orexin cells of the perifornical area and their projections being a "waking 
centre. " The data from these and other regions associated with the sleep wake cycle 
have led to the "flip-flop switch model of sleep-wake control" in which two sets of 
mutually inhibitory neurons make sharp state transitions and hence may explain the 
suddenness of falling asleep or waking up. 15 The sleep side is thought to be the VLPO 
and the arousal side includes the tubermamillary nucleus, histaminegic neurons 
(TMN), dorsal raphe (DRN) serotonergic neurons, ventral periaqueductal grey 
(vPAG), dopaminergic neurons and locus coeruleus (LC) noradrenergic neurones. 
The VLPO does not have orexin receptors so they are not part of the switch but loss 
of the orexin neurones weakens the arousal side of the switch because they have an 
excitatory effect on the neurons above. 
14 
The ARAS is now proposed to be involved in the maintenance of consciousness 
whereas the VPLO that runs in parallel with the ARAS controls sleep. 
Some hypnotic drugs may exert their effects in a regionally specific manner e. g. 
gaboxadol, a GABA receptor agonist, through activation of the VLPO. This may lead 
to the development of further hypnotic drugs, which exert their effects via the VLPO. 
1.6 Sleep in depression 
Sleep abnormalities in depression are well established. Insomnia is the most common 
complaint although hypersomnia is the dominant sleep abnormality in approximately 
30% of depressed patients. " Insomnia in depression is reported clinically as sleep 
initiation and continuity difficulties. These include difficulties falling to sleep, known 
as prolonged sleep onset latency (SOL), intermittent wakefulness during the night, 
and early morning waking (EMW), typically at 3-4am. Table 1.4 and Figure 1.5 show 
sleep architecture changes in a depressed patient and a hypnogram of a depressed 
patient. 
Over 90% of patients with major depression have sleep complaints. 19 Persistent sleep 
disturbance is related to a significant risk of relapse and recurrence of depression and 
risk of suicide. 20 
REM sleep abnormalities, rather than SWS changes, are the more robust findings in 
depression with the time taken to enter the first REM period (REM onset latency) 
being shortened as the most consistent finding although REM density is also increased 
compared to controls in some depressed patients. 21 REM onset latency increases with 
age and severity of the depression and is particularly shortened in endogenous 
depression. 
15 
Non REM sleep 
Decreased SWS 
Decreased SWS in Non REM-I versus Non REM-2 
Increased Stage I sleep 
REM sleep 
Reduced REM latency 
Increased REM during the first half of the night 
Increased REM density 
Table 1.4: Polysomnogram (PSG) abnormalities in depression showing 










Figure 1.5: Hypnogram of a depressed patient 
16 
Depressed patient 
The persistence of a depression-like sleep pattern in fully remitted depressed patients 
suggests that as well as being a "state marker, " REM abnormalities are also a "trait 
marker. " The EEG sleep patterns of subjects without a personal history but with a 
strong family history of depression differed from those of controls showing a 
depression like pattern with less SWS and increased REM density. 23 Reynolds and 
Kupfer (1987)22 postulate that redistribution of REM time to later portions of the 
sleep period combined with relatively high REM activity may explain patient reports 
of increased dreaming and nightmares while receiving antidepressants. 
1.7 Psychopharmacology of depression and possible mechanism of action of 
antidepressants. 
The first major theory, now over 30 years ago about the biological aetiology of 
depression hypothesized that depression was due to a deficiency of monoamine 
neurotransmitters noradrenaline (NA), 5Hydroxytryptamine (5HT) and /or dopamine 
in the brain. 24 25 The known antidepressants at this time tricyclic antidepressants 
(TCA'S) and monoamineoxidase inhibitors (MAOI's) both had pharmacological 
actions that boosted these neurotransmitters. MAOI'S, inhibit the enzyme MAO, 
TCA's and 5HT inhibitors block monoamine reuptake transporter pumps and 
therefore increase the amount of neurotransmitter in the synapse. 
However the monoamine hypothesis cannot explain why the timing of antidepressant 
effects on neurotransmitters is different from the timing of antidepressant effects on 
mood. Antidepressants boost monoamine immediately although their antidepressant 
17 
effect takes 2-3 weeks to appear. It is now thought that changes in neurotransmitter 
receptor sensitivity are necessary to mediate the clinical response and the time for the 
neurotransmitter receptor to down regulate and desensitize therefore delays the 
therapeutic effect. Figures 1.6-1.11 illustrate the monoamine hypothesis of depression 
with up regulation and down regulation. 
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NT = neurotransmitter A 
W =receptor 
Figure 1.6: Different time courses for three effects of antidepressant drugs, 
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Figure 1.7: Normal Functioning 
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Figure 1.8: Decrease in neurotransmitter in a depressive illness leads to up 
-regulation of post-synaptic receptors. 
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Figure 1.9: Anti-depressant (e. g. an SSRI) blocks re-uptake pump so that there is 
more neuro-transmitter in the synapse. 
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Figure 1.10: Down-regulation of receptors due to increased amount of neuro- 
transmitter in the synapse 
20 
Also important is the negative feedback by synaptic concentration of neurotransmitter 
on presynaptic autoreceptors on the cell terminal and cell dendrites. In the 5HT 
neurone the autoreceptor on the somatodendrites of the cell body is the 5HT 1A 
receptor so called "somatodendritic" receptors, and the axon terminal autoreceptor is 
the 5HTID receptor called terminal "autoreceptors. " In the NA neurone the alpha2 
adrenoreceptor is the autoreceptor and they are present as both somatodendritic and 
terminal receptors. 
There are three ways to inhibit a serotonin neuron (Figure 1.11) 
Figure 1.11: Methods of inhibition of serotonergic neuron 
1) By stimulating 5HT 1A autoreceptors 
2) By stimulating 5 HT 1D autoreceptors 
3) By stimulating alpha 2 receptors (since a different transmitter noradrenaline is 
regulating serotonin, the alpha 2 receptor is known as a heteroreceptor. ) 
21 
5HTIA receptor a2 receptor 
If this feedback mechanism is decreased by a drug that antagonises the autoreceptor, 
or the autoreceptor is down regulated, (also called disinhibition of the serotonin 
neuron) there is more neurotransmitter e. g. serotonin available and thus therapeutic 
effects in depression. 
There is however a delay in how soon the increased somatodendritic 5HT (e. g. in the 
cell body area of the midbrain raphe due to blockade of the 5HT reuptake pump by a 
SSRI, ) can down regulate the somatodendritic autoreceptors in order for the neuron to 
increase 511T in axon terminals and to increase its neuronal impulses. The delay in 
5HT arriving at the axon terminals may account not only for the delay in down 
regulation of postsynaptic 5HT2 receptors but also a delay in the therapeutic 
consequences of SSRI'S26 Therefore the presynaptic 5HT1A receptor contributes in a 
major way to the overall therapeutic profile of the SSRI's. Figure 1.12 shows some of 
the key serotonin pathways in the central nervous system. 
5HT2 
A very important postsynaptic regulatory receptor is the 5HT2 receptor. However 
5HT2 receptor stimulation as well as playing a role in some of the therapeutic effects 
of SSRI's, can mediate several of the side effects of SSRI'S (Table 1.5. ) Also 
stimulation of the 5HT3 receptor appears to be responsible for some of the 
gastrointestinal side effects of the SSRI's. These effects are mediated in the CNS and 
gut. 
22 
Type of receptor Receptors stimulation effects 




5HT1A postynaptic Decrease Temperature 
5HT1D presynaptic Anti migraine 
5HT2A postsynaptic Antidepressant 
Increase Anxiety 
Increase Temperature 






5HT3 postsynaptic Nausea 
Decrease Appetite 
Increased Gastrointestinal activity 








Figure 1.12: Key serotonin pathways in the CNS. 
When the serotonin neurone is disinhibited it turns on serotonin release in several 
pathways simultaneously. The areas in the brain in which some therapeutic effects are 
thought to be mediated are as follows: 
Pathway 1: Depression: disinhibition of the pathway from midbrain raphe to 
frontal cortex. 
Pathway 2: OCD: disinhibition of the pathway from midbrain raphe to basal 
Pathway 3: Panic Disorder: disinhibition of the pathway midbrain raphe to limbic 
cortex and hippocampus. 
Pathway 4: Bulimia: disinhibition of the pathway midbrain raphe to hypothalamus. 
Pathway 5: From midbrain raphe descending down the spinal cord. 
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A summary of antidepressant blockade and receptor effects with measured uptake 
blockade is shown in Table 1.6. 
Explanation of some of the more common side effects of antidepressants by their 
receptor action 
Side effects of TCAs include orthostatic hypotension, dizziness, dry mouth, blurred 
vision, urinary retention, constipation and weight gain. These are due to their other 
receptor actions (Table 1.6). 
Serotonin specific reuptake inhibitors (SSRIs) are safer in overdose than the TCAs. 
They do, however, cause agitation, akathisia and sexual dysfunction. 
Trazodone and nefazodone are also known as the SARIs (serotonin antagonist and 
reuptake blockers). They block 5HT reuptake weakly but powerfully block the 
postsynaptic 5HT2 receptor. Trazodone, also a 5HT2 antagonist, blocks histamine 
receptors powerfully and is therefore sedating. Trazodone administration together 
with an SSRI can be useful to mitigate the sleep disruptive effects of the SSRls. 
Trazodone also blocks cholinergic receptors. A rare side effect is priapism due to its 
alpha antagonist blocking properties. Nefazodone is a less sedating as it is less 
histaminergic than trazodone but it also weakly blocks noradrenaline uptake which 
may offset its alpha-one adrenergic blocking properties therefore accounting for less 
association with orthostatic hypotension and priapism. 
25 
The stimulation of 5HT receptors by SSRIs may treat depression but the stimulation 
of 5HT receptors elsewhere in the body may cause side effects e. g. 5HT in the 
forebrain can cause agitation and excitement and in the spinal cord lead to sexual 
dysfunction. However the SARIs e. g. nefazodone and trazodone, which combine 5HT 
reuptake blockade with stronger 5HT2 antagonism use both these actions to 
contribute to their therapeutic effect and reduce the undesired actions of 5HT. 
Clinically important consequences of blocking 5HT2 receptors are: decreased anxiety, 
enhanced SWS, less sexual dysfunction and sedation. 
Nefazodone does not usually produce the unwanted side effects of SSRIs, but some 
may occur due to excessive blocking of 5HT2 receptors. For example, over-sedation, 
palinopsia (visual streaking) and asthenia can occur. Other side effects of nefazodone 
are due to the metabolite mCPP, which is a 5HT2A/2C agonist. 4% of Caucasians 
lack the enzyme cytochrome P450 2D6 which is also inhibited by SSRIs. If 2D6 is 
absent or inhibited lots of mCPP can form leading to stimulation rather than blockade 
of 5HT2A/2C receptors causing dizziness, light headedness, insomnia, agitation and 
nausea. i. e. opposite effects to the parent compound nefazodone itself. Nefazadone 
also inhibits cytochrome P450 enzyme 3A3,4 and care should be taken if it is 
prescribed with potentially toxic substrates of 3A3,4 e. g. terfenadine. However, as 
will be discussed later, nefazodone can be a useful hypnotic antidepressant. 
Figures 1.13 to 1.18 depict the major classes of antidepressant. 
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Ant idepressant Uptak e block ade (Ki) Recepto r effects 
NA 5HT DA ACh Hi al a2 5HTJA 5HT 2 








SNRI venlafaxine ++ +++ 
NARI reboxetine ++ + 
TCAs clomipramine ++    




amitriptyline ++ +++     
dothiepin ++ +++    
lofepramine +++ ++   
trimipramine +    
Other mianserin ++     
NaSSA mirtazapine    
SARI trazodone +     
SARI nefazodone + + +    
NDRI bupropion + + 
KEY: ACh= acetylcholine, DA=dopamine, NA= noradrenaline, NARI= noradrenaline reuptake 
inhibitor, SER=serotonin, SNRI= selective noradrenaline reuptake inhibitor, 
SSRI=selective serotonin reuputake inhibitor, 
TCA=tricyclic anitdepressant 
NaSSA= Noradrenergic and Specific Serotonergic Antidepressant 
SARI = Serotonin Antagonist and reuptake inhibitor 
NDRI= Noradrenaline and Dopamine reuptake inhibitor 
Ki represents transporter binding affinity; = Ki < 100 nmol/L, + indicates 100-1000 nmol/L, ++ 
indicates 10-100 nmoUL, +++ indicates I-10 nmol/L, ++++ indicates <1 nmol/L 





Figure 1.13: A diagram of a tricyclic antidepressant. TCAs have 5 main 
actions: (i) serotonin re-uptake inhibition (SRI); (ii) noradrenaline 
re-uptake inhibition (NRI); (iii) anticholinergic-antimuscarinic 
action (M1); (iv) alpha-1 adrenergic antagonism (al); and (v) anti- 
histaminergic action (H1). 
Figure 1.14: A diagram of a selective serotonin re-uptake inhibitor. Four of the 
five main pharmacological actions of TCAs have been removed 
and only serotonin reuptake inhibition remains (SRI) - hence the 






Figure 1.15: A diagram of a dual re-uptake inhibitor (e. g. venlafaxine) which 
combines the actions of both a serotonin re-uptake inhibitor (SRI) 
and a noradrenaline re-uptake inhibitor (NRI). At high doses there 
is also some moderate dopamine re-uptake blockade (DRI). 
Figure 1.16: A diagram of a 5HT2 antagonist (e. g. Nefazodone). 5HT2 
antagonists have additional and varied pharmacological properties 
which help distinguish one from another. Nefazodone, for example, 
couples 5HT2 receptor blockade with serotonin re-uptake 
inhibition. 
29 
Figure 1.17: Trazodone blocks histamine receptors but is not a noradrenaline 
antagonist. 
Figure 1.18: A diagram of a noradrenergic and specific serotonergic 
antidepressant (NaSSA) e. g. Mirtazapine. 
30 
1.8 Antidepressants and sleep 
Most antidepressants alter sleep in the opposite direction to depression related 
changes, (This also occurs with ECT). This may mean that sleep is an indirect 
biological marker of the therapeutic effects of antidepressants. Patients who have 
sleep changes when they are depressed may respond better to pharmacological 
treatments rather than psychological treatments. 28 
The majority of antidepressants suppress REM sleep and increase REM latency. 7 
TCA treatment is also associated with increased REM density. In general, the ability 
of many antidepressant drugs to decrease REM sleep can be attributed to facilitation 
of noradrenaline and/or 5HT function or to muscarinic / cholinergic blockade. The 
potent muscarinic /anticholinergic properties particularly of TCA's mean all three 
mechanisms may be involved. REM sleep changes occur almost immediately 
although as mentioned above receptor regulation changes and antidepressant effect 
take 2-3 weeks to occur. This immediate effect is thought to be due to increases in 
5HT from uptake blockade stimulating 5HT1A receptors in the pontine tegmentum 
that act to suppress REM sleep. The evidence for this is based on the fact that in 
5HT 1A knockout mice the REM sleep suppressing effect of citalopram is absent, 
29 
and in humans selective 5HT1A agonist drugs e, g buspirone are REM sleep 
suppressing. 30 Also, decreasing 5HT availability by rapid tryptophan depletion in 
patients taking SSRIs has been shown to reverse the SSRI induced REM sleep 
suppression. This happens almost immediately but changes in 511T receptor 
sensitivity to increased levels of 5HT, which modulate antidepressant response in the 
frontal cortex, takes 2-3 weeks. 30 31 
31 
REM sleep is suppressed early in treatment but tends to return to baseline at about 8 
weeks. 32 If SSRIs are stopped REM sleep shows a rebound increase within a week, 
although ROL is less susceptible to these rebound effects. REM sleep suppression 
after SSRI treatment is probably caused by the increased levels of synaptic serotonin 
and mediated through the 5HT1A receptor. 
It has been suggested that the improvement in the symptoms of depression is related 
to REM sleep suppression, 33 however not all antidepressants act by suppressing REM 
sleep e. g. nefazodone, and trimipramine. 
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TCAs are potent REM sleep suppressors. Cloimpramine and imipramine are the most 
potent. They increase REM latency and decrease total REM sleep time with maximal 
effects after only a few days. The TCAs differ from each other in their effects on 
sleep onset and maintenance, in healthy volunteers and depressed patients. 
Cloimipramine, imipramine, dothiepin, and lofepramine tend to decreases sleep 
continuity, although amitryptiline may increase it (Table 1.7). Amitryptiline also 
stimulates the 5HT2 receptor as do the sleep promoting antidepressants e. g. 
nefazodone and mirtazepine. (The anti-psychotics that are sleep promoting are also 
5HT2 antagonists e. g. olanzapine. 34) Trimipramine is the only TCA that is robustly 
sleep promoting with decreased SOL's, increased TST's and higher sleep efficiencies 
in short term studies of healthy volunteers and depressed patients. It does not suppress 
REM sleep and it is only a weak monoamine reuptake inhibitor. Trimipramine's 
effects may be sustained in long term treatment of depression and insomnia. 
In summary polysomnographic studies of the TCAs generally support the clinical 
practice of using sedating TCAs for depressed patients with insomnia and the use of 
more activating TCAs for the hypersomnolent depressed group. 
Monoamine Oxidase Inhibitors (MAOIs) 
These are the most potent REM suppressors e. g. phenelzine and they can suppress 
REM sleep completely. 35 The effects are delayed compared to TCAs, maximal after 
about a week, and are associated with a large REM rebound on withdrawal 10 days 
after stopping the drug. 
34 
Reversible MAOI A inhibitors, (RIMAs) e. g. moclobemide may only be mild REM 
sleep suppressors. 36 
Selective Serotonin Reuptake Inhibitors (SSRIs). 
SSRls cause potent REM sleep suppression and increased REM latency 
Fluoxetine 
Studies have shown a substantial increase in REM latency compared to baseline in 
normal volunteers and depressed patients. 32 37 These studies have also shown 
fluoxetine can decrease REM sleep time by 3-5%, increase stage 1 sleep and increase 
awakenings during sleep. 
Paroxetine 
Sharpley38 (1996) compared effects of paroxetine, 20mg/day titrated up to 30mg/day 
on day 4, with nefazodone 100mg bd increased to 200mg twice a day on day 4 and 
placebo in 37 healthy volunteers. Compared to placebo subjects receiving paroxetine 
showed decreased TST, decreased sleep efficiency and an increase in wakefulness 
after sleep onset (WASO). REM sleep amount was significantly reduced and REM 
latency increased at day 1,6 and 16 in the paroxetine group. 
SSRIs cause similar changes in sleep onset and maintenance in healthy volunteers and 
depressed patients. They increase stage 1 sleep, increase arousals and WASO. 32 37 
Most studies show this effect but it tends to decrease after a few days except in the 
case of fluoxetine that may disrupt sleep continuity for up to 8 weeks. 7 SSRIs may 




Mirtazapine is a potent 5HT2 and 5HT3 antagonist. It has clinically important 
consequences as it stimulates 5HT1A receptors while blocking 5HT2 and 5HT3 
receptors. It also blocks the alpha2 autoreceptor, leading to increased SHT and NA. 
5HT2 and 5HT 3 effects may account for its antidepressant effect but it is also 
anxiolytic and sedating. There tend to be less problems with sexual dysfunction and 
nausea. It is a potent histamine blocker and it may increase sleep continuity due to this 
action. Weight gain is its main side effect probably related to its histamine 
stimulation. It increases ROL only modestly. 39 
Trazodone and Nefazodone 
Trazodone, in normal subjects, decreases numbers of awakenings and arousals, 
increases SWS increases REM latency and decreases REM sleep time, however 
results have been variable and only small numbers studied. 0 The most consistent 
effect on sleep in depressed patients is REM suppression, either decreased REM time 
or increased REM latency 41 . 
Nefazodone, a phenylpiperazine, (with active metabolites hydroxynefazodone and 
mCPP) may be unique in that it does not appear to suppress REM sleep in either 
healthy controls or in depressed patients. In two studies in normal volunteers it has 
caused an increase in REM sleep4042 and in one study, see below, in depressed 
patients compared to fluoxetine. 37 It also exerts minimal effects on sleep continuity by 
either decreasing awake and movement time and decreasing number of awakenings or 
by not affecting these parameters. 
36 
Nefazodone and fluoxetine sleep effects and antidepressant efficacy have been 
compared in a multicentred trial in 125 patients with major depression. 37 Clinical 
efficacy was comparable for both groups. With respect to sleep parameters patients 
receiving nefazodone demonstrated increased sleep efficiency, while patients on 
fluoxetine demonstrated a significant decrease in sleep efficiency and a significant 
increase in number of awakenings compared to baseline scores. Patients taking 
nefazodone demonstrated a total increase in total REM sleep time in contrast to the 
expected REM suppression associated with fluoxetine treatment. 
How does nefazodone work to improve depression and promoting sleep? It has been 
shown to possibly increase REM sleep in healthy volunteers and in depressed patients 
compared to fluoxetine, as above. Nefazodone has weak antagonist activity at alpha 
one receptors which could lead to the increase in REM sleep in the reported studies 
above, but its alpha antagonist receptor properties are weaker than trazodone's which 
decreases REM sleep. mCPP, nefazodone's metabolite also decreases REM sleep. 
Nefazodone's weak alpha one antagonist receptor blocking properties may account 
for its role in improving sleep continuity. Nefazodone's role in decreasing awakenings 
may be that its 5HT reuptake blocking effects are compensated by its 5HT2A/2C 
receptor agonist activity. 
SSRIs or TCAs have no significant effect on SWS in short or long- term treatment 
and therefore their clinical effects are unclear. 
Antidepressant effects are not restricted to REM or SWS sleep, they also alter sleep 
initiation and consolidation. Non-REM effects tend to be more varied than REM 
37 
changes both acutely and chronically and tend to vary depending on the stage of the 
illness. 27 The main mechanism behind the sedative effects of TCAs, mianserin and 
trazodone are their histamine receptor and alpha one receptor blockade but it is 
possible that 5HT2A/2C receptors are involved. 
1.9 Insomnia definitions and epidemiology 
When asking a patient what they mean when they say they have insomnia they will 
mention all or some of the following: 
Difficulty falling asleep 
Nocturnal awakenings 
Early morning wakening (EMW) and difficulty falling back to sleep 
Un-refreshing sleep 
Daytime fatigue 
Insomnia has been known and discussed by the scientific community for at least two 
thousand years beginning with Aristotle's monograph on sleeplessness written in 350 
BC. However there is still no overall agreement by patients, healthcare professionals 
and sleep researchers what constitutes insomnia. The term insomnia is used in a 
confusing way to describe a disease, complaint, symptom and a finding. 
To further complicate matters there are three main classifications of the diagnosis of 
insomnia. These are: 
International Classification of Diseases ICD-10 (WHO, 199243) 
International Classification of Sleep Disorders ICSD (ASDA 200544) 
Diagnostic and Statistical Manual of Mental Disorders 4T11 editions 
38 
The different classification systems are used by different bodies and there are 
difficulties matching one classification to another which leaves gaps when 
transferring between the systems. 
ICD 10 defines non-organic insomnia as a difficulty falling asleep or maintaining 
sleep or poor quality sleep at least three times a week for at least a month. 
DSM-1 V (R) gives as the first criterion for insomnia that the predominant complaint 
is difficulty initiating or maintaining sleep or non-restorative sleep for at least one 
month. 
The International classification of sleep disorders ICSD is the gold standard for sleep 
researchers and defines insomnia as difficulty in initiating or maintaining sleep. Table 
1.8 shows the different classifications of insomnia comparing ICSD, ICD-10 and 
DSMIV (R). 
"Psychophysiological insomnia" is an important cause of insomnia in middle aged 
women. They are usually previous light sleepers, presenting with a relatively long 
history of insomnia that waxes and wanes in severity which may have been 
precipitated by a bout of depressive illness. Sometimes, insomnia has developed 
gradually "feeding on itself'. A hallmark of psychophysiological insomnia is the 
focused absorption of the patients on their sleep problem while the same patients 
often minimize other mental or emotional concerns. 
39 
It is defined as "a disorder of somatized tension and learned sleep-preventing 
associations that results in a complaint of insomnia and associated decreased 
functioning during wakefulness". About 15% of insomniacs seen in sleep disorder 
clinics have psychophysiological insomnia but the true incidence in the general 
population is unknown. 4 Primary insomnia is a diagnosis of exclusion and accounts 
for approximately 30 % of chronic insomnia. 
ICSD ICD-10 DSM 1V R 
Adjustment sleep Non organic 
disorder insomnia 





Central sleep Sleep apnoea Breathing related 




Altitude insomnia Other effects of high 
altitude 
Short sleeper 
Fatal familial Other degenerative 
insomnia diseases 




Table 1.8: Different classifications of insomnia, comparing ICSD, ICD-10 and 
DSM IV R 
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Prevalence of insomnia 
The prevalence of insomnia, as explained above, will depend on how insomnia is 
defined. Most population prevalence has been obtained through questionnaire and 
interview surveys inquiring about `difficulty sleeping' without regard to clinical 
significance or causal factors. In a review of 25 years of epidemiological studies from 
1976-1996 46, `sleep disorders' in general were reported in 13%- 49% of respondents 
but "insomnia" specifically was reported in 3%-19% of subjects. Ohayon 200247, 
reviewed the epidemiology of insomnia by dividing the estimates of the prevalence of 
insomnia into four definitions; insomnia symptoms, insomnia symptoms with daytime 
consequences, sleep dissatisfaction and insomnia diagnoses. The first definition based 
on insomnia criteria including report of difficulty initiating or maintaining sleep or 
non restorative sleep regardless of duration or consequences, recognizes that about 
one third of a general population presents at least one of them. When daytime 
consequences are taken into account the prevalence is between 9%-15%. The third 
definition represents 8-18% of the general population and the last definition is more 
precise and corresponds to a decision-making diagnosis setting the prevalence at 6%. 
(Figure 1.19) 
These four definitions of insomnia have higher prevalence rates in women and 
increase with age. In a multinational European survey, the epidemiology of severe 
insomnia (at least two sleep complaints on 3 nights a week) and its impact on the 
quality of life and healthcare consumption was assessed in a survey of the general 
population of five northern European countries 48 The prevalence of severe insomnia 
ranged from 4%-22% and was higher in women than men but was not related to 
increasing age (although most studies do identify the elderly have an increased 
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incidence of insomnia). The UK had the highest prevalence of 22% with the highest 
incidence in the Midlands and North East although in another study in the UK the 
prevalence was similar to the European study. 49 In all countries insomnia had a 
negative impact on the quality of life and the degree of impairment was directly 
related to the severity of insomnia. People with severe insomnia also showed a higher 
level of healthcare consumption. A `working prevalence" of the incidence of insomnia 
is therefore that a third of people will suffer with mild problems sleeping but about 
ten percent of people suffer with severe insomnia at any one time. 
Insomnia symptoms 
Presence: 30-48% 
At least 3 nights a week or often or always: 16-21% 
Moderately to extremely: 10-28% 
Insomnia symptoms and daytime consequences: 9-15% 
Dissatisfaction with sleep quality or quantity: 8-18% 
Insomnia diagnosis: 6% 
Figure 1.19: Diagnosis of Insomnia 
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Factors associated with insomnia 
Numerous factors are associated with insomnia (Table 1.9. ) 
INSOMNIA 
SELF- INDUCED Life Style Shift working, irregular sleep 
wake schedule 
Use, abuse or withdrawal of Alcohol, caffeine, hypnotics, 
Psycho-active substances anxiolytics, cocaine, 
amphetamines, opioid 
SECONDARY Mental disorders Depressive disorders, bipolar 
disorders, psychotic disorders, 
anxiety disorders, eating 
disorders, psychotic disorders 
Medical Conditions Arthritis, heart disease, 
cererbrovascular disease, 
stomach or gastric ulcer, 
gastrointestinal disease, obesity, 
viral or bacterial infection, food 
or milk allergy, headache, 
migraine, menopause, head 
injury, epilepsy, Parkinson's 
disease, Huntingdon's disease 
Breathing Disorders during Sleep apnoea, hypoventilation, 
sleep respiratory insufficiency, sleep 
related asthma 
Other sleep disorders Periodic limbs movement 
disorder 
Restless leg syndrome 
Circadian rhythm disorders 
PRIMARY No identifiable factors 
responsible for the complaint 
Table 1.9: Factors associated with insomnia 
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1.10 Consequences of insomnia 
These include susceptibility to accidents, (including Road Traffic Accidents, ) medical 
and psychiatric morbidity, poor performance at work, absenteeism, and increased 
mortality. 50 Daytime tiredness and functional impairment in the daytime are also 
complained of, but there is less clear evidence for a decrease in alertness in laboratory 
studies of alertness and performance in people suffering from chronic insomnia. 51 
Insomnia sufferers have a higher prevalence of psychiatric disorder and studies of 
patients in sleep medicine clinics show psychiatric disorder is common. 2 Among a 
sample of outpatients who were consulting their GP's for insomnia 53% presented 
with psychiatric symptoms. 53 The risk of depression is probably four times more 
likely in people with insomnia, S4 and the complaint of insomnia may be an early 
marker for psychiatric disorders such as depression, anxiety and alcohol abuse. 
Alcohol abuse and other substance abuse is increased in insomniacs compared to good 
sleepers. Insomnia can also be associated with many medical conditions. 
Chilcott and ShapiroS0(1996) estimated that the direct and indirect costs of insomnia 
were between 92 -107 billion dollars a year in the U. S. A and Walsh (1995) estimated 
the direct cost of insomnia to be between 11 billion dollars a year. 55 
1.11 Treatment of insomnia 
Potential causes of insomnia (Table 1.7) should be treated. These should be 
investigated by taking a good history, which includes questions about psychiatric 
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symptoms and previous medications. It is also important to ask about alcohol use as it 
is often drunk inappropriately to aid sleep. Sleep diaries may be useful and all patients 
should be advised about good sleep hygiene. 
The role of hypnotic drugs 
The duration and cause of the insomnia should be a guide to treatment with 
medication. If a patient has insomnia secondary to depression then an antidepressant 
is a useful choice particularly those with sedating properties e. g. mirtazepine or 
trazodone. Sleep disturbances related to circadian rhythms such as jet lag, shift work, 
delayed and advanced sleep phase syndrome, should be treated with chronobiotics e. g. 
melatonin. 
The short- term use of hypnotics for the treatment of transient insomnia e. g. due to 
stress secondary to exams is appropriate, This is usually 2-3 weeks of treatment. 
It is when addressing the treatment of more chronic insomnia with hypnotic drugs 
such as benzodiazepines, zopiclone, zolpidem and zaleplon the "Z" drugs that 
controversy arises. 
Annual prescription for benzodiazepine hypnotics fell from 10 million to around 6 
million in England between 1993 and 2003 and those for the "Z" drugs zopiclone, 
zolpidem and zaleplon rose from 0.3 million to over 4 million over the same period. 
6 
This would suggest that prescribers think changing to a Z-drug may avoid the possible 
problems associated with regular hypnotic use. However, the recent National Institute 
of Clinical Excellence (NICE) guidelines have recommended that there is no evidence 
from a meta analysis to suggest that the "Z" drugs should be used in preference to 
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benzodiazepines in clinical practice due to no difference on outcome measures on 
insomnia. 57 (This is discussed further later in this chapter. ) Table 1.10 shows the 
pharmacokinetic profiles of the main hypnotic drugs. 
1.12 Psychopharmacology of hypnotic drugs 
To understand how sedative hypnotic drugs e. g benzodiazepines, zopiclone, 
zolpidem, zaleplon, barbiturates, and alcohol act in the brain one has to look at the 
benzodiazepine receptor. These drugs interact with specific binding sites on the 
GABA A receptor also known as the benzodiazepine receptor. The GABA A receptor 
is a pentameric protein, comprising of 5 subunits. The principal subunits are alpha, 
beta and gamma each with many subtypes. They form a rosette around a 
transmembrane ion channel pore permeable to chloride ions. 
Figure 1.20: Diagram of a GABA A Receptor. When GABA binds to the 
receptor, the chloride channel enlarges, leading to 
hyperpolarisation of the nerve cell. 
GABA 
Features Zaleplon Zolpidem Zopiclone Temazepam 
Class Pyrazolopyrimidine Imidazopyridine Cyclopyrrolone Benzodiazcpinc 
Mechanism of Action Allosteric modulator of Allosteric Agonist at type Agonist at type 
GABA. Selective for modulator of GABA A receptor GABA A receptor 
GABA A GAGA. Selective Non selective for 
Benzodiazepine for GAGA A subtypes 
receptor containing Benzodiazepine 
alpha one subunit receptor containing 
alpha one subunit 
Dose (mg) 5-10 5-10 3.75-7.5 10 
Effects on Sleep No effect on SWS No effect on SWS ? increases SWS Decreases SWS in 
Architecture No effect on REM No effect on REM REM decreased high doses 




tmax (hrs) 1.4 1.2 3 1.1 
t1/2 (hrs) 1 1.9 4.4 9.1 
Side Effects 
Most common Headache Dizziness, Bitter aftertaste, Yes (see text) 
somnolence dry mouth 
Residual effects No No Yes 
Yes 
Rebound insomnia No No Yes 
Yes 
Dependence/Abuse Some effect Some effect Some effect 
potential (increased 
with history of drug 
abuse) 
Next day psychomotor Yes 
or driving impairment No Yes Yes 
Some effects on 
Memory impairment Delayed recall of learnt anterograde Some effect on Yes 
words memory word recall 
Table 1.10: Pharmacokinetic profiles of hypnotic drugs 
GABA= gamma aminobutyric acid, tl/2 = elimination half-life, tmax = time to reach 
maximum plasma concentration. 
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Following occupancy of the beta sub unit by GABA molecules the GABA A 
receptor columns interact with the chloride channel to open. The increased 
chloride conductance into the neuron occurs quickly and is inhibitory to the 
firing neuron. Modern hypnotic drugs like the benzodiazepines, zopiclone (a 
cyclopyrrolone, ), zolpidem (a imidazopyridine), and zaleplon (a 
pyrazolopyrimidine) bind to the alpha subunit and this is known as the 
`hypnotic receptor. ' This receptor site allosterically modulates the GABA A site 
that in turn modulates the chloride channel, causing a large amplification in 
GABA's ability to increase the conductance of chloride through the channel. 
These drugs are therefore positive allosteric activators of the GABA A receptor. 
This protein is also the target for anxiolytic and anticonvulsant benzodiazepines 
e. g. alprazolam and clonazepam, benzodiazepine antagonists e. g. flumazenil, 
and inverse agonists that have the opposite effect to benzodiazepines e. g. 
psychostimulants and proconvulsants. (Figure 1.21. ) Inverse agonists decrease 
the probability of channel opening in response to GABA and are thus negative 
allosteric activators of GABA receptors. 
There are different forms of the alpha, beta and gamma subunits. It appears that 
the alpha subunit composition of the receptor determines the benzodiazepine 
pharmacology of the receptor. Site directed mutagenesis with `knockout mice" 
(receptor subunits are deleted due to gene ablation) or "knockin" mice (receptor 
subunits are mutated in a manner that creates a non-functional receptor site, ) has 
indicated that. benzodiazepines bind to a cleft on the GABA A receptor surface 
at the interface between the alpha and gamma subunits. Zopiclone does not 
48 
show subtype selectivity either but does exhibit a unique thermodynamic 
interaction with the benzodiazepine receptor, (this may translate into less 
receptor adaptation on chronic dosing, and so less tolerance and withdrawal than 
the benzodiazepines). Zaleplon, and zolpidem bind specifically to the alpha one 
sub unit at the rim of the cleft and therefore interact with amino acids in 
different domains to the benzodiazepines. The most prevalent GABA receptors 
in the brain are composed of alpha 1, beta 2, and gamma 2, subunits which are 
encoded by the same cluster of genes on chromosome 5. This receptor 
combination corresponds to over 50% of all GABA receptors in the brain and 







Other substances bind to sites on the receptor 
Figure 1.21: Demonstration of binding sites on the GABA A receptor 
dQ 
The roles of select GABA A receptor subunits (Table 1.11) in the different 
effects of benzodiazepines has been studied and is forming the basis of research 
to develop specific drugs to target these receptors for other functions rather than 
just sleep promotion e. g. alpha three subunit selective agonists as nonsedating 
anxiolytics and alpha 5 subunit inverse agonists as memory enhancers S8 
Interestingly, gaboxadol (see section 1.5) is an extrasynaptic GAGA A selective 




a1 a2 a3 a5 y2 02 ß3 S 
Sedation + - - - + 
Anxiolysis - + -/+ - 
Amnesia + 
Myorelaxation - + 
Motor 
Impairment 
- - - 
Anticonvulsant + - - - 
Ethanol - + 
Effects of 
Anaesthetics 
+ + + + 
Anxiety + 
Learning/Memory + 
Table 1.11: The roles of select GABA A receptor subunits 
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A molecular mechanism for hypnotic dependence, (withdrawal symptoms, 
rebound insomnia, anxiety and tolerance to the sedative effects) may be that 
there is a change in the sensitivity of the GABA receptor so that its "null 
efficacy" point drifts in the inverse agonist direction. 59 This may occur by 
down-regulation of transcription of the normally prevalent alpha-one beta-two 
gamma-two subunits and the reciprocal up-regulation of the expression of rarer 
subunits. Chronic treatment with hypnotic drugs that have less dependence 
potential e. g. zopiclone, zolpidem, and zaleplon appear to produce the more 
limited changes in GABA A receptor subunit expression. 
Hypnotic efficacy 
Two meta analyses confirm the short term (2-4 week) efficacy of GABA 
modulating pharmacotherapy in insomnia, particularly on total sleep time 
bo 61 
The Z drugs, zopiclone and zolpidem, have short term efficacy similar to 
benzodiazepine hypnotics. 62 Although zaleplon reduces sleep onset latency 
compared to placebo it does not seem to consistently improve the quality or 
63 duration of sleep or reduce nocturnal awakenings 
Problems with the use of benzodiazepine and Z drugs 
Adverse events that are reported are: 
Tolerance and withdrawal (rebound insomnia) 
Over sedation "hangover" effects (the following day) 
Cognitive impairment 
Dependence and Misuse 
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Tolerance and withdrawal (rebound insomnia) 
Addiction is a behavioural pattern of drug abuse characterized by overwhelming 
involvement with the use of the drug (compulsive use), the securing of its 
supply, (drug seeking behaviour), and a high tendency to relapse after 
discontinuation. Dependence is the physiological state of neuro-adaptation 
produced by repeated administration of a drug necessitating continued 
administration to prevent the appearance of a withdrawal syndrome. When a 
drug causes dependence, tolerance, withdrawal and rebound can occur. 
Tolerance has developed when after repeated administration a given dose of a 
drug produces a decreased effect. Withdrawal is the term for the adverse 
psychological and physiological reactions to abrupt stopping of a dependence- 
producing drug. It is important to distinguish withdrawal from rebound. 
Rebound occurs when dependence occurs in patients who have taken a drug for 
a medically sanctioned use, the drug is suddenly stopped and their symptoms 
come back in an exaggerated fashion. Withdrawal, on the other hand, is what 
happens in those who abuse a drug and then that drug is suddenly stopped i. e. 
they develop withdrawal symptoms often craving dysphoria and signs of 
sympathetic nervous symptom activity. 
Tolerance to the hypnotic effects of benzodiazepines can develop after a few 
weeks of use. 64There is however evidence that this only occurs in about a 30%- 
45% of users. 63 
Rebound insomnia, which is more likely to happen with the shorter acting drugs 
at higher doses, may occur after abrupt stopping of benzodiazepine hypnotics. It 
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is mainly for this reason that efforts to cut down or stop can be unsuccessful. 
Other withdrawal effects that may occur are anxiety, perceptual distortions, 
hallucinations, depression and uncommonly seizures and delirium. The slow 
decline of blood levels with the longer acting agents means that in effect they 
are self tapering. Rebound insomnia can be avoided as far as possible by 
tapering the dose of short acting agents before stopping them. 
With respect to the Z drugs, tolerance and rebound insomnia are claimed to be 
less common than with benzodiazepines based on the fact that zolpidem and 
zaleplon are more specific at the GABA receptor binding site and therefore 
should minimise any non-hypnotic effect, (please see later). However product 
characteristics of all three Z drugs warn that tolerance can occur after repeated 
use for a few weeks and none of the drugs are licensed for more than four weeks 
with zaleplon being licensed for two weeks 65 
Over sedation 
Longer acting benzodiazepine hypnotics with half-lives of over 24 hours can 
accumulate in the circulation when the medication is taken nightly. Residual 
dose related hangover effects may then occur which include daytime sleepiness, 
performance decrements, accidents in the home, work or while driving and 
contribute to falls in the elderly due to ataxia, motor incoordination and mental 
confusion. 66 The problems are best minimised by use of a drug with a short 
duration of action, given only intermittently in the lowest effective dose. 67 
Elderly people are especially vulnerable to over-sedation because they eliminate 
the drugs more slowly, are more susceptible to CNS depression and are more 
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likely to be on potentially interacting drugs. 66 Half the recommended dose 
should be given if possible. 
Zolpiclone and Zolpidem have shown residual daytime effects especially at 
higher doses66 (Table 1.9). Zaleplon appears to have no detectable effects at the 
usual dose of 10mg on psychomotor performance or driving when taken late in 
the night up to 2 hours before scheduled waking time, but a four hour gap is still 
advised before undertaking activities requiring psychomotor coordination. 
Cognitive function 
Global amnesia can occur but more often episodic memory is affected. There is 
probably a risk of treatment related impairment of memory with both the 
benzodiazepines and the Z drugs. 
All patients and especially those who drive or operate machinery must be 
warned about the risks of hangover effects if prescribed any hypnotic drugs. All 
hypnotics can depress respiration so should be avoided in patients with 
respiratory failure and obstructive sleep apnoea. All have additive effects with 
alcohol and other CNS depressants. 
Dependence and Misuse 
It is unusual to meet patients who have been medically prescribed 
benzodiazepines displaying drug seeking addictive behaviour but there is more 
evidence that benzodiazepines and the Z drugs are misused by people with 
alcohol dependence and polysubstance abuse. 63 Also very high doses of 
temazepam are sometimes swallowed, snorted or injected as euphoriants. 68 
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Zolpidem has been reported to be misused as a stimulant and anxiolytic in 
patients without drug and alcohol problems. 69 There are no actual studies 
comparing the comparative risks of dependence of benzodiazepines and Z 
drugs. 
Other drugs 
Table 1.12 shows other drugs apart from antidepressants, Z drugs or 
benzodiazepines that have been used in the treatment of acute and/or chronic 
insomnia. 
There is a definite need for care in prescribing hypnotic drugs, both the 
benzodiazepines and the Z drugs for short- term insomnia. They should be 
avoided in people with a history of substance abuse and then prescribed within 
their product characteristics. However, the recent NICE guidelines comparing 
the use of the Z drugs and benzodiazepines in the short term management of 
insomnia have been criticised because the committee has principally looked at 
clinical sleep parameter outcomes for insomnia and not considered the improved 
side effect profile of the Z drugs compared to benzodiazepines 70 
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Drug Efficac Side Effects 
Antihistamines including Sedation at first, tolerance Daytime sedation 
Nytol antihistamine develops quickly 
Antipsychotics Sedation can be marked Parkinsonian and 
e. g. chlorpromazine Olanzapine increases SWS anticholinergic side effects 
olanzapine Daytime sedation 
Weight gain with olanzapine 
Antiepileptic drugs Marked sedation Dangerous in overdose 
e. g. phenobarbitone 
Chloral Hydrate Doubtful efficacy Tolerance and Dependence 
can develop 
Melatonin Lack of evidence for efficacy Dosage and long term side 
in insomnia effects unknown 
Herbals e. g. valerian, Possible evidence for Interactions with other 
lavender, camomile, St John's Valerian in one trial medication 
Wort St John's Wort is an 
antidepressant 
Alcohol A small amount of alcohol Large amounts cause arousals 
will help initiate sleep `night due to withdrawal during the 
cap' night 
Table 1.12: The efficacy and side-effect profiles of other drugs used in 
treatment of insomnia. 
The benzodiazepines they considered as short acting in the NICE guidelines all 
had half-lives of 6-17 hours (temazepam-lorazepam). If a drug is used with a 
half-life of over 4 hours it is much more likely to still be active in the brain in 
the morning to cause the over sedation described above e. g. affecting driving to 
work, hip fractures in the elderly. Indeed, Verster (2004)71 has compared road 
driving effects of benzodiazepines compared to the Z drugs and found greater 
sedation when driving early the next morning with benzodiazepines and 
zopiclone but no effects at all with zolpidem and zaleplon. This would be 
expected as benzodiazepines also remain much longer in the brain the next day 
as calculated by receptor occupation. 72 
There is also now emerging evidence that there is less abuse of Z drugs than 
benzodiazepine hypnotics. 68 The socioeconomic cost of insomnia may be less 
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with Z drugs compared to benzodiazepines due to their more rapid excretion and 
therefore less risk of accidents the following day. 3 Also there may be a more 
"physiological" effect on sleep architecture in that the `Z" drugs alter sleep 
architecture less than the benzodiazepines, and this may account for the fact 
they are easier to withdraw from with less tolerance and rebound. 
Medication has a place in the management of patients with chronic insomnia, 
although it should preferably be used on an intermittent basis to relieve 
insomnia when it is at its worst, due to the potential problems with hypnotics as 
outlined above. However, the psychological and behavioural treatment of 
insomnia has become important particularly for people with chronic insomnia. 
1.13 Psychological/behavioural management of insomnia 
There is only limited information concerning primary insomnia's underlying 
pathophysiology and heritability. Deficiencies in endogenous melatonin or 
benzodiazepine receptors and hyperactivity of corticotrophin releasing factor 
neurons have been cited as potentially important to the aetiology of primary 
insomnia74 and a familial propensity towards its development suggesting genetic 
or hereditary factors may play a part. There is however general agreement that 
primary insomnia is perpetuated by the interplay of cognitive and behavioural 
mechanisms. 
Due to the potential problems with long term use of benzodiazepines and the Z 
drugs there has been much renewed interest in the psychological treatment of 
insomnia. 
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To introduce this field, consideration of the factors that may play a part in the 
development and maintenance of insomnia from a psychological basis 
particularly concentrating on cognitions related to insomnia are useful to 
consider: 
1. Faulty Conditioning 
Is insomnia the product of maladaptive sleep habits? Difficulty falling asleep 
may result from failure to establish discriminative stimuli for sleep or the 
presence of stimuli incompatible for sleep. These "letting down to sleep 
instructions"75 are known as stimulus control therapy (SCT) , (see appendix 
for 
a copy). Stimulus control may also reduce sleep anticipatory anxiety as well as 
improving sleep. 
2. Poor Chronobiological training 
In primary insomnia it has been suggested that there may be an element of 
chronobiological dysfunction. For example some insomniacs go to bed early 
and spend excess time in bed either habitually as often in the case of older 
adults as a response to having slept poorly the previous night. This contributes 
to poor sleep efficiency. Also napping contributes to reduced nighttime sleep 
drive in adults. Stimulus control instructions contain elements of temporal 
adjustment, and may contain zeitgebers for healthy sleep. Sleep restriction 
therapy (SRT) is another technique that may act as a circadian harmonic and a 
reinforcer of homeostatic drive76. Stimulus control and sleep restriction 
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therefore overlap and the term "sleep scheduling" is sometimes used for the 
combination. 
3. Physiological hyperarousal 
There is limited evidence that some insomniacs have heightened autonomic 
arousal, and muscle tension. However insomniacs may display measurable 
neurobiological differences from normal sleepers. Differences in oxygen 
consumption in people with insomnia compared to controls have been found'? 
and this increased metabolic rate could be viewed as a `higher arousal set 
point. " 
Relaxation techniques and biofeedback (a visual or auditory feedback) can be 
provided to the patient to control pre-determined physiological parameters e. g. 
frontalis EMG, and can be used to decrease arousal in insomniacs. There seem 
to be similar treatment effects on SOL with both methods but relaxation is 
quicker to teach to a patient and also more applicable in a group situation. 
4. Cognitive hyperarousal 
The consideration of a broad range of cognitive processes is important for a full 
understanding of insomnia. In the 1960's and 1970s the role of "attribution" 
"expectation" and "perception" were emphasised. In the 1980's the emphasis 
was on the role of `unwanted intrusive thoughts" and in the 1990's unhelpful 
beliefs about sleep were considered in more detail. The latest lines of research 
have begun to investigate the neural basis of cognitive arousal; the role of 
78 attentional processing in insomnia and the role of perception is being revisited. 
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(a) Thought content and form of thought 
The actual thought content of the intrusive and worrying thoughts of people 
with insomnia has been analysed in a few studies. 
Espie (1989) used an extended version of the `Sleep Disturbance Questionnaire" 
(SDQ), 79 and reported six factors, mental activity and rehearsal, thoughts about 
sleep, family and long term concerns, positive plans and concerns, somatic 
preoccupations, work and recent concerns. Harvey (2000) reported that pre- 
sleep cognitive activity or "pre-sleep worry " of people with insomnia could be 
distinguished from normal sleepers by being more focused upon worry about 
not getting to sleep, general worries, solving problems, the time and noises in 
the house, and getting less focused upon nothing in particular. 80Wicklow and 
Espie (2000) obtained voice activated audiotape recordings of pre-sleep 
spontaneous thoughts and sleep actigraphic data from twenty poor sleepers over 
3 consecutive nights81. There was a positive correlation between pre-sleep 
cognitive activity and SOL measured by actigraphy. Content analysis yielded 8 
categories of pre-sleep intrusion which were divided into one of 3 factors: active 
problem solving e. g. rehearsing/planning events, present state monitoring e. g. 
thinking about sleeping /not sleeping, and environmental reactivity e. g. 
attending to external noises. Thinking about sleep and the anticipated 
consequences of poor sleep were the strongest predictors of SOL. 
In the last few years the "form of thought" has been emphasised, that is 
rumination, worry and intrusion are distinguishable entities. "Intrusive 
thoughts" are spontaneous, unwanted, unbidden, uncontrollable and discrete 
thoughts, images or urges. While some intrusions are easily dismissed under 
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certain circumstances they will trigger worry and rumination "Worry" is a chain 
of thoughts and images, negatively affect-laden and relatively uncontrollable. 
Worry is more likely to occur as verbal thought, as opposed to images. Verbal 
thought has also been shown to be more likely to be involved in the 
maintenance of worry as opposed to thinking in images 82. "Rumination" refers 
to the repetitive focusing on the "causes, meanings and consequences" of one's 
feelings and symptoms. 
(b) Racing thoughts and thought management (strategies of "thought 
control") 
Most studies have also reported cognitive arousal or "having an 
overactive/racing mind, " as the consistent complaint of people with insomnia. 
Results from administering the Sleep Disturbance Questionnaire (SDQ) 
involves rating twelve statements for the extent they are relevant to their typical 
sleep pattern. 79 The thoughts most endorsed by people with insomnia were 
intrusive thoughts such as "My mind keeps turning over" and "I am unable to 
empty my mind". Ree and Harvey (2005) have examined the management of 
these thoughts with "thought control strategies" that categorise how the 
thoughts are controlled by people with insomnia, and then compared how good 
sleepers and people with insomnia deal with them. 83 They have developed the 
"Thought control questionnaire insomnia- revised (TCQI-R)" which measures 
these six factors of thought control: 
1. Aggressive suppression, (I get angry at myself for having the thought, ) 
2. Cognitive distraction, (I think pleasant thoughts instead) 
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3. Reappraisal, (I try a different way of thinking about it) 
4. Social avoidance, (I keep the thought to myself) 
5. Behavioural distraction, (I keep myself busy) 
6. Worry, (I dwell on other worries) 
With the exception of cognitive distraction, individuals with insomnia, relative 
to good sleepers, more frequently used every thought control strategy. The 
strategies of aggressive suppression and worry, in particular, appear to be 
unhelpful, with the use of these strategies predicting sleep impairment, anxiety 
and depression. The use of cognitive distraction appeared to be helpful, with the 
use of this strategy predicting better sleep quality. Harvey (2003a)84 also 
showed catastrophic worry was common in primary insomnia and that 
compared to a control group led to increased negative affect and perception of 
threat. 
Imagery training (visualization technique to focus on some pleasant or neutral 
images) seeks to reduce cognitive arousal rather than somatic arousal. Harvey 
(2003b)85 have demonstrated thought management via distraction with imagery 
versus general distraction facilitates sleep onset and reduces the discomfort 
associated with intrusive and worrisome thought. 
Paradoxical intention 
This model of insomnia proposes that anxiety responses may be conditioned not 
only to external, situational cues but also to an individual's behaviour. In 
paradoxical treatment attempts to fall asleep are replaced by the intention of 
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remaining passively awake or by giving up any direct effort to fall asleep. 
Paradoxical intention has demonstrated efficacy in controlled trials. 86 However, 
Wegner (1994) has suggested a self -loading system that under certain 
conditions the thwarted attempt to control a particular mental state can yield the 
opposite of what is desired. 87 This he called "Ironic processes of mental 
control". More recently, Harvey (2003b) has explored the effects of 
suppressing pre-sleep cognitive activity i. e. thought suppression on sleep-onset 
latency. 85 A cohort of people with insomnia and good sleepers were allocated to 
either a suppression condition (suppress the thought most likely to dominate 
your thinking as you get into bed, ) and a non suppression condition (think about 
anything as you get into bed, including the thought you would most likely think 
about before you go to sleep. ) Suppression participants reported longer sleep 
latencies and poorer sleep quality regardless of whether they had insomnia or 
not. Harvey concluded that thought suppression appeared to have the opposite 
effect, in that it prevented sleep-onset, in a manner consistent with Wegner's 
theory of ironic mental control. 
However when the relationship between pre-sleep cognitive activity and sleep 
onset latency is measured subjectively and objectively they do not always 
correlate. 
There is a possibility therefore that pre sleep cognitive arousal is integral to 




Charles Morin in the 1990's, made a major contribution to the field of insomnia 
research. He showed that older adults with insomnia held more unhelpful 
thoughts about sleep than good sleepers, were less realistic about how much 
sleep they required and had more negative thoughts than good sleepers at 
bedtime". He argues that beliefs and attitudes play a critical role in insomnia. 
The development of cognitive therapy within multicomponent CBT for 
insomnia to tackle these beliefs stems from this research, and the development 
of a 30 item questionnaire to identify irrational affect-laden thoughts that 
intrude prior to sleep-onset, the Dysfunctional Beliefs and Attitudes about sleep 
scale (DBAS). 88 
Meta Cognition 
Meta Cognition has only just being explored in insomnia. Meta-cognition refers 
to the thoughts and beliefs that people hold about thoughts, or the processes that 
are involved in keeping track of or appraising and controlling thought. 
Pathological worry may be maintained because the individual believes the 
worry may lead to positive consequences. The individual thinks that worrying in 
bed "helps sort out things in my mind. "89 
Attentional processing or "Sleep related threat" / Sleep Effort 
"Attentional processing" research has found that the tendency to attend 
selectively to internal and external sleep related threats is higher in patients with 
insomnia than good sleepers. 90 For example, when patients with insomnia wake 
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up they monitor their body sensations for signs of fatigue (internal sleep related 
threat), and the clock to calculate how much sleep they have obtained, (external 
sleep related threat). 
Beginning and during the night On waking During the day 
if woken up 
Body signs Body sensations for signs of Body sensations for signs of 
consistent/inconsistent to poor sleep (internal) fatigue (internal) 
falling asleep (internal) 
Environmental signs of not The clock to see how much Mood for indications of 
falling asleep (external) sleep was obtained (external) tiredness/not coping 
(internal) 
The clock (external) Performance for indications 
that attention, memory and 
concentration are failing 
(internal or external) 
Needing to pass urine (internal) 
Table 1.13: Sleep related threats (internal and external) 
A questionnaire has been developed to assess sleep related threat, `The sleep 
associated monitoring inventory' (SAMI). 91 Tang (2007)92 has investigated the 
sleep threat of "clock monitoring" further and found the monitoring of the clock 
by people with insomnia and good sleepers triggered pre-sleep worry but in both 
groups. They suggest that clock monitoring can fuel pre-sleep worry and also 
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exacerbate sleep misperception in people with insomnia. For examples of sleep 
related threat please see Table 1.13. 
Perception 
Distorted perception of sleep is one of the key cognitive processes in pertaining 
to insomnia. It was noticed and first researched in the 1970's that good sleepers 
underestimate wake time and overestimate total sleep time, 78 but it has also been 
shown that cognitive arousal and physiological arousal in healthy subjects can 
contribute to sleep misperception. 93 
People with insomnia tend to overestimate how long it takes them to go to sleep 
and underestimate how much sleep they get in total. This is called "sleep 
misperception" (SMP) or "subjective insomnia. " Mercer 2002, measured sleep 
wake perception with forced waking of good sleepers and people with insomnia. 
They demonstrated that when people with insomnia are woken they are much 
more likely than good sleepers to report having already being awake. 
4 This 
effect occurs in awakenings from REM sleep and particularly stage 2 sleep. The 
PSG measures of these findings correlated significantly with subjective sleep 
diary defined wakefulness therefore suggesting an additional mechanism 
underlying SMP that may involve a tendency towards interpreting sleep as 
wakefulness. There is evidence that monitoring for "sleep related threat" see 
above, cognitive arousal (e. g. worry, ) and physiological arousal all fuel the 
distorted perception of sleep in insomnia. 90 93 
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There is also evidence that SMP is not just the result of a general deficit in time 
estimation. Tang and Harvey (2005)95 showed no difference in time estimation 
between insomniacs and good sleepers in certain time estimation tasks both in 
the day and their bedroom at night. The subjective perception of sleep 
immediately on waking may also contribute to the maintenance of insomnia. 
Another recent study randomly allocated patients with primary insomnia to 
receive either positive or negative feedback about their sleep immediately on 
waking on three consecutive mornings. Negative feedback impaired daytime 
functioning with more negative thoughts during the day, sleepiness, "safety 
behaviours" during the day and monitoring for sleep related threat. 6 Examples 
of "Safety behaviours" are "try to stop all thinking" leading to paradoxical 
excessive cognitive activity, "having a night cap" leading to poorer sleep 
continuity, "having a quiet day" leading to boredom and more time to think 
about the consequences of not sleeping. 
How often does sleep misperception occur? The underestimation of total sleep 
time and overestimation of sleep latency and number of awakenings in primary 
insomnia has been said to be 25-50%97 but it also occurs to some extent in 
insomnia associated with depression. 
Armitage (1997)98 compared a group of healthy controls and a group of patients 
with major depression and their objective and subjective sleep measurements. 
They found SOL, and TST were well correlated in both controls and those with 
major depression, but number of awakenings, depth and sleep quality were not. 
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This was also shown in a more recent study comparing objective and subjective 
sleep measurements in major depression. 99 
There is debate as to whether there should be a separate diagnostic category of 
SMP. ISCD does classify sleep misperception as a subtype of primary insomnia 
but DSM1V does not. Reynolds et al (1991)10° argue that SMP represents one 
extreme of a continuum and accounts for only 5% of people with primary 
insomnia, and that diagnosis is often only based on a single PSG recording. 
However, Hauri and Wisbey (1992)101 compared subjective estimates of sleep 
time with objective measures derived from PSG and actigraphy within the 
primary insomnia subtypes, psychophysiological insomnia and sleep 
misperception. They found those with sleep misperception have more motor 
activity in bed during sleep and wakefulness than do individuals with a more 
obvious PSG defined form of insomnia. This may suggest conventional sleep 
measures may not reflect the nature of sleep disturbance afflicting the so-called 
subjective sleep sufferers. Bonnet (1997)102 showed that subjects with primary 
insomnia and sleep state misperception (SMP) had an increased metabolic rate, 
(although this was less so in the SMP group, ) compared to controls, again 
perhaps supporting evidence for a separate diagnostic group. 
Perlis (200 1)103 have shown that people with insomnia exhibit more high 
frequency EEG at or around sleep onset relative to good sleepers, whether this is 
due to physiological arousal or cortical arousal is unknown. They have shown 
that objective and subjective insomniacs have different EEG amplitude profiles 
or EEG sleep pathology by EEG spectral analysis and have shown that 
subjective insomniacs have greater alpha, sigma, and beta amplitude i. e. high 
frequency EEG is correlated with the extent of sleep misperception. 
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1.14 Multi-component cognitive behavioural therapy for insomnia 
Multi-component treatment of insomnia therefore includes some or all of the 
following: 
Sleep hygiene 








Sleep hygiene education targets health practices e. g. (diet, exercise, substance 
use) and environmental factors e. g. light, noise, temperature, and mattress that 
may be detrimental or beneficial to sleep. 
Stimulus control techniques 
Stimulus control therapy is based on the premise that insomnia is a conditioned 
response to temporal (bedtime) and environmental (bed/bedroom) cues that are 
usually associated with sleep. (See appendix 1 for more details of sleep hygiene 
and stimulus control techniques). 
69 
Cognitive therapy 
Cognitive therapy seeks to alter faulty beliefs and attitudes about sleep. The 
objective of cognitive therapy is to short circuit the vicious cycle of insomnia, 
emotional distress, dysfunctional cognitions and further sleep disturbances. 
Treatment targets for cognitive therapy include unrealistic sleep expectations 
e. g. "I must get 8 hours of sleep every night", misconceptions about the cause of 
insomnia e. g. my insomnia is entirely due to a chemical imbalance, 
amplifications of its consequences e. g. I can accomplish nothing after a poor 
night's sleep and performance anxiety resulting from excessive attempts at 
controlling the sleep process. Cognitive therapy consists of identifying patient- 
specific dysfunctional sleep cognitions, challenging their validity, and replacing 
them with more adaptive substitutes through the use of restructuring techniques 
such as reattribution training, de-catastrophizing, hypothesis testing, reappraisal, 
and attention shifting. 
Relaxation therapy 
Relaxation based therapies interventions are based on the observation that 
insomnia patients often display high levels of arousal both physiological and 
cognitive. Progressive muscular relaxation (a method of tensing and relaxing 
different muscle groups throughout the body, ) and biofeedback (a visual or 
auditory feedback is provided to the patient to control some pre-determined 
physiological parameters) seek to reduce somatic arousal e. g. muscle tension. 
(For further information on relaxation techniques please see appendix 1) 
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Imagery 
Attention focusing procedures such as imagery training104 and thought stopping 
are intended to lower pre-sleep cognitive arousal (e. g. intrusive thoughts, 
"racing mind. ") 
This involves focusing on a pleasant image or image of six common objects 
when patients cannot fall asleep. Patients can be asked to visualise the shape, 
colour, movement and texture of the common objects. 
Thought stopping 
Aims to interrupt unwanted pre sleep cognitive activity by instructing the 
patient to repeat sub vocally, the word "the " every 3 seconds ("articulatory 
suppression") or to say "stop" subvocally. 105(For further information please see 
appendix 1) 
Paradoxical intention techniques 
This method consists of persuading a patient to engage in his or her most feared 
behaviour i. e. staying awake. It is hoped that performance anxiety will be 
alleviated and sleep may come more easily. (For further examples please see 
appendix 1) 
Sleep restriction 
Sleep restriction therapy consists of curtailing the amount of time in bed to more 
nearly matching the subjective amount of time asleep. For example if a person 
reports sleeping an average of 5 hours per night out of 8 hours spent in bed the 
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initial prescribed sleep window from initial bedtime to final arising time would 
be 5 hours. Then the allowable time in bed is increased by 15-20 minutes for a 
given week when sleep efficiency exceeds 90%, decreased by the same amount 
of time when sleep efficiency is lower than 80% and kept stable when sleep 
efficiency is between 80-90%. Adjustments are made until optimal sleep 
duration is achieved. (For further details please see appendix 1) 
There have been some important meta-analyses and reviews in the last 10-15 
years of the non-pharmacological treatment of insomnia e. g. Morin 1994106 & 
1999107 and Murtagh & Greenwood. 108 The American Academy of Sleep 
Medicine Standards of Practice Committee have also published Practice 
Parameters for the non-pharmacological treatment of insomnia based on the 
1999 review by Morin and a further review of forty eight clinical trials 
regarding the efficacy of the non-pharmacological treatment of insomnia. 109 
The criteria for inclusion of a study in the 1999 review were, that the main 
diagnosis was insomnia, that one of the treatment conditions was non 
pharmacological, the dependent measures included sleep onset latency (SOL), 
number and/or duration of awakenings, Total Sleep Time (TST), or sleep 
quality, and the study design had a control/comparison condition or a clinical 
case series evaluating a well defined treatment modality with a minimum of 10 
clinical patients. It included 48 clinical trials and the two meta-analyses by 
Morin and Murtagh and Greenwood (see above). One hundred studies were 
identified but more than half were excluded as they did not meet the inclusion 
criteria. The main reasons for exclusion were that treatments were entirely 
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pharmacological, there were less than 10 patients or the subjects were of only 
college students. 
The main findings of Morin's review showed 70-80% of people treated with 
non-pharmacological interventions benefited from the treatment and that three 
treatments met the American Psychological Association criteria for empirically 
supported psychological treatments for insomnia. These were stimulus control, 
progressive muscular relaxation and paradoxical intention. 109 (Table 1.14) 
In absolute terms, these improvements are to decrease sleep onset latency to 30 
minutes (from baseline to post treatment) or below, and to increase total sleep 
time by 30 minutes (from baseline to post treatment). These changes were 
sustained for at least 6 months after treatment. 
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Standard: Level 1 and 11 generally accepted patient care strategy 
Stimulus control 
Guidelines: Level 11 and 111 moderate degree of clinical certainty 
Progressive muscular relaxation 
Paradoxical Intention 
Biofeedback 
Options: Inconclusive evidence 
Sleep Restriction 
Multicomponent Cognitive behavioural therapy 
Table 1.14: The ASSM recommendations for psychological treatment of 
insomnia treatment 1999 (levels of evidence based on Sackett'so) 
Note: Sleep Hygiene, Education, Imagery Training and Cognitive 
therapy had insufficient evidence to be recommended as a 
single therapy. 
In 2006 Morin et al updated their 1999 review with the results of studies from 
1998-2004.51 This review was of a further 37 studies, analysed in a separate 
paper, using the same inclusion criteria as the 1999 metaanalysis, i. e the main 
diagnosis was insomnia primary or co-morbid, at least one treatment option was 
psychological or behavioural, the study design was a randomised controlled 
trial, a non randomized group design, a clinical case series, or a single subject 
experimental design with more than ten subjects, and had at least one sleep 
parameter, as a dependent variable. There were five randomized clinical trials 
(grade 1 evidence) four of them using CBT, since 1998. (Table 1.15) 
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Treatment Study Findings 
CBT without Relaxation 
Relaxation 
Edinger 2001 CBT>Relaxation>Placebo 
Relaxation 
Sleep Restriction 
Lichstein 2001 Relaxation>Placebo 
Sleep Restriction >Placebo 
CBT without Relaxation Morin 1999 CBT> Placebo 
CBT with Relaxation (Group 
treatment) 
Espie 2001 CBT>Waiting List Control 
CBT with Relaxation Jacobs 2004 CBT> Placebo 
Table 1.15: Randomised clinical trials of CBT for primary insomnia 
from 1998-2004 (Grade 1 evidence trials) 
Findings backed up the original review with empirical evidence now supporting 
the use of the psychological treatments: stimulus control, progressive muscular 
relaxation, paradoxical intention, sleep restriction and cognitive behaviour 
therapy for primary insomnia. 
However there was little evidence to show if other complaints of people with 
insomnia e. g. daytime functioning were improved with treatments, this is 
because this is still an under researched area. There has also been shown to be 
improvements in insomnia of older adults, patients with chronic pain, cancer, 
alcohol dependence and older adults with medical or psychiatric disease using 
psychological and behavioural treatments as reviewed by the meta-analyses. 
The efficacy of psychological and behavioural interventions for insomnia in the 
context of hypnotic use was also reviewed and the use of psychological and 
behavioural treatments to support medication withdrawal. 
75 
Other aspects of both meta-analyses for the treatment of primary insomnia 
reviewed were: 
Single or multifaceted interventions 
In most of the literature there is a clear trend to combine two or more 
psychological treatments when treating insomnia. The most common 
combination involves an educational (sleep hygiene, ) behavioural, (stimulus 
control, sleep restriction, relaxation, ) and a cognitive therapy component, and is 
usually referred to as Cognitive Behavioural Therapy. Some studies can be 
grouped into the above without relaxation and others into a group without the 
cognitive therapy. There has been no isolation of each single treatment within 
the same study to measure the efficacy of each component. 
Treatment format 
Since the 1999 review there have been more studies carried out in a group 
format. There is however only one study comparing the relative efficacy of CBT 
implemented in a group or in individual sessions, or through self- help written 
materials combined with brief telephone consultations. "' There was no between 
group difference between any sleep measure. In the last few years there have 
been studies looking at self -help, telephone consultation and internet based 
treatment formats. ' 12 113 They have had improvements at the time of therapy but 
have shown falling off in improvements compared to face-face consultations. 
Type of therapist may also be less important as long as the therapist has 
undergone specific training. 114 
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Treatment duration 
No specific recommendations in the meta-analysis have been made but the 
average treatment time was 5.7 consultation visits over a mean treatment period 
of 6.5 weeks. 
Treatment durability 
A very robust finding is that treatment produced changes in sleep parameters are 
well maintained at short, 1-3 month follow up, intermediate, 6 month, and long 
term, 1 year follow up. (Most studies followed up patients 1 month after 
treatment. ) However, follow up after a year was rare and attrition rates do 
increase over time. 
1.15 Combination of behavioural and pharmacological therapies 
It is common clinical practice to provide general sleep hygiene guidelines along 
with a hypnotic drug when treating insomnia. 
Morin (1999)107 states that therapeutic gains in 4-8 weeks of treatment are 
comparable for behavioural, pharmacologic and combined treatment. 
Problems with meta-analyses in chronic insomnia are: 
(i) Incompatible study designs 
(ii) Different outcome measures 
(iii) Inconsistent criteria for the definition of insomnia 
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However, Smith 2002 115 have performed a more recent comparative meta- 
analysis of pharmacotherapy and behaviour therapy for short term, i. e. 2-5 
weeks, therapy of persistent insomnia. They compared 21 studies for primary 
insomnia where the outcome measures were sleep diaries. Behavioural 
treatments included stimulus control or sleep restriction and pharmacological 
agents included benzodiazepines, zopiclone, zolpidem and zaleplon. 
There were no differences in magnitude between pharmacological and 
behavioural treatments in the measures, number of awakenings, WASO, TST, 
and sleep quality, but behaviour therapy resulted in a greater reduction of SOL 
than pharmacotherapy. However, they concluded that overall behaviour therapy 
and pharmacotherapy produce similar short- term treatment outcomes in 
primary insomnia. 
Morin's 200651 review looks at five recent controlled studies comparing 
medication versus psychological therapies for primary insomnia. (Table 1.16) 
In summary the current evidence shows CBT is more effective for SOL and 
sleep quality while medication is more effective for TST and number of 
awakenings. 5' Also, recently Vallieres (2005) has carried out a small pilot study 
on patients with chronic insomnia to investigate how CBT and medication can 
be integrated to optimise treatment. Three sequences were investigated for 10 
weeks. CBT and zopiclone started together with the zopiclone discontinued 
after 5 weeks, medication alone, with the CBT then started after 5 weeks, and 
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CBT alone. Results showed patients who had CBT alone at the start of the study 
or with medication were most improved at three month follow up. 
As mentioned above the long-term follow-up (i. e. 6-24 months) of behavioural 
and pharmacological treatment modalities show that behavioural treatments 
retain their clinical benefits very well over time, whereas pharmacological 
treatment benefits tend to return to baseline values when the medication is 
discontinued. What is more uncertain is the long-term outcome of patients 
receiving a combined approach. Although it might be expected that a combined 
approach may be superior to either of its single components long-term, the 
evidence available indicates that patients receiving both hypnotic drugs and 
behaviour therapy assessed at 2 years later do not retain their clinical gains at 
follow up as well as those treated with behaviour therapy alone. ' 16 This could 
be a negative attributional effect. Patients treated with hypnotic drugs even 
when combined with a behavioural intervention may attribute sleep 
improvements to the drug alone and such attributions may undermine the 
development of appropriate coping skills or discontinuing the behaviour 
therapy. 
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Treatment Study Findings 
CBT vs Medication Morin 1999 Combined and Single 
(temazepam) vs Combined vs treatments>Placebo 
Placebo ? Combined better 
CBT vs Medication Jacobs 2004 All treatments improved TST 
(zolpidem) vs Combined vs but not difference between 
Placebo CDT group and combined 
treatment group 
Medication vs relaxation, Rosen 2000 No group difference on any 
imagery training, sleep outcome 
hygiene 
Modafinil vs CBT Perlis 2004 No improvement in sleep 
continuity but improved day- 
time alertness 
Benzodiazepine vs relaxation Waters 2003 Medication>all treatments 
vs stimulus control vs sleep 
restriction 
Table 1.16: Recent controlled studies comparing medication versus 
psychological therapies in insomnia 
1.16 Clinical significance of the treatment of insomnia 
This is the difference to a patient's life that the treatment of their insomnia 
makes rather than statistically significant improvements in objective sleep 
parameters, e. g. improved daytime performance, reduction in hypnotic usage, 
fatigue, mood, quality of life, improved concentration and memory. Do 
insomnia treatments make a real difference to the patient's everyday life? 
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Outcome measures in insomnia can be defined according to multiple 
measurement systems, e. g. subjective-sleep diaries, behavioural-actigraphy, and 
physiological-polysomnography. Daily sleep diaries remain the most widely 
used measure of sleep quality. Despite significant discrepancies between the 
subjective and objective polysomnographic measures in patients with insomnia, 
diaries do reflect on the subjective complaint and perception of sleep. 
Neuropsychological measures have sometimes been used to measure daytime 
functioning such as attention and concentration, information processing speed, 
reaction time and motor coordination, and quality of life measures are now 
being looked at to evaluate more fully the "functional status" of people with 
insomnia (discussed more fully in chapter 4). However, the current assessment 
tools may not be sensitive enough to detect the often subtle changes in daytime 
functioning related to insomnia. 
It is also important to consider that participants in Randomised Clinical Trials 
(RCTs) for chronic insomnia have sleep recordings in a hospital sleep 
laboratory, are often taken off their medication and are only looked at in a 
research setting. Espie (2001 a)1 14 has performed a randomised controlled trial of 
cognitive behavioural therapy for insomnia (group format) in a UK general 
practice setting together with a reduction in medication (see chapter 4). There 
has also been a similar community (but in an individual format) randomised 
CBT versus control trial for chronic insomnia carried out also in the context of 
trying to decrease long term hypnotic use in general practice (see chapter 4). 1 17 
They have both shown improvements in SOL, WASO and TST. 
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Espie has proposed that any realistic alternative to hypnotics must be available 
to patients simply, efficiently and locally. Psychologists arc often not trained or 
interested in sleep medicine and may not be available. They felt training health 
visitors in cognitive behaviour therapy (CBT) for insomnia would provide the 
most accessible and valid approach to managing insomnia in primary care 
settings and they have also looked at the improvements in a clinical significant 
way for insomnia sufferers (see chapter 4). 
There is still however little evidence that the psychological treatments for 
insomnia have any significant impact on daytime performance and 
psychological wellbeing. This is unfortunate as it is often daytime impairments 
in these areas that worry patients most and prompt them to seek treatment. The 
development of measurement of quality of life after psychological treatment for 
insomnia may help assess these areas further. 
The following chapter in this thesis, chapter 2, describe the sleep architecture 
effects of two antidepressants in patients with moderate to severe depression. 
The effects of antidepressants on sleep in discussed in detail in this introduction 
but chapter 2 describes extension of this knowledge with respect to the 
antidepressants nefazodone and paroxetine. 
Then, in the light of the knowledge of beneficial effects of nefazodone on sleep 
in depressed patients, it was decided to investigate whether nefazodone would 
have a similar effect on the sleep of patients with chronic insomnia. This is the 
work described in chapter 3. 
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In order to then include the psychological treatment of chronic insomnia it was 
decided to include the data from five "CBT for insomnia" treatment groups. The 
patients in these groups may have had primary insomnia or secondary insomnia, 
often due to a depressive illness, but chapter 4 brings together the results of the 
addition of psychological treatment to medication for this group of patients. 
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Chapter 2. 
A comparison of the effects on sleep in depressed patients of a 
serotonin antagonist/re-uptake inhibitor and a specific serotonin 
re-uptake inhibitor 
This study is a double blind placebo controlled trial, and compares the effects of 
two anti-depressants, nefazodone and paroxetine, on the sleep of patients with 
moderate to severe depression. Nefazodone was found, compared to paroxetine, 
to increase sleep efficiency, total sleep time and decrease number of awakenings 
as measured objectively by polysomnography. These effects were evident early 
in treatment, by day 3. 
My role in the study was to recruit patients and to check the scoring of all the 
PSG recordings after they had been scored by the computer (visual correction. ) I 
also analysed the data and wrote the paper for publication. 
2.1 Introduction 
Disturbed sleep is one of the most frequent and distressing symptoms in 
moderate and severe depression. It is an advantage for the patient if sleep can be 
improved even before the onset of antidepressant action. The use of 
conventional anti-depressants can have some unwelcome side effects. Tricyclic 
antidepressants (TCAs) can have immediate sleep promoting effects but there 
are other disadvantages to their use such as danger in overdose and anti- 
cholinergic side effects (see chapter one). The selective serotonin re-uptake 
inhibitors (SSRIs) are not sleep promoting and tend to exacerbate sleep 
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fragmentation acutely until there is a resolution because of improvement of the 
depressive illness. 32 
Nefazodone, a serotonin 2 antagonist/reuptake inhibitor (SARI), antagonises the 
reuptake of serotonin (5-HT) and noradrenaline (NA), but it also blocks the 
postsynaptic 5-HT2 receptor (see chapter! ). Nefazodone may be unique in that 
it does not appear to suppress REM sleep in either healthy controls or in 
depressed patients, as TCAs and SSRIs produce marked suppression of REM 
sleep (see chapter 1). By contrast, in two studies in normal volunteers 
nefazadone has caused an increase in REM sleep 4042 However, these results 
were not confirmed in two later studies also in healthy human volunteers. 8 118 
In normal volunteers nefazadone may also improve sleep continuity by either 
decreasing awake and movement time and decreasing number of awakenings42 
and this has also been shown in an open label study of nefazodone in depressed 
patients. 119 
The sleep effects and antidepressant efficacy of nefazodone compared to 
fluoxetine, a SSRI, have been compared in a multicentre trial in 125 patients 
with major depression. 37 Anti-depressant efficacy was comparable for both 
groups. With respect to sleep parameters, patients receiving nefazodone 
demonstrated increased sleep efficiency, and decreased number of awakenings 
while patients on fluoxetine demonstrated a significant decrease in sleep 
efficiency and a significant increase in number of awakenings compared to 
baseline scores. Patients taking nefazodone demonstrated an increase in total 
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REM sleep time in contrast to the expected REM suppression associated with 
fluoxetine treatment. 
This study was designed to compare the effects of nefazodone and paroxetine; 
another commonly used SSRI, on sleep and mood in patients with moderate to 
severe depression, without psychotic features. It also sought to examine the 
claim that nefazodone can improve sleep even before the onset of antidepressant 
action. It was the first drug trial comparing the effects of an SARI and SSRI to 
use recordings carried out at home rather than in a sleep laboratory. 
2.2 Method 
Patients 
40 depressed patients between 18 and 65 years were recruited. There were 17 
males and 23 females mean age 43. Patients were recruited from general 
practice, a psychiatry outpatient clinic, and regional mental health teams. They 
were screened with a full medical and psychiatric history, a mental state 
examination and a physical examination. Patients had to fulfil the diagnostic 
criteria for DSM IV (American Psychiatric Association 199445) moderate to 
severe depression, and score 18 or over on a Hamilton Depression Scale120 
(HRSD). (For example of this questionnaire please see appendix 2. ) 
Exclusion criteria included a history of schizophrenia, mania, active suicidal 
ideation, alcohol misuse and illicit drug use; patients unable to maintain a 
consistent sleep pattern e. g. shift workers or those with a current sleep/wake 
disorder; pregnant or nursing females and women of child-bearing age who 
were not taking adequate precautions against pregnancy; patients who had 
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participated in a clinical trial within 30 days of the study or were involved in 
another current clinical study at the time of assessment. Subjects who had 
previously taken psychoactive medication including benzodiazepines 
were required to undergo a two-week (or five weeks in the case of fluoxetine) 
washout period before entering the trial. There were six patients that had 
received benzodiazepines but none in the previous year. Four patients had 
received fluoxetine in the previous year with one ceasing for the study. 
Determination of sample size 
The sample size was calculated to detect the smallest clinically relevant 
differences in two sleep parameters (i. e. total sleep time and number of 
awakenings) measured by electroencephalogram with an 80% power at the 5% 
significance level based on variance data from a previous sleep study conducted 
in our laboratory. 121 The two-sample method was applied. The estimated sample 
size was 18 patients in each group providing valid data for at least three sleep 
assessments. The target sample size was extended to 22, to allow for drop-outs. 
Study Design 
The study used a double - blind, randomised, parallel group, single centre 
design. Patients gave written informed consent and the study was approved by 
the local research ethics committee. The acute phase of treatment either with 
paroxetine or nefazodone was 8 weeks, but patients who showed improvement 
on the Clinical Global Impression Improvement scale 122(CGI) continued to be 
studied clinically but without sleep measures for a further 16 weeks. (Please see 
appendix for an example of a CGI). 
87 
The initial daily doses of nefazodone and paroxetine were 200mg and 20mg 
respectively. Patients were assessed clinically at day 3, day 10, week 3, week 4, 
week 6 and week 8, and medication increased according to clinical response to 
the antidepressant. Nefazodone treated subjects were titrated to a dose between 
200-600mg a day while paroxetine treated subjects were titrated to a dose 
between 20-40mg a day. Subjects received 8 weeks of double-blind treatment. 
Equal numbers of patients were randomised to receive either nefazodone or 
paroxetine. Adverse events were monitored at each visit and recorded. No 
additional psychoactive medication was allowed during the washout and 
treatment phase of the study and all other non-psychological/non 
pharmacological medications were kept to a minimum if at all possible. Figure 
2.1 shows a schematic of study design. 
2.3 Measurement of sleep 
Objective measurement 
Polysomnogaphy is the gold standard method of measurement for obtaining 
information about timing and structure of sleep. The Rechtshaffen and Kaless 
report (see introduction) recommends minimum standards and methods of 
recording polysomnograms including specifications about recording equipment 
and electrode positions to be used. The report also recommends that assigning 
stages to sleep should be done using portions of recording (epochs) lasting 30 
seconds each, a convenient interval when paper recordings were used and an 
open two pages represented 30 seconds. 
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Procedure for obtaining overnight recordings 
Polysomnograms were recorded at home using the Medilog ambulatory system 
prior to treatment (baseline), night 3, night 10, and after 8 weeks of treatment. 
The recordings in this chapter were carried out by Dr Sue Wilson, Mrs Ann 
Rich and Dr Spilos Argyropoulos. 
Subjects were visited in their homes during the evening and the recording 
equipment was attached. After the electrode impedance and the input into the 
recorder was checked the subjects were then left to sleep normally. The patients 
were asked not to bathe or shower with the equipment on but were told that 
otherwise they could carry on with their normal domestic routine. They were 
instructed to keep to their normal bedtime routine and to press the event marker 
on the recorder when they turned out the lights and tried to go to sleep and on 
waking the following morning. They were visited the next morning and the 
equipment was removed. On the same day the cassette from the sleep recording 
system was checked for the presence and quality of recording. Thereafter tapes 
were stored until all recordings on that subject were finished and then they were 
analyzed blind to both date and treatment allocation. 
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Figure 2.1: Schematic of study design 
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Antidepressant Efficacy Baseline, day 3, day 10, weeks 3,4,6 and 8 
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Recording equipment 
The studies described in this thesis used the Medilog 9000-2 recorder, an 
ambulatory eight channel recorder with acquisition of the sleep recording on to 
an audiocassette. The recorder is small and may be worn attached to a belt 
while the subject is awake and moved to a position under the pillow at 
bedtime. The recording system allows for sensitivity of 5 µV/mm when 
displayed on replay with a bandwidth approximately 3dB down at 0.5 and 
30Hz. A conventional 90 minute audiotape will record for 15 hours using the 
geared-down tape transport system, and a 120 minute tape gives 24 hours. A 
reliable artifact reduction system minimizes airborne and movement-related 
artifacts. Monitoring of incoming signals from the subject may be carried out 
via a socket on the recorder in order that integrity of signal may be determined 
before leaving the patient. 
Electrodes 
The International 10-20 system of electrode placement was employed. 123 The 
minimum requirement for sleep staging is one channel of EEG (here C4-A1). 
In addition EEG channel C3-O1 was used. Electroculogram (EOG) were 
recorded from electrodes placed above and laterally to the right eye and below 
and laterally to the left eye, referred to A2 as a common reference. 
Electromyogram (EMG) was recorded from electrodes placed on the right and 
left chin. 
For the scalp recordings silver-silver chloride electrodes (Oxford Medical) 
were attached with collodion, the skin below scarified and the cup filled with 
electrode gel (Dracard) and then sealed over with collodion once impedance 
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was satisfactory. Electrodes on the face were disposable neonatal ECG 
electrodes (Medicotest) consisting of a small strip of chlorided silver to which 
electrode gel was applied, surrounded by adhesive foam and were applied to 
the skin with Skinpure (Nihon-Kohden) abrasive paste. Electrode impedances 
were measured using the Oxford Medical impedance meter and re-scarified if 
necessary until they were below 10 KE2 per pair. 
Replaying cassettes 
Cassette tapes were replayed on the Medilog 9200 replay system that displays 
successive 16 second sections of the recording on a computer screen. Sleep 
was scored at first automatically by the Medilog 9002. A sleep stage was 
assigned to each epoch i. e. each 30 seconds or 2 successive screens of data. 
Data were entered via the keyboard of a PC into a spreadsheet during replay at 
20 times real time, with appropriate stops for review. A hypnogram was then 
constructed in the spreadsheet and the following parameters were derived from 
the sleep recordings: 
(a) Staging time- the interval between the patient pressing the event markers 
(when these were omitted the sleep scorer judged these times from the EEG 
recording when the patient closed their eyes at night and when they opened 
them and started to move around the next morning). 
b) Total Sleep Time, (TST) time in all stages of sleep. 
c) Sleep Efficiency /oTotal Sleep Time/Total Staging time. 
d) Number of Awakenings were defined as those over 16 seconds in duration. 
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e) Sleep onset latency (SOL), the time from the patient pushing the button to 
start their night's sleep to the first two minutes of stage 2 sleep. 
f) Duration of Stage 1,2,3,4, and Rapid Eye Movement (REM) sleep (in 
minutes and as percentage of TST). 
g) REM onset latency, the time to the first continuous 2 minutes of REM from 
the onset of stage 2 sleep. 
h) Wakefulness after sleep onset (WASO) total time spent awake after sleep 
onset (in minutes). 
Automatic staging with visual correction 
This was carried out using the Medilog 9200 automatic staging system as 
above with visual correction by an experienced sleep scorer (Dr Jane Hicks). 
Although the Medilog system uses the Rechstaffen and Kales criteria 
correction of the automatic scoring by an experienced observer is necessary 
because misclassification of epochs can occur. 
Some of the reasons the automatic scoring system misclassifies data are 
enumerated below: 
1) REM can be overestimated due to the fact that EMG level is averaged over 
the night and in a subject that wakes a lot and therefore has a high average 
EMG, short term drops in EMG sufficient to cause a classification into REM 
are frequent and thus REM is over estimated. 
2) Stage I sleep is identified by the absence of alpha rhythm, high EMG, sleep 
spindles and delta activity, so quiet waking in a subject with little alpha rhythm 
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is confused with stage 1, and in a subject with poorly defined sleep spindles 
such as in depression, with stage 2. 
3) Some movement artifacts are confused with EEG delta activity particularly 
teeth grinding and scratching. 
It should also be emphasized that scoring according to the Rechtshsaffen and 
Kales criteria is difficult when examining a depressed patient's EEG. They 
have poorly defined sleep spindles and less obvious sleep stages. (Very 
recently there has been a new scoring system derived by the ASDA that may 
help to improve scoring criteria. ) 
In general, REM sleep, waking and stage 1 sleep show the least agreement 
with visual scoring and require the most correction. Once corrected this system 
produces a hypnogram and sleep statistics can be derived. 
Outcome Measures: 
Objective measurements 
Primary objective sleep variables were: 
Sleep Efficiency, Total Sleep Time and Number of Awakenings. 
Secondary sleep parameters were also measured. 
Subjective measurements 
Subjective measures of sleep used in this study were: 
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1) St Mary's Hospital Sleep questionnaire (SMHSQ) evaluations 124 were 
made on the mornings after the baseline night recordings. 
2) The SMHSQ and Leeds Sleep Evaluation Questionnaire (LSEQ) 125 
were performed at days 3 and 10 and week 8 of treatment after the 
overnight recording. 
3) The patients also kept a diary recording the quality of their sleep for the 
first 21 days of treatment 
(Copies of these questionnaires appendix 2) 
Answers to the SMHSQ were obtained on the morning after the baseline 
recording. Thereafter the SMHSQ and the LSEQ were performed at days 3 and 
10 and week 8 of treatment. Patients kept a diary of sleep quality and number 
of awakenings for the first 21 days of treatment. 
Subjective measures of depression, HRSD, Montgomery Asberg Depression 
ratings scale (MADRS), 126 and a Clinical Global Impression score (CGI)122 
were carried out at baseline, days 3,10, and weeks 3,4,6, and 8. Please see 
appendix 2 for copies of these questionnaires. 
2.4 Statistical Analysis 
Statistical Analysis of the objective sleep data was carried out using STATA 
version 7.0 for Windows 127. Information on the variables was collected at 
baseline and at three time points after initiation of the therapy (i. e. day 3, day 
10 and week 8). Descriptive statistics were derived for each of the variables. 
Tests for normality showed that the variables stage 1, stage 3, sleep onset 
latency, REM onset latency, and wakefulness after sleep onset were not 
normally distributed. The values for stage 1 sleep and sleep onset latency, and 
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wakefulness after sleep onset were normalized by logarithmic transformation, 
whereas it was necessary to use the square roots of the values for stage 3 sleep, 
REM onset latency, and wakefulness after sleep onset to produce normally 
distributed data. Complete data sets i. e. four sleep assessments, were available 
on 29 individuals and this resulted in an unbalanced design. Consequently a 
sequential fitting of the different sum of squares was used. Split plot analysis 
of variance, (split plot ANOVA) was used to investigate the effects of the two 
drugs on all the sleep variables. This analysis separates the variance ascribable 
to pre-treatment differences between the two treatment groups, due to the 
effect of time, due to the interaction between time and treatment and due to the 
effect of the treatments themselves. 
Dr Spilios Argyropoulos analysed the subjective data and is a co-author on 
the paper which details the results of this study (see appendix). 128 As regards 
the subjective sleep data, descriptive statistics, comparison tests at days 3,10 
and week 8 and ANOVA were performed on the scores of LSEQ, the items 5, 
6,9-11 and 13 of SMHSQ and the sleep items of the HSRD. Values from the 
daily diary of sleep quality were analyzed with descriptive statistics and 
scrutinized for possible trends in the data. An average score for each week of 
the study was compared for the two groups. 
Data from HRSD, MADRS and CGI severity and improvement scales were 
tabulated using both the observed values and with last observation carried 
forward (LOCF) in the whole (intent to treat; ITT) group. Number of 
responders (50% or more reduction on baseline IISRD) and remitters (HSRD 
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less than or equal to 8) were tabulated for each treatment group. Total scores 
for the rating scales were analyzed using ANOVA, first at baseline and on the 
change from baseline at the end of the specific weeks and end-point (subject's 
last available observation). 
Adverse events were cross-tabulated by treatment, severity and clinical 
estimate of relation to study medication, to detect any evidence of drug-related 
trends or increased incidence. 
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2.5 Results 
Forty patients (23 females, 17 males) were randomised to nefazodone (n=20) 
or Paroxetine (n=20). Demographic data and past psychiatric history data, 
including co-morbidity, are presented in Table 2.1. There were no significant 
differences between the groups in these variables. The number of patients that 
completed the study and the reasons for early discontinuation are presented in 
Table 2.2 
Table 2.1: Baseline demographic and clinical data 
Baseline Characteristic Nefazodone (n = 
20) 
Paroxetinc (n = 
20) 
Age (years) (mean, s. d. ) 42.75 (11.93) 42.95 (10.12) 
Median (range) 46 (18-62) 44.5 (23-59) 
Male (%) 8 (40) 9 (45) 
Women (%) 12 (60) 11(55) 
Past History of Depression (%) 12 (60) 11(55) 
Previous anti-depressants (%) 16 (80) 13 (65) 
Number of previous episodes (mean, s. d. ) 2.11 (3.75) 2 (4.01) 
Age at onset of first episode (years) (mean, 
s. d. ) 
32.11 (13.09) 31.6 (12.34) 
Length of previous episodes (weeks) 
(mean, s. d. ) 
23.33 (16.91) 37.33 (27.39) 
Length of current episode (weeks) (mean, 
s. d. ) 
50.65 (57.80) 42.6 (45.75) 
Co-morbidity (%) 
Dysthymia 4 (20) 200) 
Anxiety Disorders 5 (25) 2 (10) 
Chronic Physical Conditions 2 10) 5(25) 
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Table 2.2: Reasons for discontinuing study 
Reason for 
discontinuation 
Nefazodone 8 week 
sleep study 
Paroxetine 8 week 
sleep study 
Completed study (%) 15 (75) 17(85) 
Non-completers (%) 
Adverse experience 4 (20) 1(5) 
Lost to follow-up 1 (5) 
Lack of efficacy 2 (10) 
Total discontinuations 5 (25) 3(15) 
Patients excluded from the analysis were: 
Patient 1- because they only completed the baseline assessment. 
Patient 12 - completed baseline and day 3 assessments, but the day 10 
recording was technically unsatisfactory. 
Patient 18 - because the baseline recording was technically unsatisfactory. 
In addition, patient 15's day 3 recording was technically unsatisfactory but 
baseline, day 10 and week 8 were included. Patients 7,10,11,25 and 27 had no 
week 8 recording as they left the study. In the paroxetine group, 4 patients at 
day 3 and 1 patient at day 10 had no REM sleep at all. In these patients the 
REM latency was taken to be the staging time minus sleep onset latency. 
The mean nefazodone dose (standard deviation) used in the study was 
495mg/day (82.6) and for paroxetine it was 29.5mg/day (8.9). These doses 
were well within the therapeutic range advised for these drugs for the treatment 
of depression 
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Objective sleep data 
Table 2.3 shows the polysomnographic data of sleep parameters: sleep 
initiation, length, maintenance and sleep architecture with the results of the 
split plot ANOVA statistical analysis. 
There were significant pre-treatment differences between the two treatment 
groups on nearly all the sleep measures with sleep in the paroxetine group 
being generally worse. These pre-treatment differences occurred entirely by 
chance because treatment allocation was random. As described in the methods 
section, this baseline difference was taken into account when assessing the 
treatment effects by using the split-plot ANOVA. 
There were significant treatment effects on total sleep time, sleep efficiency, 
number of awakenings, wakefulness after sleep onset, stage 1 sleep, REM 
latency, and REM sleep (see figures 2.2-2.8). There were non-significant drug 
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Figure 2.2: Total Sleep Time 
Results of Split-plot ANOVA of total sleep times - Nefazodone vs Paroxetine, 
and graph of mean total sleep times at baseline, day 3, day 10 and week 8. 
Source Seq. SS Df MS F Prob >F 
Model 171422.39 32 5356.95 1.73 0.037 
Pre-treat 42830.27 1 42830.27 11.69 <0.005 
Treatment 18500.96 1 18500.96 5.05 < 0.05 
Error (1) 95249.16 26 3663.43 1.18 0.30 
Time 7021.45 2 3510.72 1.13 0.33 
Time*treat 7820.55 2 3910.27 1.26 0.29 
Error (2) 167193.34 54 3096.17 
Total 338615.72 86 3937.39 
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Figure 2.3: Mean sleep efficiency 
Results of Split-plot ANOVA of sleep efficiency - Nefazodone vs Paroxetine, 
and graph of mean sleep efficiency at baseline, day 3, day 10 and week 8. 
Source Seq. SS Df MS F Prob >F 
Model 6074.33 32 189.82 2.05 0.0098 
Pre-treat 1184.3 1 1184.3 9.98 < 0.005 
Treatment 1362.9 1 1362.9 11.49 < 0.005 
Error (1) 3084.5 26 118.6 1.28 0.22 
Time 144.89 2 72.45 0.78 0.46 
Time*treat 297.79 2 148.90 1.61 0.21 
Error (2) 4999.67 54 92.59 
Total 11073.99 86 128.77 








Figure 2.4: Number of Awakenings 
Results of Split-plot ANOVA of number of awakenings - Nefazodone vs 
Paroxetine, and graph of mean number of awakenings at baseline, day 3, day 
10 and week 8. 
Source Seq. SS Df MS F Prob >F 
Model 5656.65 32 176.77 3.5 0.0000 
Pre-treat 1593.99 1 1593.99 16.8 < 0.001 
Treatment 712.07 1 712.07 7.51 < 0.025 
Error (1) 2466.66 26 94.87 1.88 0.025 
Time 510.44 2 255.22 5.06 0.0097 
Time*treat 373.50 2 186.75 3.7 0.031 
Error (2) 2724.07 54 50.45 
Total 8380.71 86 97.45 
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Figure 2.5: REM Onset Latency 
Results of Split-plot ANOVA of REM onset latency - Nefazodone vs 
Paroxetine, and graph of mean REM onset latency at baseline, day 3, day 10 
and week 
Source Seq. SS Df MS F Prob >F 
Model 1405.05 32 43.91 4.95 0.0001 
Pre-treat 15.86 1 15.86 1.89 n. s. 
Treatment 1113.69 1 1113.69 133.05 < 0.001 
Error (1) 217.67 26 8.37 0.94 0.55 
Time 15.47 2 7.74 0.87 0.42 
Time*treat 42.36 2 21.18 2.39 0.10 
Error (2) 479.14 54 8.87 
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Figure 2.6: Stage I sleep 
Results of Split-plot ANOVA of Stage 1 sleep - Nefazodone vs Paroxetine, 
and graph of mean Stage 1 sleep at baseline, day 3, day 10 and week 8. 
Source Seq. SS Df MS F Prob >F 
Model 37.33 32 1.17 5.33 0.0001 
Pre-treat 12.31 1 12.31 17.9 < 0.001 
Treatment 4.24 1 4.24 6.33 < 0.025 
Error (1) 17.47 26 0.67 3.07 0.0002 
Time 1.16 2 0.58 2.66 0.079 
Time*treat 2.14 2 1.07 4.88 0.011 
Error (2) 11.81 54 0.22 
Total 49.14 86 0.57 
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Figure 2.7: WASO 
Results of Split-plot ANOVA of Wakefulness after sleep onset (WASO )- 
Nefazodone vs Paroxetine, and graph of mean WASO at baseline, day 3, day 
10 and week 8. 
Source Seq. SS Df MS F Prob >F 
Model 566.89 32 17.72 2.62 0.0009 
Pre-treat 141.19 1 141.19 11.9 < 0.005 
Treatment 85.01 1 85.01 7.2 < 0.025 
Error (1) 308.36 26 11.86 1.76 0.041 
Time 16.66 2 8.33 1.23 0.30 
Time*treat 15.68 2 7.84 1.16 0.32 
Error (2) 364.52 54 6.75 
Total 931.41 86 10.83 
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Figure 2.8: REM sleep 
Results of Split-plot ANOVA of total REM sleep - Nefazodone vs Paroxetinc, 
and graph of mean total REM sleep at baseline, day 3, day 10 and week 8. 
Source Seq. SS Df MS F Prob >F 
Model 91821.75 32 2869.43 2.39 0.0023 
Pre-treat 695.17 1 695.17 0.49 n. s. 
Treatment 41623.23 1 41623.23 29.4 < 0.001 
Error (1) 36878.04 26 1418.39 1.18 0.30 
Time 6778.55 2 3389.28 2.82 0.068 
Time*treat 5846.76 2 2923.38 2.43 0.097 
Error (2) 64903.36 54 1201.91 
Total 156725.10 86 1822.38 
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Figures 2.2,2.3 and 2.7 demonstrate the significant drug effects on total sleep 
time, sleep efficiency, and wakefulness after sleep onset, with nefazodonc 
improving these and paroxetine worsening them early in treatment but both 
drug groups returning towards baseline by 8 weeks. 
Number of awakenings (Figure 2.4) and Stage 1 sleep (Figure 2.6) also showed 
significant treatment effects and these were more obvious at 8 weeks, with 
both measures being increased in the paroxetine group. Number of awakenings 
showed a significant time x treatment effect, with the differences between the 
two treatment groups increasing as time on treatment increased. There was a 
similar time x treatment interaction on stage 1 sleep with the paroxetine group 
having significantly more stage 1 sleep over time when compared to the 
nefazodone group. 
There were highly significant treatment differences on REM sleep, with 
paroxetine increasing REM latency and decreasing the total amount of REM 
sleep throughout the 8 weeks of treatment. Figure 2.5 shows that paroxctine 
dramatically increased REM latency by day 3 of treatment whereas the 
nefazodone group showed a slight decrease in REM latency and that this 
difference between the two treatment groups was maintained throughout the 
trial period. Figure 2.8 shows that the paroxetine group had a rapid reduction in 
the total amount of REM sleep by Day 3 whereas the nefazodone group had a 
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modest increase in REM sleep. The differences in total REM sleep time 
between the two groups tended to decrease over the 8 weeks of the trial. 
Neither slow wave sleep nor stage 2 sleep showed significant time or group 
differences. 
Subjective sleep data 
Subjective data from the SMHSQ were not distributed normally and there was 
a significant difference between the two treatment groups at baseline. 
Changes from baseline scores were derived for all patients and these were 
found to be distributed normally and thereafter used in subsequent testing. A 
significant difference was found at night 3 for sleep quality (item 5: how well 
did you sleep? t=2.12, d. f. = 36, p=0.04) with the nefazodone group showing 
greater improvement from baseline. On the ANOVA there was a treatment 
effect for sleep quality (p = 0.042) and for sleep depth (p = 0.042) with the 
nefazodone group showing more improved scores on both. 
There was no significant treatment effect on the variables of LSEQ. The four 
factors of the LSEQ are: 
Factor 1: Getting to Sleep 
Factor 2: Sleep Quality (a higher score shows a worse quality of sleep) 
Factor 3: Morning Tiredness 
Factor 4: Behaviour on Awakening (clumsiness and tiredness in the morning) 
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Factor 4 "Behaviour on Awakening" showed a trend for less clumsiness and 
tiredness in the morning with paroxetine but more with nefazodone. The 
differences from baseline, however, were small. The week-by-week analysis of 
the sleep diary averages for sleep quality (how well I slept) and continuity 
(how many times did you wake up? ) and the HSRD sleep items were not 
significantly different in the two groups. 
Adverse Events 
There were no serious adverse events related to either of the medications. One 
patient on paroxetine was hospitalized for worsening of her primary diagnosis 
of depression and emerging suicidal ideation, following the day 3 visit. The 
randomization code was broken and the patient was continued on open-label 
paroxetine and made a good recovery. Table 2.4 shows the non-serious side- 
effects attributable to the medications. These were similar to those described in 
previous reports. 
Anti-depressant efficacy 
Response was defined as a 50% or greater reduction from the initial I-IRSD 
score, whereas remission was defined as a final IISRD score of 8 or less. 
There was no significant difference between the two medications in these 
variables. At week 8,11 patients on nefazodone and 16 patients on paroxetine 
were responding to treatment. At the end of the 24-week study, a total of 12 in 
the nefazodone group and 14 in the paroxetine group had responded to 
treatment, while 9 patients on nefazodone and 12 patients on paroxetine were 
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classified as remitters. Between 8 and 24 weeks, 2 patients in the paroxetine 
had experienced a worsening of depressive symptoms. 
There were no significant differences between the two drugs in IISRD, 
MADRS, CGI Severity and Improvement scales, either on observed data or on 
Last Observation Carried Forward (LOCF) data. Data from the MADRS 
questionnaire, (which has only one question about sleep, ) were as follows 
(observed cases): nefazodone group baseline 27.5 (s. d. = 4.1), 8 weeks 13.0 
(s. d. = 7.7); paroxetine group baseline 27.1 (s. d. = 3.5), 8 weeks 8.4 (s. d. = 
6.2). 
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Table 2.4: Number of non-serious adverse events occurring in more than 
5% of patients (% of patients reporting) 
Type of adverse event Nefazodone Paroxctine 
Stomach upset, nausea, vomiting, diarrhoea 13 (40) 25 (65) 
Headache, migraine 15 (50) 15(50) 
Tiredness, asthenia 9 (40) 13(55) 
Drowsiness, sedation 11(40) 5 (25) 
Dry mouth 6(25) 7(35) 
Dizziness 5 (25) 3(15) 
Flu-like symptoms 2 (10) 4 (15) 
Unsteadiness, giddiness, ataxia 6 (25) 3(15) 
Sweating 0 7 (35) 
Sexual dysfunction 0 5 (20) 
Light-heartedness, spaced-out feeling 1 (5) 4 (20) 
Rash, itching 1 (5) 4 (20) 
Tremor, Shakiness 0 4 (20) 
Constipation 1 (5) 3 (15) 
Other (each reported in only one patient) 13 12 
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2.5 Discussion 
Baseline sleep architecture changes in these depressed patients, compared to 
normal sleepers, were low TST and sleep efficiency, shortened REM latency 
and increased Stage 1 sleep. This was to be expected. However the two groups 
sleep parameters were different at baseline with patients in the paroxetine 
group having poorer sleep . 
There were statistically significant differences between patients prescribed 
nefazodone and paroxetine (taking into account pre-treatment differences 
between the two groups). Patients taking nefazodone had increased total sleep 
time, increased sleep efficiency and decreased number of awakenings 
compared to those taking paroxetine. These findings were evident early in 
treatment i. e. from day 3. 
Rush (1998), in a multi centred trial compared the effects of nefazodone and 
fluoxetine on the sleep of outpatients with major depressive disorder at 2,4, 
and 8 weeks of treatment. 7 They found nefazodone and fluoxetine were 
equally effective in reducing depressive symptoms, but nefazodone increased 
sleep efficiency and reduced the number of awakenings over the 8 weeks of 
treatment. Fluoxetine but not nefazodone, prolonged REM latency and 
suppressed REM sleep. They also showed patients taking nefazodone had less 
stage 1 sleep compared to patients taking fluoxetine. Our results arc similar to 
this trial's findings except that the differences in this data at 8 weeks are less 
marked. Only the number of awakenings and amount of stage I sleep were 
higher at this stage in the paroxetine group than the nefazodone group and the 
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sleep onset latency in the nefazodone group was shorter. One explanation for 
this observation is that paroxetine has a less disturbing effect than fluoxctinc 
on sleep in longer term treatment. 
The results above, that of Rush (1998)37 and previous work on depressed 
patients 119 and healthy volunteers 3840 have shown similar effects of 
nefazodone on REM sleep, i. e. that nefazodone does not suppress REM sleep 
or increase REM latency. Rush 1998 showed nefazodone increased REM sleep 
compared to fluoxetine. Table 2.5 shows a summary of the effects of 
nefazodone on sleep architecture in published work. 
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Table 2.5 Published studies of the effects of nefazodone compared to 
placebo. fluoxetine or paroxetine on sleep architecture in normal or 
depressed patients. 
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How does nefazodone work to improve depression and promoting sleep? It has 
weak antagonist activity at alpha one adrenoreceptors which could lead to the 
increase in REM sleep in some of the reported studies above, but its alpha 
antagonist receptor properties are weaker than trazodone's which decreases 
REM sleep. mCPP, one of nefazodone's metabolite also decreases REM sleep. 
Nefazodone's weak alpha one antagonist receptor blocking properties may 
account for its role in improving sleep continuity, and its role in decreasing 
awakenings could be that its 5HT reuptake blocking effects are compensated 
by its 5HT2A/2C receptor agonist activity. However, nefazodone's role in not 
suppressing REM sleep like most antidepressants remains unexplained. 
Subjective sleep quality and depth of sleep was increased in patients taking 
nefazodone early in treatment. This difference then decreased as treatment 
progressed and was not statistically significant at 8 weeks. There may be some 
sleep promoting effect of nefazodone, or the SSRI's sleep disturbing effect 
may be diminished as neuro-adaptive changes take place in the brain as the 
patient takes it for longer. Also as patients depression improves their reporting 
of clinical complaints may decrease despite continuing objective sleep 
disruption. 121 
Nefazodone has been shown in this trial and that of the multi"ccntered trial of 
Rush to improve TST, sleep efficiency and decrease number of awakenings 
compared to the SSRIs, fluoxetine and paroxetine. A newly presenting 
depressed patient may therefore benefit from commencing nefazodone rather 
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than fluoxetine or paroxetine if sleep complaints are a prominent symptom. 
The beneficial effects of nefazodone compared to paroxetine at only day 3 of 
treatment are evident in these results for TST and sleep efficiency which could 
help alleviate symptoms quickly in a sleep deprived depressed patient. One of 
the limitations of this study however is that there was no control group 
although the two drugs were directly compared against each other. 
Since 2003 nefazodone has only been available on a named-patient basis in the 
UK. It has been associated rarely with hepatotoxicity. The incidence of death 
from liver failure under nefazodone is reported to be 1 in 250,000 to 300,000 
patient years of treatment, which is greater than the general population. This 
has therefore resulted in a switch to the prescribing of trazodone, nefazodone's 
sister drug which has shown sedative effects in depression'29 but may have 
more problem with side effects, which include sedation, dizziness and 
psychomotor impairment and priapism. The incidence of priapism is between 1 
in 1000 and Iin 10,000130 and has been shown to occur more frequently with 
trazodone than nefazodone 40 
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Chapter 3 
Does Nefazodone improve sleep in primary insomnia? A 
presentation of objective and subjective data. 
This second study describes a cross over trial that investigates whether 
nefazodone compared to placebo has beneficial effects on sleep in patients 
with primary insomnia. 
Nefazodone was not found, compared to placebo, to increase sleep efficiency, 
total sleep time or decrease number of awakenings in patients with primary 
insomnia. 
My role was recruitment of patients performance of the EEG recordings at 
patients homes, visual correction of the PSG recordings after they had been 
scored by the computer, analysis of the results and write up for this chapter. 
3.1 Introduction 
The use of the more sedating antidepressants as treatment for insomnia has not 
been sufficiently supported by clinical trials. Some antidepressants are used in 
clinical practice to promote sleep in patients with insomnia but without signs 
and symptoms of clinical depression. However this practice is anecdotal and is 
not backed up by published research in the literature. There is only a small 
amount of evidence from randomized placebo controlled trials showing 
efficacy for doxepin131 and trimipramine'32 and paroxetine133 in patients with 
primary insomnia. The antidepressant trazodone is also used in primary 
insomnia. In open label studies beneficial effects of trazodone on the sleep in 
healthy young adults 134 have been shown but there have been no controlled 
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trials of its use in primary insomnia. This is perhaps surprising as it is now 
quite widely used for primary insomnia or insomnia secondary to depression. 
The considerable effects on sleep of antidepressants (see chapter one) can be 
demonstrated in healthy and depressed patients. The properties of 
antidepressants thought to improve sleep are: 
(i) Antihistaminergic action e. g. sedating tricyclics such as triimipramine, 
trazodone (nefazodone has a weaker anti-histaminergic action), and 
mirtazapine 
(ii) 5HT 2 receptor antagonism e. g. amitriptyline, nefazodone, trazodone, and 
mirtazapine 
(iii) Inhibition of the alpha one adrenergic receptor e. g. trazodone (weaker 
action, nefazodone) 
The use of nefazodone as a hypnotic in insomnia has also not been fully 
investigated. As discussed in chapter two, there have been two studies in 
normal volunteers in which nefazodone has caused an increase in REM sleep 40 
42 However, these results were not confirmed by Vogel (1998). 118 In depressed 
patients nefazodone also exerts minimal effects on sleep continuity, as opposed 
to SSRIs, by increasing sleep efficiency, decreasing awake and movement time 
and decreasing number of awakenings or by not affecting these parameters. 7 
119128 These studies also found a possible increase in REM sleep and unaltered 
REM latencies in contrast to the clear REM sleep suppression and increased 
ROL under SSRI treatment. 
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There has been one open label study, in primary (psychophysiological) 
insomnia, investigating the effect of nefazodone on sleep in 32 patients. 135 
Patients met the DSM 1V (1994) criteria for primary insomnia and 
simultaneously the ISCD (1997) criteria for psychophysiological insomnia, 
therefore denoting a form of chronic insomnia without underlying medical or 
psychiatric disease. Patients with depression were included if they scored over 
15 on the Hamilton Anxiety and Depression (HAM-D). They underwent two 
baseline polysomnographs on consecutive nights, after fourteen days free from 
any medication with central nervous system action. The patients then took 100- 
400mg of nefazodone daily before bedtime (the dose was increased after 5 or 
10 days depending on efficacy and tolerability of the drug. ) After 27 and 28 
days two further sleep recordings were performed. Subjective sleep 
measurements were assessed using the Pittsburgh Sleep Quality Index (PSQI) 
136, and a" Morning Questionnaire" on the previous night's sleep. 
Comparing night 2 and night 28 the polysomnographic data showed significant 
increases in SOL, stage 2 and REM sleep. Number of awakenings and stage 
one were significantly decreased. However, TST and sleep efficiency and 
REM onset latency were not significantly increased. There were however 
significant improvements in PSQI total scores and all subscales except for 
subscale 2 (sleep latency) improved significantly from baseline to night 28 
under treatment. 
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The trial described in this chapter had a crossover design comparing 
nefazodone 100mg daily taken before bedtime with placebo in 10 patients to 
investigate whether nefazodone was associated with any objective or 




Patients were selected who were aged between 18 and 65 years, who met the 
diagnostic criteria for primary insomnia (International Classification of Sleep 
Disorders 2001) and who had no current history of depression. Patients were 
excluded if they were taking other psychotropic medications, were allergic to 
nefazodone, had current or past mental illness within the last year, or who had 
current substance abuse problems. 
This was a double blind crossover study to look at the effects of nefazodone on 
sleep in primary insomnia. Patients were given a two week washout from any 
psychotropic medication. Ten patients were randomized to start nefazodone or 
placebo for two weeks. After a two-week washout period, they crossed over to 
either nefazodone or placebo for a further two weeks of treatment. 
Objective sleep measurement 
At the end of each of the two-week treatment periods overnight sleep was 
measured at home by polysomnography. The Medilog 9000-2 system was used 
to measure the EEG using the montage (C4-A1, C3-01). The methodology for 
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collecting objective sleep data mirrored exactly that used in the ncfazodonc 
and paroxetine in depression study described in Chapter 2. The main outcome 
variables were the objective sleep parameters (Sleep Efficiency, TST, and 
number of awakenings) as in Chapter 2. Other sleep parameters were also 
measured. Automatic scoring with visual correction (by JAH) was also applied 
as in chapter 2. 
Subjective sleep measurements 
The following subjective sleep measures were used: 
1. St Mary's Sleep Questionnaire (Please see appendix for copy) 
2. Leeds Sleep Questionnaire (Please see appendix for copy) 
Both questionnaires were completed on the morning after each objective sleep 
measurement. 
3. Sleep diaries were also completed for each night of the treatment periods. 
Each subject had by the end of the study completed a sleep diary for 2 weeks 
while on medication and for 2 weeks while on placebo. 
Determination of sample size 
If objective and subjective sleep measures are compared between each 
treatment period using paired t tests, a sample size of 10 patients has 92% 
power at the 5% significance level to detect a 10% difference in mean total 
sleep time between drugs. 
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3.3 Statistical Analysis 
Paired t tests or Wilcoxon Sign Rank tests were performed to compare the 
objective data and subjective data when the patients were on nefazodone 
compared to placebo. 
3.4 Results 
Objective Results 
All sleep parameters except SOL, ROL, WASO and Number of awakenings 
were normally distributed. A paired t test was carried out on the normally 
distributed data (see Table 3.1) and a Wilcoxon Sign Rank on the non- 
normally distributed data (see Table 3.2). Data shown here is for TST, Sleep 
efficiency, and number of awakenings. (The other objective sleep parameter 
data is available in the appendix 3. ) Figures 3.1,3.2, and 3.4 graphically 
portray in bar charts the primary outcome varaiables, Total sleep time (TST), 
Sleep efficiency, and Number of awakenings on nefazadone versus placebo. 
(Figure 3.3 of SOL is in appendix 3. ) Patient 6's placebo recording was not 
analyzed due to poor tape quality. It should be noted that all sleep efficiencies 
were above 60% and the majority of sleep efficiencies were above 80%. There 
was no significant change in any sleep parameters comparing nefazodone 
treatment with placebo. 
»z 
Sleep Nefazodone Placebo Mean Standard t P value 
Parameter (Mean value (Mean Difference Deviation statistic 
for whole value for (paired 
group) n=10 whole t test) 
group) 
n=10 
TST (min) 405.7 390.3 -15.4 74.8 -15.4 ns 
Sleep 85.9 82.7 -3.2 9.0 -3.2 ns 
Efficiency(%) 
Slp eff N sleep efficiency SOL =sleep onset latency ROL= REM onset latency 
SD =standard deviation of the difference df - degrees of freedom ns - non- 
significant 
Table 3.1: Paired t test Results 
Nefazodone Placebo z value P value 
(Mean value (Mean value 
for whole for whole 
group) n=10 group) n=9 
except for SOL 
when n=10 
Number of 14.8 15.1 0.3 ns 
Awakenings 
Table 3.2: Wilcoxon Sign Rank Test Results 
»a 




















  Sleep Eff Placebo 



















  Number Awakenings Placebo 
  Number Awakenings 
Nefazodone 
Table 3.3 tabulates the results and statistical analysis of the St Mary's Hospital 
Questionnaire. Figure 3.8 shows "how well you slept data. " (Please see 
appendix 3 for other graphs of SMHQ data, Figures 3.5-7) but there were no 
significant differences for any of the SMHQ Questionnaire scores when 
















SD t statistic p value 
SOL (mins) -48 74 26 93.4 0.9 ns 
Depth 4.0 3.7 -0.3 2.1 0.7 ns 
Awakenings 2.6 2.9 -0.3 1.9 0.6 ns 
How much 
(mins) 
281.5 294 12.5 135.2 42.8 ns 
How well 3.1 3.5 0.4 1.4 0.5 ns 
Clear -3.5 3.6 0.1 1.0 0.3 ns 
Satisfied -2.5 3.2 0.7 1.7 0.5 ns 
Difficult -1.8 1.9 0.1 1.3 0.4 ns 
How long to 
sleep (mins) 
-54.5 91 36.5 91.0 29.0 ns 
Table 3.3: Results of St Mary's Hospital Questionnaire 
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Table 3.4 tabulates the results and statistical analysis of the Leeds Sleep 
Questionnaire. Figures 3.9 to 3.12, (please see appendix 3, ) graphically present 
the results for the subjective sleep variables "Getting to sleep", "Sleep 
Quality", "Morning Tiredness" and "Behaviour on Awakening". There were 
no significant differences for any of the Leeds Sleep Questionnaire scores 
when comparing nefazodone and placebo. Note that Patient 8 did not complete 
the Leeds sleep questionnaire on the placebo night. 
I)Q 
Factor Nefazodone Placebo Mean SD t statistic p value 
(Mean value (Mean Difference 
for whole value for 
group) n=9 whole 
group) n=10 
Factor 1 39.1 46.3 7.1 14.3 1.3 ns 
Getting to 
Sleep 
Factor 2 Sleep 44.7 42.8 1.9 22.9 0.3 ns 
Quality 
Factor 3 47.8 46.8 1.0 23.7 0.1 ns 
Morning 
Tiredness 
Factor 4 49.6 48.7 0.89 12.3 0.2 ns 
Behaviour on 
Awakening 
Table 3.4: Leeds Sleep Questionnaire Results 
(A higher score on the Sleep quality factor of the LSQ represents worse sleep. ) 
Sleep Diaries 
Sleep Diaries were completed for the 14 days of treatment with nefazodone or 
placebo. Table 3.5 tabulates the statistical analysis and results of sleep diary 
data. The three variables, "Sleep Onset Latency", "Total Sleep Time", and 
"Sleep Quality" were analyzed. There were no statistically significant 
differences between results for nefazodone and placebo. Figures 3.13-3.15 
graphically depict the same data. 
1')Q 
Mean Mean Mean SD t statistic p value 
Nefazodone Placebo Difference 
day 1-14 day 1-14 
SOL (m ins) 93.7 86.7 -7.0 60.7 -0.4 ns 
TST (mins) 289.8 305 15.2 36.0 1.3 ns 
Sleep 4.7 4.9 0.2 1.1 0.4 ns 
quality 
Table 3.5: Sleep Diary Data 
Figure 3.13: Sleep Diary (means dayl-14) Sleep Onset Latency 
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Figure 3.14: Sleep Diary (means day 1-14) Total Sleep Tlme(TST) 
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Treatment effect Day 1-14 
In order to establish if there was a treatment effect from day 1-14 of 
nefazodone the means of SOL, TST, and sleep quality were plotted and are 
shown in Figures 3.16-3.18. 
ý, 
: ýý">: 
Figure 3.16: Sleep Onset Latency (SOL) Days 1-14 Nefazodone 
versus Placebo 
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As can be seen from the graphs 3.16-3.18 there was no evidence of a treatment 
effect. 
Comparison of Objective and Subjective Sleep Nefazodone versus Placebo 
Comparisons of the subjective sleep diary measurements with the objective 
measurement of patients 1-10 SOL and TST are not possible in the data quoted 
here. The sleep diary data is a mean of day 1-14 of treatment with nefazodone 
or placebo, and the subjective measurement SMQ and Leeds questionnaire 
were only completed on morning 14 of day 1-14. 
It is however possible to compare objective and subjective data for patients 1- 
10, using SMHQ subjective SOL, subjective TST and subjective number of 
awakenings as all data refers to night 14 of placebo or nefazodone. See Figures 
3.19 - 3.21: 
Figure 3.18: Sloan Qua*ty Drys 1-14 Plec. eo v 0- F- -e 
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Figur. 3.19: Comparison of objKthr. PSG and subjective SMHQ SOS 
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Figure 3.20: Conmprison of objective PSG and subjective Total Sleep 
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Figure 3.21: Comparison of objsct .s PSG versus subjectfvu SMHQ Number 
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Nearly all patients underestimated "How much Sleep" they got subjectively 
when comparing their subjective SMHQ scores with objective TST 
measurements. This was true for both placebo and nefazodone. 
Overestimation of SOL, which may be expected in people with insomnia, is 
however not as clear as for TST from these results except for patients 8 and 9 
who greatly overestimated their sleep onset compared to objective 
measurement on their placebo nights. 
Number of Awakenings would be expected to be higher for both nefazodone 
and placebo when measured objectively by EEG. This is because patients will 
not be aware of every arousal, if it is brief, even though it is scored on an EEG 




data for number of awakenings, however there was no significant difference 
between number of awakenings on objective and subjective measurements 
between nefazodone and placebo. There was also no significant correlation 
between objective and subjective awakenings when patients were taking 
placebo or nefazodone. 
3.5 Discussion 
There were no significant changes in the main objective outcome variables 
SOL, TST and Number of awakenings. There were also no significant changes 
in any of the other objective sleep parameters. Patient 2 complained bitterly of 
poor TST and quality sleep. This would seem to be supported by the objective 
data showing a sleep efficiency of around 60%. However, he may have had a 
lower sleep efficiency due to spending more Time in Bed but not actually 
sleeping and his TST was unremarkable compared to the rest of the patients. In 
fact Patient 2's Time in Bed results were the highest of the patients recorded at 
over 600 minutes for placebo night and over 550 minutes for nefazodone. 
Patient 6 also has a lower sleep efficiency than the rest of the patients, (there 
are no recordings for patient 6 on nefazodone as this tape had technical 
problems) however, Time in Bed for patient 6 was also high: 531 minutes 
(nefazodone) and 563 minutes (placebo). 
In this study nefazodone has also not made any subjective improvements in 
sleep as measured by three separate subjective measures: SMQ, Leeds, and 
fourteen-day sleep diary. These objective and subjective results are in contrast 
to Wiegand et al who demonstrated significant increases in SOL, stage 2 sleep 
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and REM sleep. 135 However they found TST, sleep efficiency and REM sleep 
onset latency were not significantly increased. In Wiegand's study, the number 
of awakenings, stage one sleep and SWS were significantly decreased; they 
therefore showed that nefazodone's effect in primary insomnia might be on 
sleep continuity. 
Wiegand, however, found more pronounced subjective changes in sleep than 
objective changes. Pittsburgh Sleep Questionnaire Index (PSQI) scores, 136 
decreased and all subscores decreased except for sleep latency after four weeks 
administration of nefazodone. The subjective improvement described by 
Wiegand could be related to the antidepressant action of the drug despite the 
exclusion of clinically relevant depression. Nowell et al. 133 looked at 
paroxetine in a small study in primary insomnia (n-=14). There were no 
objective improvements on PSG, but eleven patients decreased PSQI scores. 
Trimipramine may have some sleep promoting properties in insomnia. It has 
been compared in a double blind placebo and lormetazepam-controlled study 
in patients in primary insomnia. 132 Objective PSG measurements showed 
increased sleep efficiency but not increased TST, of subjects taking 
trimipramine compared to placebo. Lormetazepam decreased wake time 
compared to placebo. Trimipramine and lormetazepam had significant effects 
on decreasing overall PSQI scores compared to placebo. On some items of the 
PSQI, trimipramine demonstrated better results than lormetazepam. 
Doxepin has also been investigated in a 4-week placebo controlled trial (n=47) 
in patients with primary insomnia. Objective measurements showed increased 
117 
sleep efficiency. Subjective sleep quality, daytime performance and energy 
were also assessed and statistically significant improvements in sleep quality 
were found 
131. 
However all these studies are with relatively small numbers with some high 
drop out rates and also raise questions as to whether statistically significant 
changes are clinically significant to the patient. 
The limitations to this study are also small patient numbers, and that patients 
recruited in this study with insomnia do have sleep misperception (SMP) i. e. 
they sleep better when measured objectively than they perceive subjectively. 
SMP may mean the patients in this study were less severe "insomniacs" than 
they perceive or we anticipated, as when measured objectively, the majority 
had sleep efficiencies of 80% and above. Consequently the measurable effects 
of any sleep promoting medication may have been less marked. Objective and 
subjective measurements of total sleep time was underestimated by most of 
this group of insomnia patients by approximately 100 minutes, which shows a 
large SMP. Interestingly SOL was not overestimated by the majority of 
patients by such an amount or as consistently. 
How often does sleep misperception occur? The underestimation of total sleep 
time and overestimation of sleep latency and number of awakenings in primary 
insomnia has been said to be 25-50% 137, but it also occurs in insomnia 
associated with depression. 99 The patients in this study most of who have had 
primary insomnia for many years probably have SMP. They could be helped 
further by the work of Tang and Harvey 138139, (see chapter one and five). Tang 
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and Harvey have investigated verbal and behavioural techniques to feedback 
objective and subjective differences between people with insomnia's 
actigraphic and sleep diary recordings. They have shown that this can help 
correct SMP for the following night's sleep. 
In this study, using 100mg of nefazodone, there were no reported side effects. 
However Wiegand who used 100-400mg of nefazodone (with the majority 
taking 200-400mg by day 28) had 11 dropouts from 31 patients due to side 
effects that included predominantly nausea, vertigo and a dry mouth. 
Interestingly the majority of dropouts occurred at doses of I00mg or 200mg 
and between days 3-15 of the study. Wiegand recommended a lower dose 
range in order to achieve better tolerability of the drug. It should be noted that 
he used doses recommended for the treatment of depression. Other 
antidepressants that have been used for insomnia rather than depression have 
an effect at lower doses e. g. doxepin. 131 However in this small study 
200mg/day may have produced more biological and clinical effects without 
side effects. Perhaps the insomnia relieving effects of nefazodone reported in 
the other studies above is exclusively caused by its blocking action on 5HT2 
receptors that is independent from its antidepressant effect. 
Since 2003 nefazodone has only been available on a named-patient basis in the 
UK, see chapter two This has led to nefazodone's sister drug trazodone (which 
is used widely in the USA, ) and now more commonly in the UK, being used to 
treat depression with associated insomnia and occasionally used to treat 
primary insomnia. As mentioned above it has been shown to promote sleep in 
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healthy controls, 134 in depression, 129 and in open studies in primary insomnia. 
A double blind placebo controlled trial of trazodone in primary insomnia 
and/or depression with secondary insomnia is now required to establish its 
efficacy in primary insomnia. Mirtazepine as mentioned above, has sleep 
promoting properties. It has been shown to increase SWS in normal volunteers 
140 and to promote sleep in depressed patients39 and may also have a place in 
the treatment of primary insomnia when fully investigated. 
tan 
Chapter 4 
Psychological Therapy in insomnia and depression 
This chapter explores the treatment of primary insomnia or secondary 
insomnia (e. g. insomnia secondary to depression) using a cognitive behaviour 
therapy group approach 
Patients with primary insomnia did report improvements in dysfunctional 
attitudes and beliefs about insomnia and improvements in energy/vitality and 
mental health, as measured by the SF36 quality of life scale, after attending 
group cognitive behavioural therapy (CBT). Sleep parameters were not 
significantly improved when compared pre and post CBT. 
My role in this group work was in recruitment of patients, coleader of the 
insomnia groups, data analysis and the writing up of the results. 
4.1 Introduction 
The psychological management of insomnia is topical. Due to the potential 
problems of chronic benzodiazepine usage as detailed in chapter one and the 
cost of their prescription, the National Institute of Clinical Excellence (NICE) 
are strongly advocating the psychological management of insomnia. 57 This 
chapter will report some initial findings on group psychological therapy for 
people with chronic insomnia carried out on outpatients referred to a 
neuropsychiatry service in Bristol. The group work was carried out as part of a 
clinical service. In the introduction, the background of group therapy in 
insomnia is explained, as is the group programme. The outcome measures used 
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such as the Dysfunctional Beliefs and Attitudes Scale (DBAS) and the Quality 
of Life Questionnaire (SF-36) are then discussed followed by the results of five 
insomnia groups. 
What really matters to the person with chronic insomnia? Clinical 
improvements in sleep parameters have much more relevance to patients than 
statistically significant results. Clinical improvements as defined by Espie 
(2001) 114 are: 
(i) An increase in TST by 30 minutes 
(ii) A decrease in SOL to under 30 minutes and/or a reduction by 50% or more 
(iii) A decrease in WASO of 30 minutes and/or a reduction by 50% or more 
(iv) A sleep efficiency of 80% or more 
Relief of daytime symptoms, better sleep quality and being able to "carry on 
with the rest of their lives" are also more important to the sufferer than extra 
minutes sleep at night and/or falling asleep marginally faster. 
In order to address these factors, studies on people with insomnia based in the 
community rather than in research trials or sleep laboratories have become 
important. These studies may include people with insomnia who may or may 
not be taking hypnotic medication. 
IAl 
Arguably, Cognitive Behavioural Therapy (CBT), forms the mainstay of 
treatment for chronic insomnia. It includes, stimulus control, sleep hygiene, 
relaxation, biofeedback, paradoxical intention, and cognitive therapy (sec 
chapter one). Their individual effectiveness is discussed in chapter one, 
however it is increasingly common to use a combination of these treatment 
procedures known as multi-component behaviour therapy, multi-component 
CBT or usually `CBT' to offer effective clinical management of insomnia, as 
some patients may respond better to some treatments rather than others. 
Due to limited resources and cost effectiveness, it is also important to consider 
the mode of delivery of CBT. The use of CBT in a group setting has been 
carried out in the studies in Table 4.1.114 141.145 They have all shown 
improvements in sleep parameters and other scales. However, they are difficult 
to compare because of inclusion criteria that use different definitions of 
insomnia (see chapter 1, ) whether the participants were advertised for or 
presented for treatment, the different age-groups of the patients studied, the 
fact that they use objective or subjective sleep measures and the types of 
outcome rating scales used. 
There have been three recent community research studies in UK general 
practice. In the first study, people with insomnia received CBT in a group 
format compared to a control group 114 (Table 4.1. ) After 6 weeks, CBT was 
associated with a mean 30-minute reduction in SOL, and WASO. At 12 month 
follow up, TST was also improved by 30 minutes and over 80% of patients 
initially using hypnotics remained drug free. In the second, Espie (2007)146, 
patients with insomnia received CBT in a group format compared to a control 
1Al 
group and were assessed by actigraphy, sleep diary, PSQI and SF36 (Table 
4.1). Sleep diaries showed reductions in 60 minutes per night in SOL and 
WASO and a 9% increase in sleep efficiency. SOL was the most improved 
post group but SOL and WASO improvements were only partly sustained at 
follow up compared to sleep efficiency. The third study, also in general 
practice, was in an individual format. ' 17 Patients at 3 and 6 month follow up 
treated with CBT reported significant reductions in SOL, and improvements in 
sleep efficiency. They also had improved quality of life (SF-36 scale) and less 
hypnotic use than the non-treatment group. 
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Table 4.1: Summary of Group CBT studies for chronic insomnia 
Participants Diagnosis and Controls Sleep Diary/ Outcome Follow up 
advertised for or Protocol PSG/Actigraphy 




Espie 2007 Advertised for Chronic Yes Sleep PSQ Post group and 
participants primary and Diary/Actigraphy 
secondary SF36 6 mths 
insomnia 
in General HRSD 
Practice 
CBT vs ESS 
Control 
Jansson Advertised for Chronic Yes Sleep Diary HRSD 1 year 
2005 participants primary and 
secondary DBAS 
insomnia 
CBT vs Self 
Help 
Backhaus Presented for Chronic Yes Sleep Diary PSQI Post gp, 3,12, 
2001 treatment primary 






Espie 2001 Presented for Chronic Yes Sleep PSQI Post gp, 12 
treatment primary Diary/Actigraphy 
insomnia in BDI mths 
General 




CBT vs CBT 
deferred vs 
Control 
Morin1999 Presented for Chronic Yes Sleep Diary/PSG Sll 3,12,24 mths 










Jacobs 1996 Presented for Chronic No Self designed Nil I and 6 mths 
treatment primary and questionnaire 
secondary 
insomnia 
Kupych- Presented for Chronic No Sleep Diary Nil Nil 




Key to Table 4.1 
SI Hyg = Sleep Hygiene 
STAI = State Trait Anxiety Inventory 
PSG = Polysomnogram 
DBAS = Dysfunctional Beliefs and Attitude Scale 
ISQ = insomnia symptom questionnaire 
PSQI = Pittsburgh sleep quality index 
SII = Sleep Impairment Index 
HSRD = Hamilton Depression Scale 
PSQW - Penn State Worry Questionnair 
ESS ° Epworth Sleepiness Scale 
BDI = Beck Depression Inventory 
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Recent evaluations of CBT for insomnia have been carried out through self- 
help approaches such as books, audio/video tapes, telephone support and the 
internet. Mimeault (1999)112 tested self-help CBT `bibliotherapy' ( six 
booklets each covering a specific component of CBT) with and without 
supportive phone consultations against a waiting list control group. Compared 
to a control group, both treatment groups showed sleep improvements that 
were maintained at 3 month follow up. However, adding professional guidance 
to bibliotherapy produced further improvements. The presence of a therapist 
seems, therefore, to optimize treatment response. Bastien' 11 (2004) also 
reported comparable effectiveness of CBT for primary insomnia delivered in 
an individual, group and telephone consultation format. This study was the 
first to compare different modes of delivery of therapist led CBT for insomnia. 
The results showed that CBT did not lose its effectiveness when delivered in a 
less costly format such as in groups or over the telephone. A study using an 
internet-based intervention produced a greater improvement in several sleep 
parameters relative to controls but the attrition rate was higher than in studies 
using face-to-face consultation visits. 113 There has also been a recent study 
comparing group versus individual CBT in primary insomnia147 in which 
similar improvements were seen in sleep variables and quality of life scales 
between individual and group treatment, with these improvements being 
maintained at follow up. 
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4.2 Outcome Measures (Quantitative and Qualitative assessments of 
subjective sleep) 
Quantitative and qualitative assessments of subjective sleep that are 
commonly used (see Table 4.1) are: 
1) Sleep diaries. (see appendix 1 for copy) 
2) Quality of life assessment (SF36). (Medical Outcomes Trust 1992148) (see 
appendix 4 for copy) 
3) Visual analogue scales for Dysfunctional Beliefs and Attitudes about sleep 
questionnaires DBAS (Morin 199388). (see appendix 4 for copy. ) 
1. Sleep Diaries 
A seven-day measure of total sleep time, sleep onset latency and sleep 
quality as estimated by each group member for the previous night's sleep. 
2. SF36 (Short Form36) Quality of Life Scale 
Quality of Life is a "complex and multidimensional term that has been defined 
as a concept encompassing a broad range of physical and psychological 
characteristics and limitations which describe an individual's ability to 
function and to derive satisfaction from doing so. "149 It includes the following 
domains, the physical, encompassing the ability to conduct activities of daily 
living, the psychological, or emotional, and the social, encompassing 
interactions with family, friends and community. Insomnia may affect each or 
all of these domains. 
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The SF36 quality of life questionnaire measures generic health concepts 
relevant across age, disease and treatment groups, and provides a 
comprehensive, psychometrically sound and efficient way to measure health 
from a patient's point of view by scoring standardised responses to 
standardised questions. 
The SF36 was developed from the Rand Corporation's health insurance 
experiment in the USA, "The Medical Outcomes Study "(MOS). 150 This was a 
comprehensive evaluation of alternative methods of financing healthcare in the 
USA. The SF36 consists of eight multi-item scales containing two to tcn items 
each and a single item measure of reported "health transition" (Table 4.2) SF 
36 items are scored so that a higher score indicates a better health state. For 
example, functioning scales are scored so that a high score indicates better 
functioning and even the pain scale is scored so that a high score indicates 
freedom from pain. After data entry the raw data scores were recoded and 
transformed to a 0-100 scale using a computer software package. Scores 
between these values represent the percentage of the total possible score 
achieved. Transformed scale scores can be compared with norms derived from 
the Medical Outcomes Study and other published results based on the scoring 
rules. '5' 
1 i2 
Concepts Number of Items Summary of content 
Physical Function 10 Extent to which health limits 
(PF) physical activities e. g. 
walking 
Role 4 Extent to which physical 
Physical health interferes with work or 
(RP) other daily activities 
Bodily Pain (BP) 2 Intensity of pain and effect of 
pain on normal work in or 
outside the home 
Role Mental 5 Extent to which emotional 
(RE) problems interfere with work 
or other daily activities 
Social Function 4 Extent to which physical 
(SF) health or emotional problems 
interfere with normal social 
activities 
Mental Health 2 General mental health 
(MH) including depression anxiety 
Energy and Vitality 3 Feeling energetic and full of 
(VT) life versus feeling tired and 
worn out 
Health Perception (GH) 5 Personal evaluation of health 
Change in Health (HT) 1 Evaluation of current health 
compared to one year ago 
Table 4.2: Health Concepts, numbers of items and summary of content 
for eight SF-36 scales and the health transition item. 
Use of the SF36 in insomnia 
As well as complaining about poor sleep, sufferers complain of impaired 
daytime functioning e. g. poor concentration, poor memory, tiredness and 
irritability. Indeed the ICSD definition and the DSM IV definition both include 
daytime consequences (see chapter one. ) It has therefore been suggested that 
quality of life measures may reflect more accurately the daily impact of 
insomnia. 
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There have been only a handful of studies designed to evaluate the impact of 
insomnia on the quality of life. Hatoum (1998)152' and Zammit (1999) 1' used 
the SF36 to evaluate the quality of life of a group of people with insomnia 
compared with good sleepers (Hatoum also controlled for demographic 
variables and co-morbid conditions), and showed insomnia is associated with 
significant quality of life impairments in all domains. As part of a European 
survey of severe insomnia 48, (chapter one, ) SF36 scores were obtained on 
people with severe insomnia, and mild to moderate insomnia. The scores were 
then compared with controls in five northern European countries. SF36 scores 
were lowest in those with severe insomnia. The greatest range in scores was in: 
1) Problems with work or activities resulting from physical ill health (role 
physical) 
2) Social activities with family, friends etc (social functioning) 
3) Problems with work and activities as a result of emotional problems (role 
mental) 
Physical vitality was also particularly low among those with severe insomnia. 
In the UK sample SF36 scores for the severe insomnia group were compared to 
those obtained from a chronically ill population 154 and revealed on most 
domains the chronic severe insomnia group had worse quality of life scores 
than those patients with chronic physical illness. 
Leger (2001)155, after controlling for anxiety and depression, also compared 
SF36 scores in 3 groups of people with insomnia, DSM IV defined 
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insomniacs, a matched group of people with mild insomnia, and a matched 
group of good sleepers. They found a gradation between the three groups, 
confirming that the more severe the insomnia the worse the quality of life. 
They found that eight out of nine dimensions of the SF36 were significantly 
worse in people with insomnia than in good sleepers. All groups estimated that 
their health status at the time of the study was on average similar to that of the 
previous year. Leger suggests this is because insomnia impairs quality of life 
progressively over several years and to a lesser extent in the short term. 
More recently, Morgan (2003)1 17 took a wide range of people aged 31-92 years 
from general practice with insomnia. He carried out a randomized controlled 
trial comparing people who had had a CBT (individually), and those who had 
had no additional treatment by post treatment assessments starting at 3,6, and 
12 months. As well as measuring sleep quality (see chapter 1) the SF36 was 
measured at these intervals. They found statistically significant improvements 
in energy and vitality at 3 months, physical functioning at 6 months, and 
mental health at 6 months in the people that had received CBT. 
3. Dysfunctional Beliefs and Attitudes Scale (DBAS) Morin 199388 
The scale comprises 30 items (see appendix for copy. ) There are five 
subscales: 
1. Misconceptions of the causes of insomnia 
2. Misattributions or amplifications of the consequences of insomnia 
3. Unrealistic sleep expectations 
4. Diminished perceptions of control 
5. Faulty beliefs about sleep promoting practices 
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Morin (2002)156 used the DBAS scale to assess if changes in beliefs and 
attitudes about sleep are related to sleep improvements after treatment of 
insomnia. Older adults with chronic and primary insomnia received CBT, 
pharmacotherapy (PCT), combined CBT and PCT or a medication placebo. In 
addition to daily sleep diaries and sleep laboratory measures, the participants 
completed the DBAS at baseline and post- treatment. The results showed that 
CBT and combined treatment produced greater improvements of beliefs and 
attitudes about sleep at post-treatment than PCT and placebo. Reductions of 
DBAS scores were significantly correlated with improvements in sleep 
efficiency as measured by daily sleep diaries and by polysomnography. 
Since 1999, in response to clinical need and the availability of suitably trained 
staff at two centres in Bristol, we have been able to combine to set up one of 
the few clinical group treatment programmes in the UK for the treatment of 
chronic insomnia. This was aimed at helping people cope with chronic 
insomnia whatever the initial cause and was based on the report of group 
therapy for insomnia carried out in Toronto, Canada in the mid 1990's by 
Kupych-Wloshyn and Colin Shapiro. 157 
A number of factors motivated us to establish the insomnia groups. Firstly, the 
group approach was considered a cost effective way to treat several patients 
simultaneously. Secondly, we had a number of difficult to treat people with 
insomnia at our clinic for whom other therapeutic interventions such as 
medication had not been totally effective. Thirdly, we sought to provide an 
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alternative strategy for helping these patients to give them optimism about a 
different treatment approach (realising that many of the patients had previously 
received various components of the treatment package individually. ) We were 
hoping to expose the participants to therapeutic factors associated with group 
work. The kind of therapeutic factors associated with group work are listed 
below (Yalom 1985): 158 
(i) Instillation of hope 
(ii) Universality 
(iii) Imparting of information 
(iv) Altruism 
(v) Development of socializing techniques 
(vi) Imitative behaviour 
(vii) Catharsis 
(viii) Corrective recapitulation of the primary family group 
(ix) Existential factors 
(x) Group cohesiveness 
(xi) Interpersonal learning 
The outcome measures described above were chosen to assess the outcome of 
the insomnia groups. The sleep diary gave a subjective interpretation of how a 
participant thought they slept at the beginning of the group programme 
compared to at the end. 
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The SF36 was chosen to measure any changes in quality of life from the start 
of the first group to the end of the group sessions. (Daytime functioning, 
quality of life and insomnia are known to be closely related in people with 
insomnia as discussed above. 155) The DBAS scale was chosen to see if seven 
weeks of group work could change attitudes to insomnia which would 
therefore improve the subjective sleep of partieipants. 156 
(The initial four groups run were pilot groups with differing session content in 
each group and not all the outcome measures were obtained. The data from 
these groups was not therefore analysed. ) 
4.3 Components of treatment group 
The groups were led by a doctor (sleep specialist), two occupational therapists 
and a research sleep scientist. There could be a different combination of 
leaders at each session but there are always two group leaders present. 
The occupational therapist assessed potential participants. Qualities sought 
before entry to the group were willingness to try a group as a form of 
treatment, and commitment to the programme of sessions. Patients with 
depression were included as long as they were well enough to attend and 
participate. 
Participants joined the group whether they were taking sleep related 
medication or not. If any group members were keen to use the support of the 
group to decrease hypnotic medication or to cease taking hypnotics they were 
encouraged to do so. "Homework" and completion of sleep diaries were also 
part of the programme as was small group work (splitting the group members 
into two groups of no more than three members, so each group member could 
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discuss their sleep problems individually with the group leader. ) Individuals 
were encouraged in the small groups to work, each week, on their own specific 
insomnia solutions. Informal support from other members of the group was 
also encouraged. Group courses lasted seven weeks and each group had a 
maximum of eight participants. 
4.4 Group Programme 
The programme consisted of seven ninety minute sessions spread over seven 
weeks. The format and timetable of the group sessions is shown below: 
Week 1 
Introduction and explanation of group rules. We asked what do the group 
members understand by "insomnia? " Individual goals for each group member 
were written down on a flip chart. Information was given about sleep science 
and sleep architecture to educate and inform group members. Detailed 
information was provided about sleep hygiene, stimulus control, thought 
stopping, imagery and paradoxical intention techniques. Small group work was 
used to discuss putting into practice the techniques suggested above and 
explanation was given about the use of individual sleep diaries. The concept 
of using a sleep diary for the next 7 nights was explained. Group members 
completed the SF36 and DBAS. 
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Week 2 
Cognitive Therapy (1) 
There was an introduction to the principles of cognitive therapy and 
challenging "Negative automatic thoughts" (NAT's) about sleep and insomnia. 
We used the DBAS completed in the previous week to identify personal 
underlying beliefs about insomnia. We set homework to try and practice 
challenging personal NAT's and to write these down. There was further small 
group work. 
Week 3 
Cognitive therapy (2) 
There was revision of challenges to personal NATS about insomnia using their 
homework examples and/or examples from the attitudes and beliefs about 
sleep questionnaire (DBAS) . There was further small group work to review 
group members sleep using the suggested techniques. 
Week 4 
Relaxation (1) 
The senior occupational therapist performs an hour's relaxation session based 
on a method derived from progressive muscular relaxation. 159 The group 
members are trained to be aware of muscle tension by first tensing and then 
relaxing certain groups of muscles. Some autogenic relaxation techniques and 
imagery techniques are also used. Autogenic relaxation differs from 
progressive relaxation in that while both seek to induce a state of muscular 
relaxation, autogenic relaxation aims to involve vasomotor and cognitive 
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processes as well. 160 This is achieved by teaching the trainee a series of mental 
exercises involving sensations of heaviness and warmth. Tapes for home use 
were also given out 
Week 5 
This was a session centered on questions and discussion about past or present 
medication. There was further small group work. 
Week 6 
Relaxation (2) 
Time for general discussion of topics to do with sleep bought up by members 
of the group. Further questions about sleep science answered. 
Small groups and sleep diary given out to return for week 7. 
Week 7 
Completion of post group SF36 and DBAS 
Feedback comments were asked for from the group members about the course 
in an open feedback session in the last group. Participants were then asked to 
fill in a written feedback sheet with comments that could remain anonymous if 
they so wished. 
Sleep diary results comparing week 1 and week 2 were reviewed. 
A follow-up meeting in 3 months time was organised. 
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4.5 Statistical Analysis 
Week one and week seven means of the self rated sleep diary, for SOL, TST, 
and sleep quality were compared by a paired t test. Similar comparisons of 
week one and week seven scores were made for the SF36 and DBAS. 
4.6 Results 
Number people referred. 43 
Attended assessment interview 41 
Commenced group 38 
Completed at least 5 of 7 sessions 34 
Table 4.3: Referrals for five insomnia groups 
The demographic table shows people with chronic insomnia attending the 
group were predominantly female > 70%, and aged between 45-60 i. e middle 
aged. Most participants had had insomnia for under 10 years but over 2 years 
(50%) but the second largest group had had insomnia for between 10 and 20 
years (30%). 30% had a psychiatric diagnosis of depression and or anxiety. 
Over 50% of people were taking hypnotics while approximately 30% were 
taking antidepressants. 
Data from the five groups was analysed. However, only 23 pairs of sleep 
diaries were completed for a variety of reasons mostly because of non- 
attendance at week 6 or non-return of sleep diaries at week seven. Some diaries 
were completed incorrectly. Non-completion of sleep diaries in the first week 
also occurred, as occasionally some people joined the group after the first 
session and therefore did not complete a pre treatment sleep diary. People had 
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absences from the group because of holidays, illness and work/children 
commitments that also affected data collection. The SF36 and DBAS scales 
had more data available for analysis n=33, because patients completed the 
questionnaires during group time and it was therefore possible to collect more 
complete data. 
n=38 % 
Male 14 27 
Female 24 73 
Age Range (22-77) 
<30 7 9.5 
30-45 7 9.5 
45-60 23 60 
>60 1 3 
Duration of insomnia 
<2 years 4 11 
<10 years 19 50 
10-20 years 12 31 
>20 years 3 8 
Status 
Married/Partner 22 58 
Single 13 34 
Divorced 3 8 
Occupation 
Employed 13 34 
Unemployed 7 18 
Student 2 6 
Retired 4 11 
Housewife 12 31 
Psychiatric Diagnosis 
Depression /Anxiety 12 31 
Medication 
Hypnotics 20 53 
Antidepressants 14 27 
Concomittant illnesses 5 
Hypertension n=2, 








Mean Mean sd t statistic p value 
weekl week? 
Start of End of 
group group 
SOL(mins) 75.0 64.2 35.1 1.02 ns 
TST(hours) 5.3 5.4 1.0 -0.6 ns 
sleep quality 4.3 4.6 1.3 -1.2 ns 
Table 4.5: Results of paired t tests comparing mean scores at weeks 1 
and 7. 
There were no significant differences between SOL, TST and sleep quality 
results after the seven-week insomnia group programme (Table 4.3). Initial 
three-month follow up results are shown in the following table. Statistical 
analysis was not carried out on this data due to small numbers. 
Sleep onset latency Number (%) Total sleep time Number (%) 
Worse. 5(31.2) 
Improved 11(68.8). 
>30 minutes less 3(18.8). 
Worse. 
Improved 
>30 minutes more 9(56,3) 
5(31.2) 
I 1(68.8). 
Table 4.6: Numbers of participants showing change in sleep (compared 
with start of course) at three-month follow-up (n =16)161 
tin 
SF36 results (n=33) 
There were statistically significant results after the insomnia group programme 
in the following domains of the SF36 quality of life measure (Table 4.5): 
" Mental Health 
9 Energy and Vitality 
" Health perception 
" Social Function and Role Physical very nearly reached significance 
Mean Mean sd t statistic p value 
week 1 week 7 
Start of End of 
group group 
Physical 81.4 82.4 15.3 -0.7 0.693 
Function 
(PF) 
Role 36.4 47.7 33.3 -2.0 0.06 
Physical 
(RP) 
Role 43.4 53.5 49.0 -1.19 0.243 
Mental 
(RE) 
Social 51.2 59.3 23.4 -1.99 0.055 
Function 
(SF) 
Mental 52.8 59.4 15.6 -2.4 0.022 
Health 
(MH) 




Pain 66.0 71.2 21.2 -1.4 0.172 
Health 49.2 56.6 11.9 -3.62 0.001 Perception 
Change in 43.9 48.5 21.2 -1.23 0.230 Health 
HT 
Table 4.7: Comparison of SF36 scores at weeks 1 and 7 (n = 33) 
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Figure 4.1: Graph of mean SF36 scores pre (week! ) and post (week 7) 
group therapy 
Domain 
1= Physical Function 
2= Role Physical 
3= Role Mental 
4= Social Function 
5= Mental Health 9= Health Transition 
6= Energy & Vitality 
7= Pain 
8= Health Perception 
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DBAS (n = 33) 
There was a statistically significant difference between the mean DBAS scores 
of the 30 item questionnaire between week 1 and week 7, t statistic= 4.1290 
and p value = 0.0002 
Feedback from open discussion and written sheets 
The general feedback points were: 
Information about the most up to date techniques to help coping with chronic 
insomnia was thought to be useful. 
The support of the group members was also well appreciated. 
The specific sessions on cognitive therapy were applied well by most people 
and were thought to be something that they could not learn easily or practice 
elsewhere. 
The medication session was also liked in the way it helped to disentangle 
misinformation or confusion about the medical treatment of insomnia. 
The small groups were also popular due to the time that was made available for 
individual assessment of group members' sleep. 
Negative comments were few. 
Members in one group exchanged names and addresses and met up to continue 
supporting each other. A summary of the common themes in feedback is 
shown in Tables 4.8 and 4.9. 
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Percentage 
Support and sharing ideas with others with similar problems. 51 
`Finding that I am not alone' 33 
Ideas and strategies 33 
"Expert advice" the facts 30 
Informal, open and frank discussion. 16 
`Finding that I am not as bad as others. ' 4 
Table 4.8: What participants liked about the course and percentage 
mentioning each factor (respondents could mention more 
than one item) 
Percentage 
No change. 44 
Improved sleep (unspecified) 31 
Improved sleep quality. 19 




More relaxed about insomnia; more positive 31 
Table 4.9: Reported changes in sleep at the end of the course and 
percentage mentioning each factor (respondents could 
mention more than one item) 
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4.4 Discussion 
It is acknowledged that the data presented in the results are from a clinical 
pragmatic group. Participants could enter the group as long as they complained 
of persistent insomnia whatever the cause. (They had primary insomnia or 
secondary insomnia e. g. due to depressive illness or other medical conditions. ) 
They could also be "on" or "off' medication or taking it on an as needed basis. 
We wanted to know if our group made a difference subjectively to people 
suffering from long-term insomnia at a clinical level and if we could help them 
move on in their lives instead of getting "stuck" with their insomnia. 
In summary, the sleep diary results from these five groups show no statistically 
significant changes for the sleep variables TST, SOL or sleep quality after 
seven weeks. However, there were statistically significant improvements in 
quality of life scales in mental health, energy and vitality and health 
perception. Social function and "Role Physical" (i. e. how a person can function 
physically at home and in the work place, ) also came close to statistical 
significance after the seven-week course. There were also highly significant 
decreases in dysfunctional attitudes and beliefs about insomnia as measured by 
the DBAS. 
Sleep diaries 
Comparison of these results with other data is difficult. Most of the studies 
carried out previously have been on individually treated patients in a research 
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setting. Patients in these studies had a diagnosis of primary insomnia and they 
were often comparing two treatment modalities i. e. CBT versus medication or 
CBT versus control. Outcome measures used in these studies have been 
objective (e. g. polysomnogram) and/or subjective (e. g. sleep diary) and have 
concentrated on statistical rather than clinical significance. Furthermore, there 
has been little research performed on quality of life, usually considered a 
secondary sleep variable, and this may be more important to the patient than 
improvements to their sleep. Table 4.7, in the introduction to this chapter, 
shows the trials to date that have compared CBT, performed in a group setting, 
versus either a waiting list control and/ or medication. 
One of the relevant studies with which to compare these data, due to patients 
being treated in a group setting, was with a group of patients with insomnia 
from general practice in 2001. Trained health visitors taught CBT over a six- 
week course. In this research trial 139 insomniacs were randomised to either 
CBT or a self- monitoring control (SMC) group. CBT consisted of six group 
sessions with 4-6 patients in each group. 114 After the controlled phase SMC 
patients entered deferred treatment. Follow up was post-treatment group, post- 
SMC deferred treatment, and at 12 month post-treatment group. After 6 weeks 
CBT was associated with a mean 30 minute reduction in SOL, and WASO. 
However, TST was increased by a mean of 30 minutes in both the treatment 
group and the deferred group only at 12 month follow up. The CBT deferred 
group showed the same changes in SOL and WASO after they had received the 
6 weeks of treatment. In an analysis of outcome data at 12 month follow up, 
the sleep improvements were maintained. 162 Two thirds of patients achieved 
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and maintained a sleep latency of 30 minutes or under and a similar proportion 
achieved 30 minutes or less wakefulness during the night. Almost half of the 
patients reduced sleep latency and night-time wakefulness by 50% or more. 
These results are broadly comparable with the 1999 American Sleep Societies 
Meeting (ASSM) meta-analysis article 107 (see chapter 1). The meta-analysis 
states that between 70-80% of insomnia patients benefit from CBT treatment, 
with 50% achieving "clinical meaningful outcomes" and about a third 
becoming good sleepers. 
Similarities between Espie's study and the Bristol clinical insomnia group 
were that in both studies patients carried on taking sleep related medication as 
prescribed unless they wanted to decrease or stop it. However, Espie had much 
larger numbers, there was a control group and they recruited from general 
practice rather than hospital outpatients. The Bristol group above may have 
been a more difficult patient group to treat as Espie excluded patients with 
major depression, while this insomnia group had patients with mild to 
moderate depression (albeit they were deemed to be well enough to take an 
active part in the group). The patients in these insomnia groups could have had 
more severe insomnia as they were recruited from a hospital rather than 
general practice setting, but comparison of the chronicity of insomnia between 
the people in these groups and Espie's, shows most people had had insomnia 
for between 2 and 10 years and 10 and 20 years, however in Espie's groups 
there were also a similar proportion of people with insomnia for over 20 years. 
Length of insomnia problems do not necessarily predict severity. With respect 
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to treatment outcome, Espie performed a regression analysis based on his 2001 
study using a number of pre-treatment variables, and showed that initial 
severity of insomnia and the use of medication for insomnia did not predict a 
poor outcome with CBT. 162 Espie (2001b)162 also followed up patients at 12 
months compared to the three month follow-up described in our study. 
The sleep diary results in our study showed no statistically significant results in 
any of the sleep parameters. However, the numbers are small and a trend exists 
towards a clinically meaningful result to the patient e. g. clinical significance. It 
is possible that we followed up our patients too soon. However, the three- 
month post-group follow-up was determined by clinical as well as research 
needs. Espie only had statistically significant results for TST at 3 month follow 
up and not immediately post group therapy. 114 This could indicate that follow 
up at 3,6 and 12 months is more important than directly post-group, and that 
outcome should not be assessed directly after group work for insomnia. 
The other group CBT studies "4141.145 all found subjective and objective 
improvements in sleep after CBT in a group format up to 3 years after 
treatment. This is consistent with meta-analysis findings that demonstrate that 
individual CBT for chronic insomnia has a lasting effect. Medication for 
chronic insomnia, by comparison, is only effective as long as it is taken-' 16 
Recruitment factors are also important. Jansson (2005) and Morin (1999) used 
advertisements to recruit patients while all the other studies in the Table 4.6 
used patients presenting for treatment. Therefore in these two studies there are 
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patients who sought treatment who may differ from individuals who do not 
seek treatment. It may be that patients seeking treatment have higher 
psychological distress and may respond to treatment differently. Also, Espic 
(2001) was not the only study cited in table 3.4 to exclude patients with mild to 
moderate depression i. e. secondary insomnia. Patients with depression, as well 
as those with drug dependant insomnia may be those most likely to present to 
sleep clinics and doctors, be more refractory to treat but also in the most in 
need of treatment. 
Espie (2001b) 162 examined age and other demographic factors and found they 
were not of significant predictive value for a good outcome to CBT treatment. 
Indeed symptoms of anxiety and depression (note these patients were not 
depressed), and thinking errors positively predicted good outcome. Neither 
gender nor occupational status differentiated responders from non-responders. 
This has also been demonstrated in Espie's most recent study of group CBT 
for insomnia in 2007.146 
Patient perceived improvement is also extremely important as discussed in 
chapter one. Negative cognitive appraisals appear to be instrumental in 
perpetuating the cycle of emotional arousal and insomnia and therefore may be 
the most relevant factor in the aetiology and maintenance of insomnia and its 
consequences, including increased health care utilization. If patients do not 
perceive improvement in insomnia symptoms the insomnia has not been 
effectively treated since the failure to alter sleep perceptions will likely 
perpetuate the insomnia cycle. Therefore the results of patient's cognitive 
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attitudes and beliefs after treatment in the insomnia group, as discussed below, 
are crucial. 
SF36 (Quality of Life. ) 
The treatment of insomnia with CBT in this study improved Mental Health, 
Energy / Vitality and Health Perception post group and had a nearly 
statistically significant effect on social function and role physical. 
One of the few studies to have compared SF36 scores before and after CBT 
was by Morgan (2003. )l 17 This was not in a group format and outcome 
measures were not conducted directly after the end of the treatment group but 
at 3-6 months follow-up. However, Morgan found that the domain of Energy 
and Vitality improved at 3-month follow up which is compatible with these 
results. At 6-month follow-up, he found that physical function and mental 
health scores were also statistically significantly improved and this result also 
appears to concur with these findings. Espie (2007) is the first study to use the 
SF36 pre and post group CBT (which is directly comparable to this group 
programme. ) 146 They had time effects on ANOVA on the four domains: 
physical functioning, mental health, energy/vitality and health perception. 
Significant group time interactions, suggesting treatment response after CDT 
were obtained for two domains: mental health and energy/vitality. This is in 
agreement with my results where mental health and energy/vitality were 
significantly improved. It would be interesting to see whether the 
improvements in SF36 scores in this group were maintained at 3,6, and 12 
month follow up and this is an avenue for further work. 
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DBAS Cognitive Attitudes and Beliefs 
The data shows a very significant improvement in beliefs and attitudes in sleep 
after CBT. This is in agreement with all the other research into changes in the 
DBAS with CBT. Edinger (2001), 163 showed that individual CBT provided 
larger changes on the DBAS in insomniacs than relaxation or a sham 
behavioural intervention. These changes persisted during the follow up period. 
Morin (2001 ), 156 also demonstrated that changes in beliefs and attitudes about 
sleep are related to sleep improvements in the treatment of insomnia. In his 
1999 study, comparing the efficacy of group CBT and pharmacotherapy for 
late life insomnia, patients completed the DBAS at baseline, post-treatment 
and at 3,12, and 24 month follow up assessments after they had been assigned 
to individual CBT, pharmacotherapy, a combination or a placebo group. The 
results showed that CBT and combination treatments produced greater changes 
of beliefs and attitudes about sleep at post-treatment than pharmacotherapy and 
placebo. Reductions of DBAS scores were significantly correlated with 
improvements in sleep efficiency as measured by daily sleep diaries and by 
polysomnography. Post-treatment DBAS scores were also significantly 
correlated with sleep efficiency at each of the three follow up assessments at 3, 
12 and 24 months. This is a similar outcome to that found in Jansson's study. 
141 At the one-year follow-up in Jansson's study, 64 of CIIT treated patients 
had a 23% reduction in DBAS scores compared to an 8% reduction in the 
control group. 
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Findings relating to changes measured by DIAS raise the question whether 
changes in attitudes and beliefs are essential to treat insomnia cffcctivcly? This 
idea would be supported by Morin's results as he found significant correlations 
between the magnitude of changes on sleep-related beliefs and attitudes and 
the degree of sleep improvements at post-treatment. 156 Furthermore, Morin 
found that the strength of the relationship between cognitive changes and sleep 
improvements increased over time. Morin also points out that patients treated 
with CBT obtained DBAS scores that were comparable to those obtained in 
older adults without insomnia complaints in two other studies. 137144 Changes 
in thoughts about sleep were more strongly associated with subjective (sleep 
diaries) than with objective (PSG) sleep improvement. This finding could be 
explained by the fact that untreated insomniacs may overestimate their sleep 
problem and underestimate their sleep duration i. e. they have sleep 
misperception. As cognitive therapy addresses such misperceptions, patients 
treated with CBT may perceive their sleep more accurately over time which in 
turn contributes to a stronger relationship between cognitive changes and 
subjectively assessed sleep improvement. 
Scores on the DBAS have also reduced when CBT is delivered in other 
modalities. As mentioned above, ßastien and Morin (2004) showed the DBAS 
was significantly reduced post treatment in all treatment modalities i. e. 
individual, group and telephone consultations. Strom (2004)113 investigated the 
effects of internet based CBT treatment for insomnia. Compared to a control 
group there was also a significant decrease in DBAS scores. 
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The DBAS reveals that stronger beliefs in the negative long-term 
consequences of insomnia motivation are associated with a good SOL outcome 
(e. g. "I am concerned that chronic insomnia may have serious consequences 
on my physical health") providing supporting evidence that dysfunctional 
thinking may be a positive indication for the CIIT treatment of insomnia and 
that there is a "cognitive pathway" for mediating treatment effects. It is, 
however, important to emphasise that most CBT for insomnia analyses only 
considered pre-treatment variables that influence outcome. Many other factors 
can play a part in the prediction of clinical response, including readiness to 
change, motivation and compliance. 
In summary, in this study of a pragmatic clinical group therapy for chronic 
insomnia statistically significant changes in attitudes and beliefs about 
insomnia and improvement in quality of life were found. There were no 
significant changes in subjective sleep outcome variables such as TST and 
SOL. Patient satisfaction with the group was high. Further work should include 
collection of more outcome data post-treatment at intervals up to a year or 
longer after the end of treatment, particularly concentrating on quality of life 
data such as the SF36. This will help establish if the effects of CBT are long 
lasting. It would also be useful to encourage reduction or discontinuation of 
medication in the group participants. 
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Chapter 5 Conclusion 
This series of studies has examined the treatment of insomnia both in 
depression and chronic insomnia. There are two pathways to effective 
treatment, medication and psychological treatment. 
In chapter two nefazodone, as a treatment for insomnia in depression, is 
discussed. After the demonstration that nefazodone improved sleep continuity 
in depressed patients with insomnia it was decided to investigate the use of 
nefazodone as a drug treatment in chronic insomnia (chapter 3). 
Psychological treatment in insomnia is reviewed in chapter one and at the 
beginning of chapter four. In chapter four the outcome data from five insomnia 
treatment groups is analysed and discussed. 
The treatment of depression with medication must be paramount if someone 
has moderate to severe symptoms and has suicidal thoughts. Chapter two 
demonstrates that nefazodone is more effective at relieving the sleep symptoms 
of depression than paroxetine particularly at the beginning of treatment when 
patients complain most bitterly of sleep problems. Significant differences 
showing that nefazodone improved Total Sleep Time, Sleep Efficiency and 
decreased Number of Awakenings compared to paroxetine. This was 
demonstrated after 3 days of treatment and clinically this is important as over 
90% of patents with depression suffer from insomnia. Unfortunately, 
nefazodone is now not prescribed due to the rare but serious side effect of 
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hepatotoxicity. However, its sister compound trazodone is available, used quite 
widely and is thought to treat sleep complaints in depression (although grade I 
evidence from a placebo controlled trial for this is lacking. ) The antidepressant 
mirtazapine is also effective at relieving sleep symptoms and is also used 
clinically when sleep complaints are a major problem for the patient with 
depression. 
A natural follow on to the nefazodone in depression study described in Chapter 
2 was an investigation into nefazodone's effect on sleep in patients with 
chronic primary insomnia. The results in chapter three show that, in the small 
group of patients studied, nefazodone did not have a significant effect on sleep 
in patients with chronic insomnia contrary to the patients with depression. (The 
primary outcome variables studied were Sleep Onset Latency, Total Sleep 
Time and Number of Awakenings. ) A follow up study is being carried out at 
the present time in our department to establish the effect of trazodonc on sleep 
in patients with primary insomnia. 
One of the reasons for the disappointing results in the nefazodone in insomnia 
study may be that some of the subjects recruited were suffering from "sleep 
misperception"(SMP) and depressed patients with insomnia show less sleep 
misperception. 99 Subjects in this trial, who were recruited, complained bitterly 
of poor sleep subjectively but this was not verified via polysomnography. The 
sleep efficiency of most patients in chapter 3 while on the placebo arm of the 
crossover trial was no lower than 80%. Some patients in the study may, 
therefore, have had less severe insomnia when measured objectively than we 
»1 
had anticipated. Consequently, the results were very variable and no overall 
improving effect was detectable. Insights into SMI' may be useful to extend the 
approach when trialling a drug to help treat chronic insomnia, and develop 
psychological treatments, as is investigated in chapter 3 and in chapter four 
(discussed later. ) On recruitment to a medication trial for chronic insomnia, a 
baseline PSG may have been useful to establish the degree of SMP in each 
potential subject. The worst SMP subjects could then be excluded before 
randomisation. 
In Chapter 4 the psychological treatment of insomnia is discussed. I report on 
five groups of patients who had been referred to a tertiary centre for the 
treatment of insomnia. Overall, the participants liked the insomnia groups. 
They found them supportive and informative. Analysis of the sleep diary data 
showed no statistically significant improvement in Sleep Onset Latency, Total 
sleep Time and sleep quality, but there was a trend towards improvement in 
these variables. However, there was a large statistical difference in the 
Dysfunctional Attitudes and Beliefs Scale pre and post group with decreased 
scores post group. There was also a statistically significant difference in 
improved energy/vitality and mental health scores from the SF36. This shows 
that the group treatment improves dysfunctional beliefs and attitudes about 
sleep and therefore perhaps when larger numbers are analysed this could also 
result in a statistically significant improvement in sleep measures. '46 
Sleep misperception is a well-recognised phenomenon in people with chronic 
insomnia, see chapter one, and very relevant to the psychological management 
1 0; 
of insomnia that is discussed in chapter 4. While running the insomnia groups 
there have also been a handful of patients who at the end of the group, by their 
oral and written feedback, and diary data, have made little or no progress in 
coping with their insomnia or moving on with their lives. The common 
statement is usually along the lines of: "All I know is that I used to slccp, I 
know what that is like, but I am not doing that now. " This is despite 
polysomnographic evidence that showed over 6 hours sleep in two of these 
individuals. However, when looking at the individuals with the worst SMP in 
the groups reported on, the SF36 results they have still shown improvement in 
energy/vitality and mental health scores and therefore benefited in improved 
daytime functioning. 
Suggestions for future treatment of SMP/subjective insomnia might involve 
trying to improve the accuracy of their sleep perceptions. This might consist of 
using perceptual retraining with immediate accurate feedback following 
awakening. Downey(1992164 showed that a procedure designed to improve 
normal sleep/wake discriminations among those with sleep state misperception 
led to a reduction in sleep complaints, (although they had no control group of 
patients with objective insomnia). It was hypothesized that subjective 
insomniacs could more accurately estimate sleep latency by learning to 
differentiate wakefulness from sleep by EEG training while awake. Ten 
subjective insomniacs were randomly assigned to one of two groups. Group 1 
subjects participated in both a control and a training week; group 2 subjects 
participated only during a training week. During training, subjects were taught 
to use sleep markers (A, B or C) to help them more accurately estimate sleep 
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latency and were given feedback about the accuracy of their estimates. Marker 
A corresponded to an electroencephalographic level of wakefulness; marker 13 
corresponded to the initial sleep spindle; marker C corresponded to 5 minutes 
of continuous sleep after the first sleep spindle. In the control condition, 
subjects had no feedback and were not taught to use markers to help them 
judge sleep from wakefulness. After training, subjective sleep latency, 
correctness of estimates of sleep versus wakefulness and perceived ability to 
fall asleep significantly improved. They concluded that subjective insomniacs 
could learn to more accurately estimate sleep from wakefulness with the use of 
sleep-wake markers. More recently SMP, and the anxiety connected with it, 
has been shown by Tang (2004) to be reduced by careful comparison of sleep 
diary data and actigraphic data. 138 A group of insomniacs were asked to keep a 
sleep diary and wear an actigraph for three days. Half of the group were then 
shown the discrepancy between the diaries and actigraph and half were not. 
Sleep was then recorded for another 3 days and the group, who had had the 
discrepancy discussed with them showed an improvement in the recording of 
their SOL in the next few days of recording and less anxiety about their sleep. 
Tang and Harvey (2006) 139 have repeated their 2004 pilot study comparing a 
behavioural experiment to the verbal feedback i. e education about SMP. They 
also added other outcome measures other than sleep measures and used a 
sample population from the general public rather than university students. The 
participants in the behavioural experiment group calculated their own sleep 
misperception with guidance while those in the verbal group were told of their 
sleep misperception, (which was calculated for them. ) The participants were 
then monitored for another 2 nights. Consistent with the hypothesis the 
/7R 
behavioural group had better results on their sleep misperception scores and 
other sleep measures and rating scales. This would support behavioural 
experiments giving larger therapeutic changes than verbal techniques and 
changing the way people think and feel about their sleep. However both verbal 
and behavioural techniques gave improvements in SMP and it is promising 
clinically that simple verbal feedback will help improve subjective 
measurements of sleep which are extremely important to the patient. Tang and 
Harvey recommend further research with this technique with a wider 
population sample and to discover if the effect on lowering SMP is sustained 
over a period of time. They also suggest that this technique could be included 
in a multicomponent cognitive behaviour treatment plan for insomnia to help 
improve success rates. 
It is also thought that the subjective misperception of sleep immediately on 
waking may contribute to the maintenance of insomnia by impairing daytime 
functioning with more negative thoughts during the day. Semler and Harvey 
(2005)96 has shown that perception of a "good nights sleep" versus a "poor 
night's sleep" immediately on awakening was associated with impaired 
daytime functioning even when objective measures showed very similar sleep 
patterns via actigraphy in both groups of sleepers. It therefore may be 
important to correct an insomniac's bias towards reporting wakefulness. This 
could consist of providing information and reassurance that mental activity 
persists during sleep and extended periods sleep overnight are often 
interspersed with periods of wakefulness. 
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It could also be helpful to use cognitive therapy to directly challenge negative 
beliefs immediately on waking that may then lead to less distress during the 
day and possibly a better night's sleep the following day. We have certainly 
tried this approach as add-on therapy in a patient who has documented SMP 
and had already been through the insomnia group programme. 
Could these extra techniques be adopted into an insomnia group programme 
like the one described in chapter 4 to particularly help people with insomnia 
and SMP? Perhaps a second group programme could be arranged for those that 
had SMP with some extra cognitive work together with a PSG and behavioural 
intervention afterwards to learn what SMP is and how it can perpetuate 
insomnia. 
The recent NICE guidelines make a number of references to the non- 
pharmacological treatment for insomnia. They suggest that, if available, non- 
pharmacological methods should be tried before any pharmacological 
treatment for short- term insomnia. However, NICE make no recommendations 
about how to help patients with long-term insomnia. There are, however, few 
resources in the UK at present for the non-pharmacological treatment of 
insomnia. This is why reports of clinical effectiveness of a group insomnia 
programme for chronic insomnia run within the NHS are so important. The 
next stage after establishment of such programmes is to encourage reduction of 
medication during them. In reality, a large percentage of patients with 
insomnia take hypnotics intermittently for longer than the 2-4 weeks 
recommended by the hypnotic manufacturers. The only other effective 
lRn 
treatment for these patients is non-pharmacological i. e. cognitive behaviour 
therapy (CBT) in an individual or group format. 
With respect to CBT for insomnia, our results show improved quality of life 
scores and dysfunctional beliefs scores although little improvement in sleep 
parameters. This was in the context of a clinical pragmatic service for patients 
with primary and secondary insomnia. Harvey 2003165 argues that an effect 
size of 0.9 for SOL, 0.6 for WASO and 0.5 for TST in meta-analyses by 
Morin (1994)106 and Murtagh and Greenwood (1995)'08 of randomised 
controlled trials for CBT in insomnia were markedly lower than effect sizes 
obtained for other psychological disorders such as depression. The effect sizes 
in these papers were, in fact, z scores which can be interpreted as the distance, 
in standard deviation units, between the average treated and the average 
control patient. She argues that `We should not rest yet' and that we should 
improve the methodology and reporting of RCTs so that the results reported 
are not under- or overestimates and we should seek to improve CBT for 
insomnia. There are still 25% of people not showing any response to CBT. 107 
We would agree that there is room for improvement particularly when dealing 
with patients who have "racing thoughts" which are not obviously "affect 
laden" but come into patients' minds when they are lying awake and can't get 
to sleep. Paradoxical intention, imagery and thought stopping can all be used 
but do not provide a perfect solution to these annoying thoughts. 
A group method is certainly potentially time effective and can be cost 
effective, although evidence comparing the efficacy of group or individual 
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CBT is lacking. A very recent study by Espie (2007) has shown nurse- 
administered small group CBT for chronic insomnia was effective. 
146 This 
study however is also important, as CBT in this study is associated with 
significant positive changes in mental health and energy/vitality, (using the 
SF36) which agrees with our clinical group format findings. It was also 
showed in this study, via regression analysis, that the chronicity of the 
insomnia, the absence or presence of physical and mental health co-morbidities 
and participant age and sex was not associated with response to CIIT. 
Treatment delivery (chapterl), dosage (chapter 1), acceptability (chapter 4), 
adherence, accessibility, and cost effectiveness of CBT for insomnia are all 
important to consider. A recent publication by Edinger 2007, looked at dose - 
response for individual CBT finding twice weekly for eight weeks was the 
most effective. Stinson and Harvey (2006) also recently assessed the barriers to 
seeking treatment for primary insomnia in the UK. 166 Reasons for not seeking 
treatment were that people thought their insomnia was benign or trivial and 
they should be able to "cope on their own. " There was also a lack of 
awareness of treatment options and a perception that what was available was 
ineffective. There is little research as to whether patients find CBT acceptable 
but the indications from running the insomnia groups reported in chapter 4 
show these insomnia groups were well liked by participants. 
Accessibility is a problem because of the lack of clinical CBT programmes 
running in the UK. Adherence during and after CIIT treatment has been 
measured in a few studies and Harvey 2002 has shown that stimulus control, 
IRI) 
sleep restriction and cognitive restructuring are used in preference to other 
techniques and reported adherence to stimulus control and sleep restriction was 
the strongest predictor of clinical sleep improvements. 167 In the insomnia 
groups described above stimulus control and cognitive restructuring were 
being used at three-month follow up when group participants were questioned. 
Is a combination of medication and CBT the best alternative for those people 
with chronic insomnia? Morin would support this to maintain the best short 
and long term outcomes however acknowledges that acute insomnia is more 
easily treated with medication that is readily available with rapid relief of 
symptoms. 168 In the case of chronic insomnia perpetuating factors should be 
addressed and CBT used for more sustained improvement. 
In summary these studies have provided valuable insights into aspects of 
insomnia that have direct relevance for treatment in the future. Future work 
planned is a controlled trial of trazodone in primary insomnia and the 
collection of further data from patients completing the insomnia group 
programme with data at follow up visits to monitor if improvement is 
sustained. It is also hoped to use the group to support people with chronic 
insomnia to decrease or cease their hypnotic medication. 
1RZ 
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APPENDIX 1 
The Burden Centre: Insomnia croup 
Establishing an optimal sleep pattern 
1) Go to bed only when you are 'sleepy tired'- between 
10: 00pm and midnight. 
2) Set a threshold time after which you should monitor 
sleepiness. The difference between this and waking time 
should equate to typical mean length of sleep. 
3) Put the light out immediately you retire. 
4) Do not read or watch television in bed: these are waking 
activities. 
5) If you are not asleep within 20 minutes get out of bed and sit 
and relax in another room until you are 'sleepy tired' again. 
6) Repeat step (5) as often as is required, and also if you have 
any long awakenings in the night. 
7) Set the alarm to the same ringing time every day. This 
'anchor' should reflect your daytimetwaking schedule. 
8) Do not nap during the day. 
9) Do not take recovery sleep to compensate for a previous 
bad night. 
10) Follow the programme rigidly for several weeks to establish 
an efficient and regular pattern. 
Also: 
" Take regular exercise but no later than late in the afternoon 
" Cut out caffeine completely; i. e. tea, coffee, cola. 
(SleeoORt " Ater Espie. In Shapiro 1993) 
The Burden Centre: Insomnia Group 
Rehearsal and planning sessions 
1) Set aside 20 minutes in the early evening, perhaps after your 
meal. 
2) Sit in a quiet place. Have a pencil and notebook to hand. 
3) Treat this time as the pivotal point between daytime activities 
and the evening time. 
4) Reflect on the past day. Consider your achievements in 
relation to objectives. Encourage yourself with achievements. 
5) Consider any problem areas or loose ends. Reallocate time 
to deal with these things. Do not do the actual work needed, 
but note the decisions reached. 
6) Consider also any other matters which may intrude on the 
sleep period - for example, emotional, financial, or other 
worries. Write down the first or next positive step of action to 
take and when you will take it. 
7) If when you are in bed, you start to think about any of these 
issues, remind yourself that you have already dealt with them 
and have made (and recorded) your plans so that you do not 
need to think about them now. If new thoughts intrude 'refer 
them on to the next day. Think instead of something more 
pleasant: you can choose what you think about. 
(SlsspPl. n " from Eipk. In St aob, o93 
The Burden CeMn: Inscmn e Gmup 
Dealing with tension and developing relaxation skills 
1) Wind down during the second half of the evening. The body 
requires rest as well as sleep. 
2) Set a work/activity deadline at least 90 minutes before your 
usual bedtime. 
3) Practise a relaxation routine when in bed. 
" Concentrate on breathing. Try to breathe deeply and 
slowly. Rehearse subvocally 'in' and 'out' to respiration. 
Tense and relax major muscle groups in turn interspersed 
with breathing exercises. Muscle groups comprise arms 
neck and shoulders; face and eyes; stomach and back; 
legs. 
" Take the exercises slowly. Do not overtense muscles. 
Relaxation is about 'letting go'. 
4) Practise the relaxation routine at other times during the day. 
Try to develop this as a skill. 
(S$epRbm " from Esp+.. In Shaoko 19931 
The Bunten C. i*.: trnannii OtOUD 
Sleep scheduling 
1) Using your sleep diary, calculate your sleep efficiency: 
" Time asleep + Time in bed x 100 
" For example, if you go to bed at 10 o'clock and get up at 8 
o'clock and sleep, on average, for a total of 5% hours, your 
efficiency is: 
" 5.5+10x100 = 55% 
2) Aim to spend in bed only the amount of time that you usually 
sleep (but not less than five hours): 
" So, if you typically sleep for 5% hours and need to get up at 
7: 30am you should not go to bed until 2 o'clock in the 
morning however tired you are. On the other hand, if you 
prefer go to bed at midnight, you should get up at 5: 30am. 
3) Set an alarm clock for your selected getting up time. 
4) Get out of bed when the alarm goes off no matter how tired 
you feel. 
5) Do not sleep during the day. Go to bed at the same time 
each night. 
6) Stick rigidly to this routine. 
7) Your sleep efficiency may remain the same or decrease at 
first which is why this is a difficult strategy. When your sleep 
starts to increase you can increase the time spent in bed by 
15 minutes a night. When your sleep efficiency increases 
again, add another 15 minutes but do not increase your time 
in bed more than once in a week; give yourself time to adjust. 
rs fisch) 
The Burden Centre: Insomn d Group 
Dealing with frustration or racing thoughts 
1) Do not try too hard to fall asleep. 
2) State to yourself that'sleep will come when it is ready': that 
'relaxing in bed is almost as good'. 
3) Try to keep your eyes open in the darkened room and as 
they (naturally) try to close tell yourself to 'resist that for just 
another few seconds'. This procedure 'tempts' sleep to take 
over. 
4) Try to ignore irrelevant ideas and thoughts. 
5) Visualise a pleasing scene or try repeating a semantically 
neutral word (such as 'the') subvocally every few seconds. 
(SIpnpht fron Esple. In Shapiro tsar; 
APPENDIX 2 
(to be administered by a healthcare professional) 
To rate the severity of depression in patients who are already diagnosed as 
depressed, administer this questionnaire. The higher the score, the more severe the 
depression. 
For each item, write the correct number on the line next to the Item. (Only 
one response per item) 
i. DEPRESSED MOOD (Sadness, hopeless, helpless, worthless) 
O=Absent 
1=These feeling states indicated only on questioning 
2=These feeling states spontaneously reported verbally 
3=Communicates feeling states non-verbally - i. e., through facial 
expression, posture, voice, and tendency to weep 
4=Patient reports VIRTUALLY ONLY these feeling states in his 
spontaneous verbal and non-verbal communication 
2. FEELINGS OF GUILT 
O=Absent 
____ 
1=Self reproach, feels he has let people down 
2=Ideas of guilt or rumination over past errors or sinful deeds 
3=Present illness is a punishment. Delusions of guilt 
4=Hears accusatory or denunciatory voices and/or experiences 




1=Feels life is not worth living 
2=Wishes he were dead or any thoughts of possible death to self 
3=Suicidal ideas or gesture 
4=Attempts at suicide (any serious attempt rates 4) 
4. INSOMNIA EARLY 
O=No difficulty falling asleep 
1=Complains of occasional difficulty falling asleep - i. e., more than 1/2 
hour 
2=Complains of nightly difficulty falling asleep 
5. INSOMNIA MIDDLE 
O=No difficulty 
______ 
1=Patient complains of being restless and disturbed during the night 
2=Waking during the night - any getting out of bed rates 2 (except for 
purposes of voiding) 
7 
r 
6. INSOMNIA LATE 
O=No difficulty 
1=Waking In early hours of the morning but goes back to sleep 
2=Unable to fall asleep again If he gets out of bed 
7. WORK AND ACTIVITIES 
O=No difficulty 
___ 
1=Thoughts and feelings of incapacity, fatigue or weakness related to 
activities; work or hobbles 
2=Loss of interest in activity; hobbles or work - either directly reported by 
patient, or indirect in listlessness, indecision and vacillation (feels he has to 
push self to work or activities) 
3=Decrease in actual time spent in activities or decrease in productivity 
4=Stopped working because of present illness 
8. RETARDATION: PSYCHOMOTOR (Slowness of thought and speech; 
impaired ability to concentrate; decreased motor activity) 
O=Normal speech and thought 
1=Slight retardation at Interview 







2=Playing with hands, hair etc. 
3=Moving about, can't sit still 
4=Hand wringing, nail biting, hair-pulling, biting of lips 
10. ANXIETY (PSYCHOLOGICAL) 
O=No difficulty 
1=Subjective tension and irritability 
2=Worrying about minor matters 
3=Apprehensive attitude apparent in face or speech 
4=Fears expressed without questioning 
11. ANXIETY SOMATIC: Physiological concomitants of anxiety, (i. e., effects 
of autonomic overactivity, "butterflies", indigestion, stomach cramps, 
belching, diarrhoea, palpitations, hyperventilation, paraesthesia, sweating, 
flushing, tremor, headache, urinary frequency). Avoid asking about 







12. SOMATIC SYMPTOMS (GASTROINTESTINAL) 
O=None 
1=Loss of appetite but eating without encouragement from others. Food 
intake about normal 
2=Difficulty eating without urging from others 
13. SOMATIC SYMPTOMS GENERAL 
O=None 
__ 
1=Heaviness in limbs, back or head. Backaches, headache, muscle aches. 
Loss of energy and fatigability 
2=Difficulty eating without urging from others 
14. GENITAL SYMPTOMS (Symptoms such as: loss of libido; Impaired sexual 





O= Not Present 
_____ 
1=Self-absorption (bodily) 
2=Preoccupation with health 
3=Frequent complaints, requests for help, etc. 
4= Hypochondriacal delusions 
16. LOSS OF WEIGHT 
A: When rating by history: 





O=Acknowledges being depressed and III 
1=Acknowledges illness but attributes cause to bad food, climate, 
overwork, virus, need for rest, etc. 
2=denies being III at all 
MontgomeryAsberg Depression Rating Scale (MADRS) 
Montgomery SA Asberg M. A new depression scale designed to be sensltfre to change. (3 J Psychietq 1979; 134: 382-D. 
(Circle correct response) 
I Apparent Sadness 
" Representing despondency, gloom and despair (more than just transient low spirits), reflc ted 
in speech. facial expression and posture. Rate by depth, and ability to brighten up. 
0 No sadness 
1 
2 Looks dispirited, but does brighten up without difficulty 3 
4 Appears sad and unhappy most of the time 
5 
6 Looks miserable all the time. Extremely despondent 
z Reported Sadness 
" Representing reports of depressed mood, regardless of whether it is reflected to appearance or 
not. Includes low spirits, despondence, or the feeling of being bored beyond help and without 
hope. 
" Rate according to intensity, duration and the extent to which mood is reported to be Influenced 
by events. 
0 Occasional sadness In keeping with the circumstances 
1' 
2 Sad or low but brightens up without difficulty 
3 
4 Pervasive feelings of sadness or gloominess. The wood is still Influenced by 
external circumstances 
5 
6 Continuous or unvarying sadness, misery or despondency 
3 Inner Tension 
" Representing feet Inas of 111-deffineddI%comfort, edginess, Inner tumult, mentaI tens Ion mount Ing 
to either panic, dread or anguish. 
" Rate according to Intensity, frequency, duration and the extent of reassurance called for. 
0 Placid. Only fleeting inner tension 
1 
2 Occasional feelings of edginess and 111-defined discomfort 3 
4 Continuous feelings of inner tension or Intermittent panic which the patient can only Miter with 
5 
some difficulty 
6 Unrelenting dread or anguish. Overwhelming panic. 
h"s 1N1 
4 Reduced Sleep 
" Representing the experience of reduced duration of depth of sleep compared to the subject's own 
normal pattern when well. 
0 Sleeps as usual 
1 
2 Slight difficulty 
3 
4 Sleep reduced or broken by at least two hours 
5 
6 Less than two or three hours sleep 
S Reduced Appetite 
" Representing the feeling of a loss of appetite conpared with when well. Rate by loss of desire 
for food, or the need to force oneself to eat. 
0 Normal or increased appetite 
1 
2 Slightly reduced appetite 
3 
4 No appetite. Food is tasteless 
5 
6 Needs persuasion to eat at all 
6 Concentration Difficulties 
" Representing difficulties in collecting one's thoughts, aiunting to Incapacitating lack of 
concentration. 
" Rate according to intensity, frequency, and degree of incapacity produced. 
0 No difficulties in concentrating 
1 
2 Occasional difficulties to concentrating one's thought 
3 
4 Difficulties in concentrating and sustaining thought which reduces ability to read or hold a 
conversation 
5 
6 Unable to ready or converse without great difficulty 
7 lassitude 
" Representing a difficulty getting started or slowness Initiating and performing everyday 
activities. 
0 Hardly any difficulty in getting started. No sluggishness 1 
2 Difficulties in starting activities 
3 
4 Difficulties In starting si, ple routine activities which are carried out with effort 5 
6 Complete lassitude. Unable to do anything without help 
FSQ. ta* 
e Inability to reel 
" Representing the subjective experience of reduced Interest In the surroundings or activities 
that normally give pleasure. The ability to react with adequate emotion to Circumstances or 
people 1s reduced. 
0 Normal interest in the surroundings and In other people 
1 
2 Reduced ability to enjoy unusual Interests 
3 
4 Loss of interest in the surroundings. Loss of feelings for friends and acquaintances 
5 
6 The experience of being emotionally paralysed, Inability to feel arger. qrief or pleasure and 
a complete or even painful failure to feel for close relatives and friends 
9 Pessimistic Thoughts 
0 Representing thoughts of guilt, inferiority, self-reproach, sinfulness, remorse and ruin. 
i0 
No pessimistic thoughts 
2 Fluctuating Ideas of failure, self-reproach or self-deprecation 
3 
4 Persistent self-accusations, of definite but still rational ideas of guilt or sin. Increasingly 
5 
pessimistic about the future 
6 Delusions of ruin, remorse or unredeenuble sin. Self-accusations which are absurd and unshakablo 
10 Suicidal Thoughts 
" Representing the feeling that life is not worth living, that a natural death would be welcom. 
suicidal thoughts, and preparations for suicide. 
" Suicidal attempts should not In themselves Influence the rating. 
0 Enjoys life or takes it as it comes 
1 
2 Weary of life. Only fleeting suicidal thoughts 
3 
4 Probably better off dead. Suicidal thoughts are cci »n, and suicide 1s considered as a possible 
5 
solution, but without specific plans or intention 





Clinical Global Impressions (CGI) 
Guy W, editor. Clinical Global Impression (CGI). In, ECDEU Assessment Manual for 
Psychopharmacology. Rockville, MD: US Department of Health and Human Services, Public Health 
Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research 
Branch, 1976; 218-222. 
Severity of Illness (CG1-S) 
Considering your total clinical experience with this particular population, how 
mentally ill is the patient at this time? 
0 not assessed 
3= mildly ill 
6a severely ill 
Ia normal, not at all III 
4= moderately ill 
2- bordcrlinc mcntally ill 
5- markedly ill 
7- among the most extremely ill patients 
Global Improvement (CGI-I) 
Rate total improvement, whether or not, in your judgcment, it is entirely due to drug 
treatment. Compared to his condition at the cnd of baseline, how much has he 
changed? 
I- very much improved 2a much improved 
4= no change 5- minimally worse 
7- very much worse 
Comments 
Assessors Signature: 
3- minimally improved 
6- much worsc 
Date: 
CGI v 1.0 (1/10102) 
St. Mary's Hospital Sleep Questionnaire 
This questionnaire refers to your sleep over the past 24 hours. Please try and 
answer every question. 
Name ..................................... Date .................. 
©t what time did you: 
1) settle down for the night? ................. 
2) fall asleep last night? ................... 
3) finally wake this morning? ................. 
4) getup this morning? ....................... 
5) Was your sleep (tick box) 




3 fairly light 
E) 
4 light average 
5 deep average 
0 
6 fairly deep 
7 deep 
(3 
8 very deep 
6) flow many times did you wake upL (tick box) 
O not at all 
I once 
2 twice 
3 three times 
4 four times 
5 five times 
0 
6 six times 
E) 
7 more than six times 
slow-much 31ccD did you have 
7) last night? 
8) during the day, yesterday? 
................ hrs.......... m ins 
................ hn.......... mins 
9) }low well did you slee lR last night? 
(tick box) 




3 fairly badly 
0 




6 very well 
0 
If not well what was the trouble (eg restless, etc)? 
2 
3 
10) How clear-headed did you feel aller getting ýt p this morning? (tick box) 
1 still very drowsy indeed 
2 still moderately drowsy 
3 still slightly drowsy 
0 
4 fairly clear-headed 
19 
5 alert 
6 very alert 
0 
11) Now satisfied were you with last n ight's sleep? (tick box) 
I very unsatisfied 
0 
2 moderately unsatisfied 
0 
3 slightly unsatisfied 
0 
4 fairly satisfied 
S completely satisfied 
0 





13) Flow much difficulty did you have in gctting o to stcc Inst night2(tick box) 




4 extreme difficulty 
Q 
14) flow long did it take you to fall asicco last night? ................ hrs............. mina 
LEEDS SLEEP EVALUATION QUESTIONNAIRE 
Subject name/initials Number Date 
Each question is answered by placing a vertical mark on the line. If no change was experienced then 
place the mark in the middle of the line. If a change was experienced then the position oIyour mark 
will indicate the nature and extent of the change ie large changes near the ends of the 
line, small 
changes near the middle. 
For example, this would indicate a small change: 
VA 
How would you compare getting to sleep last night with getting to sleep normally? 
a) Easier 
Harder 
than usual than usual 
b) Quicker Slower 
than usual than usual 
c) Felt more Felt lest 
drowsy drowsy 
than usual than usual 
How would you compare the quality of your sleep last night with your usual sleep? 
a) More restful 
than usual 
More restless 
-- than usual 
b) Fewer periods More periods 
of wakefulness of wakefulness 
than usual than usual 
II did your awakening this morning compare with your usual awakening? 
a) Easier 
than usual 
b) Took less time 
than usual 
How did you feel on waking? 
Harder 
than usual 
Took more time 
than usual 
Alert Tired 
stow do you feel now? 
Alert wed 
how was your sense of balance and coordination on waking? 
Less clumsy More clumsy 
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Chapter 3: Non significant data and grai)lIs 
Non significant Objective sleep data: 
Table 3.1: Paired t test Results 
Sleep Nefazodone Placebo Mean Standard t P value 
Parameter (Mean value (Mean Difference Deviation statistic 
for whole value for (paired t 
group) n=10 whole test) 
group) n-10 
stage l (min) 43.1 37.2 5.9 16.9 1.0 ns 
stage 2(min) 209.6 200.6 -8.9 52.9 -0.5 ns 
stage 3(min) 27.8 21.6 -6.3 -9.9 -1.8 nj 
stage 4(min) 32.9 39.4 6.5 13.5 -1.4 ns 
REM 98.7 83.2 -15.5 33.2 -1.4 ns 
slecp(min) 
'rabic 3.2: Wilcoxon Sign Rank 'l'c, -%t Results 
Nefazodone Placebo z value P value 
(Mean value (Mean value 
for whole for whole 
group) n=10 group) n-9 
except for SOL 
when n° 10 
SOL(mins) 19.7 15.6 -0.4 ns 
ROL(mins) 56.9 102.7 0.8 ns 
WASO (mins) 49.9 68.5 1.4 ns 







  SOL Placebo 
50 






Non significant subjective sleep data (SMIIQ) 
Figure 3.5: Subjective Sleep Onset Latency (SOL) SMHQ Nefazodone 
versus Placebo 
  SOL Placebo 




Figure 3.6: Depth of Sleep SMHQ Nefazodone versus Placebo 
7- 
6 
Depth of sleep Placebo 





Non significant subjective sleep data (Leeds): 
Figure 3.9: "Getting to Sleep" LSQ Nefazodone versus Placebo 
U) 50 
Getting to sleep Placebo 




Figure 3.10: Morning Tiredness LSQ Nefazodone versus Placebo 
X _: A Alertness Placebo 60   Alertness Nefazodone 
c 




Figure 3.11: Behaviour on Awakening LSQ Nefazodone versus Placebo 
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A Behaviour on Awakening 
Placebo 



















2 Sleep quality Placebo 
  Sleep quality Nefazodone 
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APPENDIX 4 
The Burden Centre: Insomnia Group SF-38 
.... NAME ................................................... Date .................... 
SF-36: General Health Questionnaire 
This questionnaire asks for your views about your health and how well you are able to do your 
usual activities. 
Please answer each question by circling the appropriate number 1,2,3, ... If you are unsure 
about how to answer a question, please give the best answer you can and make a comment in 
the left margin but please only circle one number for any question. 
1. In general would you say that your health is: 
(circle one number) 
Excellent ....................................................... 1 
Very good ...................................................... 2 
Good ............................................................ 3 
Fair .............................................................. 4 
Poor ............................................................. 5 
2. Compared to one year ago, how would you rate your general health now? 
(circle one number) 
Much better now than one year ago 1 
Somewhat better now than one year ago 2 
About the same 3 
Somewhat worse than one year ago 4 
Much worse than one year ago 5 
PF RLP RLM SC MH EV p HP CIH 
I 
SF-36 
HEALTH AND DAILY ACTIVITIES 
3. The following questions are about activities you might do during a typical day. Does your 
health limit you in these activities? If so, how much? (Circle 1,2, or3 on each line). 
Yes Yes No, not 
limited limited limited 
a lot a little at all 
a. Vigorous activities, such as running, 
lifting heavy objects, participating in 1 2 3 
strenuous sports 
b. Moderate activities, such as moving a 
table, pushing a vacuum cleaner, bowling, 1 2 3 
or playing golf 
c. Lifting or carrying groceries 1 2 3 
d. Climbing several flights of stairs 1 2 3 
e. Climbing one flight of stairs 1 2 3 
f. Bending, kneeling or stooping 1 2 3 
g. Walking more than one mile 1 2 3 
h. Walking half a mile 1 2 3 
i. Walking 100 yards 1 2 3 
j. Bathing or dressing yourself 1 2 3 
2 
SF-36 
4. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of your physical health? (Please answer YES 
or NO for each question by circling 1 or 2 on each line. ) 
YES NO 
a. Cut down on the amount of time you spent on 
work or other activities 
1 2 
b. Accomplished less than you would like 1 2 
c. Were limited in the kind of work or other 
activities 
1 2 
d. Had difficult performing the work or other 
activities (for example, it took extra effort) 
1 2 
5. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? Please answer YES or NO for each question by circling 1 or 2 
on each line. ) 
YES NO 
a. Cut down on the amount of time you spent on 
work or other activities 
1 2 
b. Accomplished less than you would like 1 2 





6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours or groups? 
(circle one number) 











7. How much bodily pain have you had during the past 4 weeks? 
(circle one number) 
None ................................................. 
1 




Moderate .......................................... 4 
Severe ............................................. 
5 
Very severe ....................................... 
6 
8. During the past 4 weeks, how much did pain interfere with your normal work (including 
work both outside the home and housework) 
(circle one number) 
Not at all ............................................ 1 
A little bit ............................................ 2 
Moderately ........................................ 3 
Quite a bit .......................................... 4 




9. These questions are about how you feel and how things have been with you during the 
past month. For each question, please indicate one answer that comes closest to the 
way you have been feeling. 
How much of the time during the past month ... 
(circle one number on each line) 
All Most A good Some A little None 
of the of the bit of of the of the of the 
time time the time time time time 
a. Did you feel full of life? 1 2 3 4 5 6 
b. Have you been a very 1 2 3 4 5 6 
nervous person? 
c. Have you felt so down in 
the dumps that nothing 1 2 3 4 5 6 
could cheer you up? 
d. Have you felt calm and 1 2 3 4 5 6 
peaceful? 
e. Did you have a lot of 1 2 3 4 5 6 
energy? 
f. Have you felt downhearted 1 2 3 4 5 6 
and low? 
g. Did you feel worn out? 1 2 3 4 5 6 
h. Have you been a happy 1 2 3 4 5 6 
person? 
i. Did you feel tired? 1 2 3 4 5 6 
j. Has your health limited 
your social activities (like 1 2 3 4 5 6 




10. Please choose the answer that best describes how true or false each of the following 
statements is for you. 
(circle one number on each line) 
Definitely Mostly Not Mostly Definitely 
true true sure false false 
a. I seem to get ill 
more easily than other 1 2 3 4 5 
people. 
b. I am as healthy as 1 2 3 4 5 
anybody I know. 
c. I expect my health 1 2 3 4 5 to get worse. 
d. My health is 1 2 3 4 5 
excellent. 
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE 
PLEASE TAKE A MOMENT TO CHECK THAT YOU HAVE 
COMPLETED ALL OF THE QUESTIONS ON ALL 6 PAGES 
6 
Personal beliefs and attitudes about sleep 




Some statements about people's beliefs and attitudes about sleep are listed below. Please indicate to what extent you 
personally agree or disagree with each statement. There Is no right or wrong answer. For each statement, place a mark 
(I) 
along the line wherever your personal rating falls. Try to use the whole scale rather than placing your marks at one end. 
Please answer all the questions even if you do not have a sleep problem. 
1.1 need 8 hours sleep to feel refreshed and function well during the day. 
STRONGLY STRONGLY 
DISAGREE AGREE 
Z. When I don't get proper amount of sleep on a given night, I must catch up next day by napping or on the next 
night by sleeping longer. 
STRONGLY STRONGLY 
DISAGREE AGREE 
3. Because I am getting older, I need less sleep. 
STRONGLY STRONGLY 
DISAGREE AGREE 
4. I am worried that if Igo for I or 2 nights without sleep, I may have a 'nervous breakdown'. 
STRONGLY STRONGLY 
DISAGREE AGREE 
5.1 am concerned that chronic insomnia may have serious consequences on my physical health. 
STRONGLY STRONGLY 
DISAGREE AGREE 
6. By spending more time in bed, I usually get more sleep and feel better next day. 
STRONGLY STRONGLY 
DISAGREE AGREE 
7. When I have trouble falling asleep or getting back to sleep after night-time awakening, I should stay in bed 
longer and try harder. 
STRONGLY STRONGLY 
DISAGREE AGREE 
8.1 am worried that I may lose control over my ability to sleep. 
STRONGLY STRONGLY 
DISAGREE AGREE 
9. Because I am getting older I should go to bed earlier in the evening. 
STRONGLY STRONGLY 
DISAGREE AGREE 
10. After a poor night's sleep I know that it will interfere with my daily activities on the next day. 
STRONGLY STRONGLY 
DISAGREE AGREE 
11. To be alert and function well during the day, I believe I would be better off taking a sleeping pill rather than 
having a poor night's sleep. 
STRONGLY STRONGLY 
DISAGREE AGREE 




13. Because my bed-partner falls asleep as soon as his/her head hits the pillow and stays asleep during the night, 
I should be able to do so too. 
STRONGLY STRONGLY 
DISAGREE AGREE 
The Burden Centre: Insomnia Group PLEASE TURN OVER 
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Randomised controlled study of sleep 
after nefazodone or paroxetine treatment 
in out-patients with depression 
J. A. HICKS. S. V. ARGYROPOULOS, A. S. RICH, J. R. NASH, C. J. BELL, 
C. EDWARDS, D. J. NUTT and S. J. WILSON 
Background Sleep efrects of 
antidepressants are important clinically 
and for elucidating mechanism of action: 
selective serotonin reuptake inhibitors 
disturb sleep and S-HT2 receptor- 
blocking compounds may enhance sleep 
quality. 
Aims To compare the objective and 
subjective effects on sleep of paroxetine 
and nefazodone in patients with moderate 
to severe depression. 
Method Forty patients with 
depression were randomised to take 
paroxetine 20-40 mg! day or nefazodone 
400-600 mg/day for 8 weeks. Objective 
and subjective quality of sleep and 
depression measures were assessed 
throughout. 
Results Nefazodone significantly 
increased objective sleep efficiency and 
total sleep time, and improved subjective 
sleep on days 3 and 10. Paroxetine 
decreased sleep efficiency early in 
treatment and some sleep disruption 
remained at week 8. Paroxetine but not 
nefazodone produced marked 
suppression of rapid eye movement (REM) 
sleep. 
Conclusions Nefazodone improves 
sleep in early treatment compared with 
paroxetine in patients with moderate to 
severe depression. These effects are seen 
within the first 2 weeks of treatment and 
diminish thereafter. 
Declaration of interest Funding and 
medication were provided by Bristol- 
Myers Squibb Pharmaceuticals, UK. 
The efficacy of new antidepressants intro- 
duced in recent years generally appears to 
be equal to that of the established classes 
of drugs, particularly the tricyclics (TCAs) 
and the selective serotonin reuptake in- 
hibitors (SSRIs) (Anderson et al, 2000). 
However, some new compounds claim 
advantages over other agents, especially 
the SSRls. These advantages, which differ 
from drug to drug, either refer to specific 
side-effects, such as sexual dysfunction, or 
to symptoms of the depressive illness that 
are not adequately controlled by the SSRIs, 
such as sleep. Nevertheless, head-to-head 
comparisons between the new agents and 
the SSRIs, designed specifically to test these 
claims, are still scarce. 
Antidepressants and sleep 
One of the new compounds, nefazodone, is 
said to confer an advantage over the SSRls 
in improving sleep, even before the onset of 
antidepressant action. This clinically useful 
characteristic is shared with the TCAs but 
the latter group, unlike nefazodone, is 
handicapped by danger in overdose and 
troublesome anticholinergic side-effects. 
By contrast, the SSRIs are not considered 
sleep-promoting. Disturbed sleep is one of 
the most frequent and distressing symptoms 
in moderate and severe depression. 
Objective sleep changes in depression 
include shortened rapid eye movement 
(REM) latency, disruption of sleep 
continuity, early morning waking and 
reduction of slow wave sleep, particularly 
in the first sleep cycle (Benca et al, 1992). 
Antidepressants such as the TCAs and 
SSRIs produce marked suppression of 
REM sleep. The TCAs tend to improve 
sleep fragmentation acutely whereas SSRIs 
decrease sleep continuity until there is 
resolution because of improvement of the 
depressive illness (Wilson et a!, 2000). 
Nefazodone weakly antagonises the 
reuptake of serotonin (S-IM and nor- 
adrenaline (Tatsumi et al, 1997); it also 
blocks the post-synaptic S-f IIT1 receptor 
and the at-adrenoceptor, but does not 
block histamine or cholinergic receptors, 
the supposed mechanism producing the 
sedative effects of TCAs (Cusack et al, 
1994). In a multi-centre sleep laboratory 
study in major depression (Rush et al, 
1998) nefazodone improved sleep over an 
8-week period compared with fluoxctine. 
No study, however, has looked at the first 
2 weeks of treatment or at patients sleeping 
in their home environment. 
METHOD 
Protocol and study objectives 
This was a single-site, double-blind, 
randomised, parallel-group, 8-week study 
of sleep in patients with moderate to severe 
depression without psychotic features. The 
objective of this trial was to compare the 
effects of nefazodone and paroxetine on 
sleep and mood. The study was approved 
by the local ethics committee and all 
patients gave written informed consent. At 
the end of the acute phase of the treatment 
(8 weeks) patients who showed at least 
minimal improvement on the Clinical 
Global Impression (CGI) Improvement 
scale (Guy, 1976) continued to be studied 
clinically, but without sleep measures, for 
a further 16 weeks. 
Patient population 
Consecutive referrals to it hospital 
psychiatric out-patient clinic and direct 
referrals from two general practices were 
assessed for eligibility in the study. They 
were screened with full medical and psychi- 
atric history, mental state examination and 
physical examination. To be randomised 
into the study, patients had to fulfil 
diagnostic criteria for DSM-N (American 
Psychiatric Association, 1994) moderate 
to severe depression, scoring 18 or over 
on the Hamilton Rating Scale for Depres. 
sion (HRSD; Hamilton, 1960). Exclusion 
criteria included schizophrenia, history of 
mania, active suicidal ideation, alcohol 
misuse and illicit drug use. Patients unable 
to maintain a consistent sleep pattern, such 
as shift workers or those with a current 
slecp/wake disorder, were also excluded. 
Pre-menopausal women were required to 
have a negative pregnancy test at screening 
and to take precautions against pregnancy 
during the trial. Subjects who had 
previously taken psychoactive medication 
including bcnzodiazcpincs were required 
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to undergo a 2-week (or S-week in the case 
of fluoxetine) washout period before enter- 
ing the trial. In the event, six of the patients 
had received bcnzodiazepincs, none in the 
previous year, and four patients had 
received fluoxetine in the previous year, 
one stopping for the study. 
Patients who had received any other 
investigational drug up to 30 days before 
the initiation of therapy, or who were 
participating in another clinical study at 
the time of the assessment, were not consid- 
ered for inclusion in this protocol. Pregnant 
or nursing females, or women of child- 
bearing potential who were not using 
adequate methods of birth control were 
also excluded. 
Determination of sample size 
This was calculated to detect the smallest 
clinically relevant differences in two sleep 
parameters measured by electroencephalo- 
gram (EEG) (total sleep time and number 
of awakenings) with an 80% power 
(P=0.0S) based on variance data from a 
previous sleep study conducted in our 
laboratory (Wilson et al, 2000), and the 
two-sample method (Gore & Altman, 
1982) was applied. The estimated sample 
size was 18 patients in each group provid- 
ing valid data for at least three sleep assess- 
ment days (see later). The target sample size 
was then extended to 22, to allow for drop- 
outs. In the event of the study, fewer drop- 
outs occurred than had been anticipated. 
Study design and medication 
Forty patients were randomly assigned on 
day I of the study, after the baseline period, 
to receive either nefazodone or paroxetine. 
Randomisation was carried out by Bristol- 
Myers Squibb, in blocks of four, so that 
in any one block there were two patients 
taking nefazodone and two taking 
paroxetine. All study medication was 
re-encapsulated. Capsules and container 
bottles were identical, in shape, but of two 
different colours. Medication was provided 
for an extra 3 days a week, to allow for late 
follow-up visits. Treatment was taken in a 
twice daily regimen by mouth, with 
patients taking one or two capsules from 
the nefazodone/placebo bottle twice a 
day and a capsule from the paroxetinet 
placebo bottle in the morning. Patients 
commenced on day 1 with either morning 
ncfazodone (100 mg twice daily), evening 
nefazodone (100 mg+placebo) or morning 
paroxetine (20 mg+placebo), evening 
placebo. After 1 week, the dose of ncfazo- 
done was increased to 200 mg twice daily 
and that of paroxetine remained at 20 mg 
once a day. Further titration was according 
to clinical response and side-effects, and 
occurred during scheduled visits or urgent 
visits if there were any problems. Adverse 
events were monitored specifically from a 
checklist of 95 symptoms and recorded 
during each visit. Patients also had 24-h 
telephone access to an investigator if any- 
thing untoward occurred. The patients 
were instructed to return all unused medi- 
cation in the original package at each visit. 
No additional psychoactive medication was 
allowed during the washout and treatment 
phase of the study. Wherever possible, all 
other non-psychotropic concomitant medi- 
cations and non-pharmacological therapies 
were recorded and kept constant for the 
duration of the study. 
Assessments 
At baseline, a physical examination was 
performed; vital signs (pulse, blood pres- 
sure) were recorded, and demographic data 
were collected. Information about previous 
episodes of depression was obtained from 
case notes and patients' and relatives' recol- 
lection. A pregnancy test was performed as 
indicated above. A baseline EEG was per- 
formed using the home ambulatory moni- 
toring system (Medilog, Oxford Instruments 
Medical, Old Woking). Subjects were vis- 
ited in their homes during the evening 
and the recording equipment for electro- 
encephalography, electro-oculography, and 
electromyography was attached, according 
to the standard sleep montage (Recht- 
schaffen & Kales, 1968). The subjects were 
then left to sleep normally at home. They 
were asked not to bathe or shower with 
the equipment on but told that otherwise 
they could carry out their normal domestic 
routine; they were asked not to drink 
alcohol for the 48 h before the recording 
but were allowed their normal caffeine 
intake. They were instructed to keep to 
their normal bedtime routine and to press 
the event marker on the recorder when 
they turned out the lights and tried to 
sleep, and on waking finally the following 
morning. Subjective measures of sleep 
using the St Mary's Hospital Sleep Ques- 
tionnaire (SMIISQ; Leigh et a!, 1988) 
were obtained on the morning after the 
recording. Thereafter sleep recordings and 
subjective sleep questionnaires (SMIISQ 
and Leeds Sleep Evaluation Questionnaire 
(LSEQ; Parrott & Rindmatch, 1978)) were 
performed at days 3 and 10 and week 8 of 
treatment. Patients kept a diary of sleep 
quality and number of awakenings for the 
first 21 days of treatment. 
Sleep analysis 
Sleep was scored automatically by the 
Medilog 9002 with visual correction by 
an experienced sleep scorer (j. A. 1 L) accord- 
ing to the Rechtshaffen & Kalcs (1968) 
criteria. The following parameters were 
derived from the sleep recordings. (a) 
Staging time - the interval between the 
patient pressing the event markers (when 
these were omitted, the sleep scorer judged 
these times from the EEG recording when 
the patient closed their eyes at night and 
when they opened them and started to 
move around in the morning). (b) Total 
sleep time (TST) - time in all stages of 
sleep. (c) Sleep efficiency - %TST/staging 
time. (d) Number of awakenings - these 
had to be greater than 16 s in duration. (e) 
Sleep onset latency - time from the patient 
pushing the button to start their night's 
sleep to the first 2 min of stage 2 sleep. (f) 
Duration of stage 1-4, and REM sleep 
and REM onset latency -the time to the 
first continuous 2 min of REM from the 
onset of stage 2 sleep. (g) Wakefulness after 
sleep onset - total time spent awake after 
sleep onset. 
Efficacy of the antidepressant treatment 
was measured with the IIRSD (Hamilton, 
1960), Montgomery-Asbcrg Depression 
Rating Scale (MADRS; Montgomery & 
Asberg, 1979) and CGL Severity and 
improvement scales (Guy, 1976). These 
were completed by the clinician at baseline, 
days 3 and 10, and at the end of weeks 3,4, 
6,8,16 and 24 (end of study) or at any 
point that a patient was prematurely with- 
drawn from the study. 
Statistical analysis 
Statistical analysis of objective slap 
measures was carried out using STATA 
version 5.0 for Windows (STATA 
Corporation). Descriptive statistics were 
derived for each of the variables. Tests for 
normality showed that the variables stage 
1, stage 3, slap onset latency, REM onset 
latency and wakefulness after sleep onset 
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were not normally distributed. The values 
for stage 1 sleep and sleep onset latency 
and wakefulness after sleep onset were 
normalised by logarithmic transformation, 
and those for stage 3 sleep, REM onset 
latency and wakefulness after sleep onset, 
by square root transformation. Complete 
data-sets (four sleep assessments) were 
available for 29 individuals and this 
resulted in an unbalanced design. Conse- 
quently, a sequential fitting of the 
different sum of squares was used. Split plot 
analysis of variance (split plot ANOVA) 
was used to investigate the effects of the 
two drugs on all the sleep variables. This 
analysis separates the variance ascribable 
to pre-treatment differences between the 
two treatment groups, resulting from the 
effect of time, the interaction between time 
and treatment and the effect of the treat- 
ments themselves. 
Data from HRSD, MADRS and CGI 
severity and improvement scales were tabu- 
lated using both the observed values and 
with last observation carried forward 
(LOCF) in the whole (intent to treat; ITT) 
group. Number of responders (50% or more 
reduction on baseline HRSD) and remitters 
(HRSD <8) were tabulated for each treat- 
ment group. Total scores for the rating 
scales were analysed using ANOVA, first 
at baseline and on the change from baseline 
at the end of the specific weeks and end- 
point (subject's last available observation). 
Descriptive statistics, comparison tests 
at days 3,10 and week 8 and ANOVA were 
performed on the scores of LSEQ, the items 
S, 6,9-11 and 13 of SMHSQ and the sleep 
items of HRSD. Values from the daily diary 
of sleep quality were analysed with descrip- 
tive statistics and scrutinised for possible 
trends in the data. An average score for 
each week of the study was compared for 
the two groups. 
Adverse events were cross-tabulated by 
treatment, severity and clinical estimate of 
relation to study medication, to detect any 
evidence of drug-related trends or increased 
incidence. 
All statistical tests and analysis of sub- 
jective and mood measures were performed 
using the standard SPSS package (version 
10.0 for Windows). 
RESULTS 
Participant recruitment and 
follow-up 
Forty patients (23 females, 17 males) were 
randomised to nefazodone (n=20) or 
paroxetine (n=20). Demographic data and 
past psychiatric history data, including co- 
morbidity, are presented in Table 1. There 
were no significant differences between 
the groups in these variables. The number 
of patients that completed the study and 
the reasons for early discontinuation are 
presented in Table 2. 
Patients excluded from the sleep 
analysis were: one patient who completed 
baseline only; one patient who completed 
baseline and day 3, but day 10 recording 
was technically unsatisfactory; and one 
patient whose baseline recording was tech- 
nically unsatisfactory. One other patient's 
day 3 recording was technically unsatisfac- 
tory but baseline, day 10 and week 8 were 
included, and six other patients had no 
week 8 recording as they left the study. 
The mean nefazodone dose (and stan- 
dard deviation (s. d. )) used in the study 
Table I Baseline demographic and clinical data 
was 495 mg/day (82.6) and for paroxetine 
it was 29.5 mg/day (8.9), well within the 
therapeutic range advised for these drugs 
in the treatment of depression. 
Analysis of sleep 
In the paroxetine group, four patients at 
day 3 and one patient at day 10 had no 
REM sleep at all. In these patients the 
REM latency was taken to be the staging 
time minus sleep onset latency. 
Table 3 shows polysomnographic data 
of sleep parameters with results of ANOVA 
statistical analysis. 
There were significant pre-treatment 
differences between the two treatment 
groups on nearly all the sleep measures, 
with sleep in the paroxctine group being 
generally worse. This occurred entirely 
by chance, as allocation was random. As 
Baseline characteristic Nefazodone (n=20) Paroxetlne (n=20) 
Age (years) (mean, s. d. ) 
Median (range) 
Gender (% male) 
Women (%) 
Past history of depression (%) 
Previous antidepressants (%) 
Number of previous episodes (mean, s. d. ) 
Age of onset of first episode (years) (mean. s. d. ) 
Length of previous episodes (weeks) (mean, s. d. ) 




Chronic physical conditions 
42.75 (11.93) 42.95 (10.12) 






3111 (13-09) 31.6 (12.34) 
23.33 (16.91) 37.33 (27.39) 
S0.6S (57.80) 42.6 (4S. 7S) 
4(20) 2 (10) 
S(25) 2 (10) 
2(10) S(2S) 
Table 2 Primary reasons for discontinuation 
Reason for discontinuation Nefazodone Paroxetfne 
8 week sleep 24 weeks 8 weeks sleep 24 weeks 
study continuation study continuation 
Completed study (%) IS (75) 
Non-completers (%) 
Adverse experience 4(20) 
Lost to follow-up 1(5) 
9(4S) 17 (8S) 13(6s) 
i (s) 2(10) 
Lack of efficacy 2 (10) 2(10) 3 (IS) 
Improvement I (S) 
Other known cause I (S) I(S) 
Total discontinuations S(25) 6(30) 3 (IS) 4(20) 
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described in the Method section, we sepa- 
rated this baseline difference from the treat- 
ment effects. 
'There were significant drug effects on 
total sleep time, sleep efficiency (see Fig. 1) 
and wakefulness after sleep onset, with 
nefazodone improving these and paroxetine 
worsening them early in treatment but both 
drug groups returning towards baseline by 
8 weeks. Stage 1 sleep and number of 
awakenings also showed significant treat- 
ment effects and these were more obvious 
at 8 weeks, with both measures being in- 
creased in the paroxctine group (see Fig. 2). 
Number of awakenings showed a significant 
time x treatment effect, with the nefazodone 
group showing an early decrease and return- 
ing towards baseline at 8 weeks and the 
paroxetine group continuing to increase 
during treatment. 
There were highly significant treatment 
differences on REM sleep, with paroxetine 
increasing REM latency (see Fig. 3) and 
decreasing the amount of REM throughout 
the 8 weeks' treatment. The ncfazodone 
group showed a slight increase in REM 
and decrease in REM latency. Neither slow 
wave sleep nor stage 2 sleep showed 
significant time or group differences. 
Subjective data from the SMHSQ were 
not distributed normally and there was a 
significant difference between the two 
treatment groups at baseline. 
Changes from baseline scores were 
derived for all patients and these were 
found to be distributed normally and there- 
fore used in subsequent testing. A signi- 
ficant difference was found at night 3 for 
sleep quality (item 5: how well did you 
sleep? ) (T=2.12, d. f. =36, P=0.04) with 
the nefazodone group showing greater 
improvement from baseline. On the 
ANOVA there was a treatment effect for 
sleep quality (P=0.042) and for sleep depth 
(P=0.042) with the ncfazodonc group 
showing more improved scores on both 
(Table 4 and Fig. 4). 
There was no significant treatment 
effect on the variables of LSEQ but the 
factor 'behaviour following wakening' 
showed a trend for less clumsiness and 
tiredness in the morning with paroxetine 
and more with nefazodone. The differences 
from baseline, however, were small. The 
week-bywcck analysis of the sleep diary 
averages for sleep quality (how well I slept) 
and continuity (how many times did you 
wake up? ) and the I IRSD sleep items were 
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Fig. I Mean sleep efficiency. Error bars Indicate 
s. e. m. 
+ nefazodone + nefazodone 







0 ... T- 
Baseline Day 3 Day 10 Week 8 Baseline 
Day 3 Day 10 Week 8 
Overall treatment effect (Avow) P<0.05 
Overall treatment effect (Avw+) P<0.001 
Fig. 2 Mean number of awakenings. Error bars 
indicate s. e. m. 
Fig. 3 Mean REM latency. Error bars indicate 
t. e. m. 
Table 3 Objective (EEG) sleep 
Objective sleep measure Nefazodone mean (s. d. ) Paroxetine mean (s. d. ) ANOVA (treatment effect) 
Baseline Day 3 Day 10 Week 8 Baseline Day 3 Day 10 Week 8FP 
n=19 n=19 n=18 n=14 n=18 n=17 n=18 n=16 
Time in bed 474 (61) 482(60) 466(73) 473(65) 479(83) 472(79) 4S$(6,4) 495 (S6) 
Sleep onset latency 31(32) 33(29) 3S(46) 20(9) 33(32) SS (48) 36(25) 41(35) NS 
Total sleep time 383(48) 409(67) 389 (40) 396(S3) 370(63) 334(76) 3S2(61) 388(70) 5.05 0.05 
% Sleep efficiency 81(9) 85 (I0) 84(12) 84(11) 78(11) 71(13) 77(9) 78(8) 11.49 0.005 
Wake time after sleep onset SS (42) 3S(41) 40(40) 53(60) 67(S8) 74(S4) 74(S2) 63(37) 7.2 0.025 
Number of awakenings' 1](8) 13(6) 10(6) 14(9) 17(8) 16(9) 18(e) 24(13) 7. SI 0.025 
% Stage I 10(6) 9(8) 6(4) 6(4) 10(7) 11(8) 10(6) 13(7) 6.33 0.025 
%Stage 2 45 (10) 46(9) 46(9) 46(12) 40(13) 4S(13) 45 (9) 40(9) NS 
%Stage 3 7(4) 8(s) 9(6) 11(8) 7(4) 9(8) B (S) 7(4) ISIS 
%Stage 4 8(6) 6(S) 6(6) 6(8) 9(10) 10(13) 9(I1) 6(10) NS 
% REM 21(6) 24(S) 26(8) 23(6) 20(7) 7(8) 12(6) 6(6) 29.4 0.01 
REM onset latency 78(36) 59(28) 61(42) 62(34) 73(4S) 278 (113) 227 (120) 173(S2) 133.0 0.001 
NS, non-significant. 
1. Time effect (ANOVA): F-S. 06. P. O. OIs time x treatment effect (ANOVA): F-17, P=0.03. 
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Time it took me to fall asleep (min. ) 67(S4) 41(29) 47(38) 29(21) 61(48) S9(50) 31(22) 
28(56) 
Total time I slept (min. ) 335(87) 379(78) 375 (86) 408(62) 336(82) 354(59) 395 
(10S) 441(62) 
Depth of sleep' 
(I=v. light to 8=v. deep) 3.05 (I. 5) 4.1(1.4S) 4.58 (1.61) 4.54 (0.96) 3.85 (I. 69) 3.95 (1.72) 4.33 (1.91) 
4.31(1.07) 
How many times I woke up 3.35 (I. 5) 2.7 (1.69) 1.84(l. 71) 2.29(l. 38) 2.9 (2.13) 2.84 (1. IS) 2.3S (1.73) 
3.06 (2.02) 
How well I slept' 
(I =v. badly to 6=v. well) 2.6S(2.03) 3.7 (0.8) 3.63 (1.16) 4(0.96) 3.2 (1.15) 3.31(l. 38) 
3.83(l. 29) 3.94 (0.68) 
How clear-headed I felt on waking 
(I =v. drowsy to 6=v. alert) 2.6(l. 27) 2.6 (0.94) 2.47 (1.12) 2.93(l. 07) 2.65 
(1.35) 2.53 (1.12) 2.89(l. 02) 3.07 (1.33) 
How satisfied I am with my sleep 
(I=v. unsatisfied tos=completely satisfied) 1.85 (0.88) 2.9 (1.12) 3.06(l. 34) 3.43(l. 02) 2.3(l. 13) 2.79(l. 23) 
3.33 (1.03) 3.4(1.12) 
I. Significant drug effects on ANOVA. 
Analysis of antidepressant efficacy 
and safety 
Response was defined as a 50% or greater 
reduction from the initial HRSD score, 
whereas remission was defined as a final 
HRSD score of 8 or less. There was no 
significant difference between the two 
medications in these variables. At week 8 
(end of the sleep study), 11 patients on 
nefazodone and 16 patients on paroxetine 
were responding to treatment. At the end 
of the 24-week study, a total of 12 in the 
ncfazodone group and 14 in the paroxetine 
group had responded to treatment, while 
9 patients on nefazodone and 12 patients 
on paroxetine wer classified as remitters. 
Between 8 and 24 weeks, 2 patients in 
the paroxetine group had experienced a 
worsening. 
There were no significant differences 
between the two drugs in HRSD, MADRS, 
CGl Severity and Improvement scales, 
either on observed data or on LOCF data. 
The data from HRSD scores (LOCF) are 
presented in Fig. S. Data from the MADRS 
questionnaire, which has only one question 
about sleep, were as follows (observed 
cases): nefazodone group baseline 27.5 
(s. d. =4.1), 8 weeks 13.0 (s. d. =7.7); 
paroxetine group baseline 27.1 (s. d. =3.5), 
8 weeks 8.4 (s. d. =6.2). 
There were no serious adverse events 
related to either of the medications. One 
patient on paroxetine was hospitalised 
for worsening of her primary diagnosis 
of depression and emerging suicidal 
ideation, following the day 3 visit. The 










Fig. 4 Subjective sleep measures - change from 
baseline St Mary's Hospital Sleep Questionnaire 
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Fig. S Hamilton Rating Scale for Depression 
(HRSD) scores last observation carried forward, 
intention to treat. Error bars Indicate s. e. m. 
randomisation code was broken and the 
patient was continued on open-label parox- 
etine and made a good recovery. Table S 
shows the non-serious side-effects attribu- 
table to the medications. These were similar 
to those described in previous reports. 
DISCUSSION 
At baseline, the depressed patients in this 
study had disturbed sleep, as in other 
studies. Total sleep time and sleep efficiency 
were low, median REM onset latency was 
slightly short and stage 1 sleep was in- 
creased compared with normal sleep. Slow 
wave sleep, however, was higher in our 
study than in most sleep laboratory studies 
in depression, including that of Rush et al 
(1998) with ncfazodonc. This could reflect 
the use of home recordings for these 
patients, as we found similar baseline values 
in a previous study of patients with depres- 
sion recorded at home. The two groups 
were different at baseline, with the par- 
oxetinc group having generally worse sleep. 
The key finding in this study was an 
improvement in sleep maintenance early in 
treatment in the nefazodone group, with 
sleep efficiency and total sleep time 
increasing and wake time decreasing, and 
the converse effect, i. e increased sleep 
disturbance, after paroxetine. This is in 
accordance with the previous US study 
(Rush eta!, 1998) which compared nefazo. 
done with fluoxetine. I lowever, in contrast 
to that study, the differences at 8 weeks 
were much less marked. Only the number 
of awakenings and amount of stage 1 sleep 
were higher at this stage in the paroxetine 
than the ncfazodonc group and the sleep onset 
latency in the nefazodone group was shorter. 
lt seems that paroxctine has a less disturbing 
effect than fluoxetine on sleep in long-term 
treatment, although our use of home record- 
ings could contribute to this difference. 
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Table S Number of non-serious adverse events occurring In more than S% of patients (% of patients 
reporting) 
Type of adverse event Nefazodone 0 Paroxedne 
Stomach upset, nausea, vomiting, diarrhoea 13(40%) 2 23 (65%) 
Headache, migraine IS (50%) IS (SO%) 
Tiredness, asthenia 9(40%) 13 (55%) 
Drowsiness/sedation 11(40%) 2 5(2s%) 
Dry mouth 6(25%) 7(3S%) 
Dizziness S (2S%) 3(15%) 
Flu-like symptoms 2(10%) 44 (15%) 
Unsteadiness, giddiness, ataxia 6(25%) 3 (15%) 
Sweating 0 7(35%) 
Sexual dysfunction 0 5(20%) 
Light-headedness, spaced-out feeling I (S%) 4(20%) 
Rash, Itching 1(5%) 4(20%) 
Tremor, shakiness 0 4(20%) 
Constipation 1(5%) 3(15%) 
Other (each reported in only one patient) 13 8 12 S 
*Events considered by investigator at the time as unrelated to study medication. 
REM sleep suppression remains marked 
throughout treatment with paroxetine but 
nefazodone has, if anything, a small non- 
significant promoting effect on REM, as 
in other studies (Sharpley et at, 1992). This 
is different from the TCAs, which produce 
a similar and sometimes more marked sleep 
promotion early in treatment but also 
produce a marked suppression of REM 
sleep. 
Subjective effects 
In our study, both drugs were well tolerated 
and equally effective in treating depression. 
Patients taking nefazodone reported 
increased subjective sleep quality and 
increased subjective depth of sleep as early 
as day 3 of treatment. The difference 
between the two drugs was decreased as 
the treatment progressed and by the end 
of the study was not statistically significant. 
This could be explained by some early 
sleep-promoting effect of nefazodone, or a 
decrease of sleep disruption caused by the 
SSRIs as neuroadaptive changes take place 
in the brain with prolonged administration 
and depression improves. Another possible 
explanation is a change in the perception 
and/or reporting of sleep difficulties by 
depressed patients as their clinical status 
evolves. In a previous study with fluvo- 
xamine (Wilson et al, 2000), subjective 
complaints about poor sleep were 
decreased when patients improved, in spite 
of lack of significant changes in objective 
measures of sleep (polysomnography). 
Comparison with other studies 
The SSRIs have become a first line treat- 
ment of depression over the past decade. 
They offer significant advantages compared 
with the old compounds (TCAs and mono- 
amine oxidase inhibitors), such as fewer 
side-effects and non-lethality in overdose. 
However, some useful properties of the 
TCAs, such as the promotion of sleep, do 
not apply to SSRIs. Indeed the SSRIs can 
increase wakefulness, reduce total sleep 
time and sleep efficiency. Generally, they 
have an alerting effect in acute treatment, 
although sleep disruption can ease with 
long-term treatment (Wilson et at, 2000). 
This alerting effect sometimes results in 
the use of additional short-term treatment 
with a benzodiazcpine or other hypnotic, 
with all the well-known problems associ- 
ated with such a regime. Sleep problems 
are very prominent in depressive illness, 
with up to 95% of patients with moderate 
to severe depression suffering one or more 
problems with their sleep (Thase, 1999). 
Therefore, new antidepressants that do 
not cause further sleep disruption (unlike 
the SSRIs) and are safe in overdose (unlike 
the TCAs) could offer an important advan- 
tage, especially in patients with pronounced 
sleep difficulties. 
Pharmacological mechanisms 
The main action of nefazodone is to block 
post-synaptic S-lIT2 receptors (Taylor et 
al, 1995). Evidence for the involvement of 
S-IIT2 receptors in depression comes from 
various areas of research. Although this 
relationship is complex and not yet very 
well understood, it appears that down- 
regulation of these receptors could be 
crucial for the ability of antidepressant 
drugs to exert their action (Attar-Ikvy et 
al, 1999; Yatham eta!, 2000), although this 
finding has not been replicated in all studies 
(Massou et at, 1997). The effectiveness of 
nefazodone has been established both in 
the acute and the long-term treatment of 
depression in a number of randomised 
controlled trials (Feiger et at, 1999; Keller 
et a!, 2000). The relationship of S-IIT 
neurotransmission and sleep is a complex 
one (Sharpley & Idzikowski, 1991). SSRls 
are sleep-disturbing early in treatment, 
presumably as a consequence of increased 
S-FIT function. Post-synaptic 541T2 block- 
ade, by drugs such as ritanserin, has a 
promoting effect on deep non-REM sleep. 
Trazodone, an antidepressant which shares 
the S-11T2-blocking property of nefazo- 
done, is also sleep-promoting (Mouret et 
at, 1988). 
Clinical relevance 
We compared the effect of nefazodone and 
an SSRI on sleep of out-patients with 
depression, with particular emphasis on 
the early stages of treatment. We consid. 
ered that the onset of treatment is a crucial 
period. The patient's morale is at its lowest 
and the antidepressant has not yet exerted 
its effect, therefore the symptoms are at 
their peak. Further sleep disruption, such 
as that caused by the SSRls, can lead either 
to disaffection with the treatment and early 
drop-out or poor compliance, negatively 
affecting the overall outcome, or it could 
require additional treatment with a 
hypnotic. 
Another difference with the previous 
study was that patients were studied in 
their home environment. Patients studied 
overnight in a sleep laboratory need a 
period of adjustment to the unfamiliar 
surroundings and this only adds to the 
inconveniences already produced by the 
533 
HICKS ET Al 
illness itself. As in our previous study, we 
found patients more likely to volunteer for 
the study once they knew that home record- 
ings were involved. 
Paroxetine was chosen as a comparator 
because it is the only SSRI for which 
sedative properties have been reported 
(Kerr et al, 1997), as opposed to the 
previously studied fluoxetinc. As well as 
home-based objective sleep assessment, we 
also used more extensive subjective sleep 
measures in an attempt to clarify the effect 
of the two drugs in a variety of sleep para- 
meters. The (unusual for SSRIs) sedative 
properties of paroxetine in some patients, 
which could relate to its weak anti- 
cholinergic effects, could also account for 
the small differences seen in this study, 
compared with the clear superiority of 
nefazodone over fluoxetine in promoting 
sleep, as reported by Rush et a! (1998). 
We conclude that nefazodone is an 
effective and safe antidepressant that could 
be a preferable choice over the SSRIs in 
patients with depression who have 
prominent sleep problems. 
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Abstract 
Studies of the correlation of subjective and objective sleep measures in depressed patients have produced mixed 
results so far. Further, they were carried out in sleep laboratories and tended to obtain one-off assessments, thus not 
taking into account the effect of treatment. We investigated forty (40) patients over the course of 8-week treatment 
of depression with either paroxetine or nefazodone. We used home polysomnography at baseline, nights 3 and 10, 
and week 8 of treatment, with extensive assessments of subjective sleep, the morning after each sleep recording. The 
patients were able to judge accurately their total sleep time and sleep onset latency, both before and during treatment. 
However, they were inaccurate in estimating the number of times they woke up during the night. Sleep satisfaction 
correlated negatively with Stage 1 sleep at baseline. Sleep quality was represented by a combination of subjective 
parameters measuring the case of initiation and maintenance of sleep, and it appeared to derive from slow wave sleep 
and sleep continuity as seen in polysomnography. The partial discrepancy between subjective and objective measures 
suggests that a cognitive element is combined with the biological element to produce the sleep problems reported by depressed patients. 
0 2003 Elsevier Ireland Ltd. All rights reserved. 
Keywords: Sleep onset latency (SOL); Total sleep time (TST); Stage 1 sleep; Slow wave sleep (SWS); Sleep quality; Sleep 
electroencephalography; Polysomnography 
1. Introduction 
Depression is closely associated with sleep dis- 
turbances, both in clinical (Benca et al., 1992) and 
epidemiological samples (Ford and Cooper-Pat- 
rick, 2001). In the clinic, over 80% of depressed 
patients complain of at least one of the following: 
*Corresponding author. Tel.: +44-117-9253066; fax: +44- 
117-9277057. 
E-mail address: sue. wilson@bristolae. uk (S. J. Wilson). 
difficulty with the initiation of sleep, fragmented 
sleep, disturbing dreams, early morning wakening, 
decreased amount of sleep, not feeling refreshed 
in the morning, and being tired during the day 
(Reynolds and Kupfer, 1987; Hamilton, 1989). 
The added importance of poor sleep is highlighted 
by its significant association with increased suici- 
dality in depressed subjects (Agargun et al., 1997). 
The assessment of these complaints has been 
standardised, and a number of detailed self-report 
0165-1781/03/$ - see front matter ® 2003 Elsevier Ireland Ltd. All rights reserved. 
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questionnaires are now available (Parrott and 
Hindmarch, 1980; Leigh et at., 1988; Buysse et 
al., 1989; Akerstedt et al., 1994). 
Objective assessment of sleep may be provided 
by electroencephalographic (EEG) study of sleep 
(polysomnography), an established method of 
studying sleep architecture. It is generally well 
accepted by patients, whether it is performed in 
sleep laboratories or, more recently, at the individ- 
ual's home. Studies in mood disorders confirm 
that several aspects of the sleep process are affect- 
ed. Compared with normal controls, depressed 
subjects show significantly prolonged sleep laten- 
cy, as well as reduced total sleep time and reduced 
sleep efficiency. Rapid eye movement (REM) 
sleep is also affected. REM latency is shortened 
and the duration of the first REM period is 
increased. The REM density over the whole night 
is increased and the same applies to the percentage 
of REM (%REM) sleep over the total sleep time. 
Finally, overall non-REM sleep, slow wave sleep 
(SWS) and the percentage of slow wave sleep 
(%SWS) over the total sleep time are also reduced 
(Benca et al., 1992). It is estimated that short 
REM latency, decreased SWS and increased wake- 
fulness are present in 40-70% of depressed out- 
patients (Armitage et al., 1997). 
While both subjective and objective measure- 
ments may be very useful in tracking the course 
of the illness and the treatment effects, as well as 
offering prognostic indicators for outcome and 
relapse (Kupfer et al., 1981,1990), they often 
overlap in what they measure. What is not very 
well established is how they relate to each other, 
in other words, whether the subjective sleep com- 
plaints correspond to discernible alterations of 
sleep structure and vice versa. The implicit 
assumption that SWS, as seen on the EEG, corre- 
sponds to the experience of deep restorative sleep 
has been challenged (Armitage et al., 1997). Fur- 
ther, a comparison of the prevalence (cited above) 
of subjective and objective sleep disturbances in 
depressed patients indicates that the former may 
be more common than the latter. Indeed, it is not 
unusual in clinical practice to see patients com- 
plaining of poor sleep without any abnormal poly- 
somnographic findings. In a study by Mayers et 
at. (2003), depressed patients experienced more 
`sleep distress' than healthy individuals even 
though their estimates of sleep disturbance were 
similar to those of controls. 
Previous studies of the correlation of subjective 
and objective sleep measures in depression have 
produced mixed results. Some indicate that the 
correlation may not be good (Lee et al., 1993; 
Rotenberg, 1993; Rotenberg et al., 2000), while 
others have suggested the opposite (Ilemmeter et 
al., 1995; Armitage et al., 1997). We reasoned that 
this discrepancy might be the result of methodo- 
logical issues in these studies (Table 1). Some had 
a rather small sample size or the sample did not 
consist entirely of depressed patients. The subjec- 
tive measures used for the comparisons were often 
rudimentary. On occasions, formal statistical cor- 
relations were not attempted and the researchers 
offered only casual comments on the direction of 
the comparisons. because this was not the main 
aim of their study. Control groups were used in 
some studies but not in others. Finally, some only 
provided snapshot assessments, and they did not 
study the stability of the correlations over a period 
of time. Therefore, we sought to compare subjec- 
tive and objective sleep measures in a large enough 
sample, using detailed subjective measurements 
and repeating the assessments a number of times 
during treatment. 
2. Methods 
This was part of a double blind, randomised, 
parallel group, 8-week study of 40 outpatients (23 
females, 17 males) with moderate to severe depres- 
sion, without psychotic features. The primary 
objective of the trial was to compare the effects 
of nefazodone (n - 20) and paroxetine (n - 20) on 
sleep and mood, and the local Ethics Committee 
approved the study. The patients fulfilled DSM-IV 
criteria for major depression (American Psychiatric 
Association, 1994) and had a Hamilton Depression 
Rating Scale (IHAM-D) score of 18 or over (Ham- 
ilton, 1960) (Table 2). The selective scrotonin 
reuptake inhibitors (SSRis), like paroxctine, have 
become the mainstay of the pharmacological treat- 
ment of depression in recent years. Some of the 
newer compounds, like nefazodone, claim advan- 
tages over the SSRIs in some symptom areas, 
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Table I 
Summary of previous studies assessing the correspondence of subjective and objective sleep measures 
Diagnosis Sample Control Subjective Assessments Outcome 
size group measures 
Rotenberg Mixed 75 (28 15 (not Depth of sleep, sleep Baseline only Patients not able to judge 
(1993) depressed) matched) denial, mental sleep depth accurately 
activity before 
enforced awakening 
Lee et al. Depression 15 
(1993) 
Hemmeter Depression 18 
et al. (1995) 
Armitage Depression 52 
et al. (1997) 
Rotenberg Depression 30 
et a]. (2000) 
15 (age PSQI 
and sex 
matched) 
No Total sleep time, 
sleep onset latency, 
number of 
awakenings, depth of 
sleep, refreshedness 
49 (not Time in bed, 
matched total sleep time, 
for age) sleep onset latency, 
number of 
awakenings, sleep 








after 7 nights 
of treatment 
Baseline only 
10 (not Sleep duration, sleep Baseline only 
matched) delay, number of 
awakenings 
No patient-control 
differences in objective 
measures. 
Improvement of 
subjective sleep quality 
contrasted with stability 
of objective measures 
Changes in objective 
sleep variables in parallel 
with the subjective 
variables 
Patients differed from 
controls only in sleep 
efficiency. 
Subjective and objective 
sleep measures correlated 
in both groups. except for 
number of awakenings 
Patients differed from 
controls in a number of 
objective measures. 
In patients, no 
subjective/objective 
correlations 
PSQI: Pittsburgh Sleep Quality Index. 
including sleep. However, head to head compari- 
sons testing these claims are still scarce. Further 
details of the methodology with regards to the 
Table 2 
Basic demographic and clinical characteristics of the sample 
patient population, the study design and medica- 
tion and the treatment outcome are given elsewhere 
(Hicks et al., 2002). 
Nefazodone (n-20) Paroxetine (ºº-20) 
Age in years (meant S. D. ) 42.7 (±119) 42.9 (± 10.1) 
Sex: male/female 8/12 9/11 
Medication daily dose: 495 mg (±82.6) 29.5 mg (±8.9) 
mean (±S. D. ) 
HAM-D at baseline (±SD. ) 21.8±2.6 22.4±2.7 
HAM-D at week 8 (±S. D. ) 11.2±6.5 9.0±7.8 
Responders by 8 weeks 12 16 
S. D.: standard deviation. 
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Polysomnography was performed on the patients 
at home, using the Medilog 9200 (Oxford Instru- 
ments Medical, Old Woking) ambulatory monitor- 
ing system, at baseline, on nights 3 and 10, and at 
8 weeks of antidepressant treatment. Subjective 
assessments of sleep, using the St. Mary's Hospital 
Sleep Questionnaire 
, 
(SMHSQ) (Leigh et al., 
1988), were obtained on the morning after each 
recording. The Leeds Sleep Evaluation Question- 
naire (LSEQ) (Parrott and Hindmarch, 1980) was 
also administered the morning after nights 3 and 
10 and at 8 weeks. The combined score (range: 
0-6) of the three sleep items of the HAM-D, 
covering initial, middle and late insomnia, were 
also compared with objective sleep measures. Dur- 
ing the first 3 weeks of the study, patients kept a 
daily diary of sleep quality and number of awak- 
enings using visual analogue ratings. Clinical 
assessments of depression, using the HAM-D, the 
Montgomery -Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979) and 
the Clinical Global Impression Scales (CGI) (Guy, 
1976), were performed on the days preceding the 
sleep recordings, as well as other regular intervals. 
Sleep was scored automatically with visual cor- 
rection according to established criteria 
(Rechtschaffen and Kales, 1968) by an experi- 
enced sleep scorer (JAH) who was blind to treat- 
ment and illness state. The parameters derived from the sleep EEGs were: staging time-the 
interval between the time the patients closed their 
eyes at night and when they opened them and 
started to move around in the morning; total sleep 
time (TST)-the time in all stages of sleep; sleep 
efficiency-expressed as %TST/staging time; 
number of awakenings-counting those longer 
than 16 s in duration; sleep onset latency (SOL)- 
time from the patient first closing his eyes to the 
first 2 min of Stage 2 sleep; duration of Stages 1 
to 4 and REM sleep, as well as REM onset 
latency-the time to the onset of Stage 2 sleep to 
the first 2 min of REM sleep; and wakefulness 
after sleep onset-the total time spent awake after 
sleep onset. 
The SMHSQ consists of 14 items, scored in 
variable format. It covers: timing of sleep over the 
last 24-h period; presence or absence and length 
of initial insomnia; depth of sleep; number of 
awakenings; total amount of sleep; presence or 
absence of early morning wakening; level of clear- 
headedness the following morning; and overall 
quality and satisfaction with the sleep of the night 
before the assessment. The LSEQ consists of 10 
items comparing the experience of sleep the night 
before with that before the onset of treatment. 
These items are scored on a 100-mm visual ana- 
logue scale and cover: relative ease of getting to 
sleep; number of awakenings; restless/restful 
sleep; relative ease of waking up in the morning; 
feelings of tiredness/alertness; and sense of bal- 
ance and co-ordination upon waking up. 
3. Results 
The demographic and clinical characteristics of 
the population are summarised in Table 2. Of the 
total sample, 36 patients (18 in each treatment 
group) provided technically valid polysomnogra- 
phy data for at least three sleep recordings, includ- 
ing baseline. All 36 patients also provided valid 
subjective data for the mornings after each one of 
the sleep recordings that were analysed. Of the 36 
patients, eight were withdrawn from treatment after 
the third and before the fourth and final sleep 
recording at week 8. Reasons for discontinuation 
were: side effects (nefazodone s 4, paroxetine - 
1); lost to follow up (nefazodonea 1); and lack 
of efficacy (paroxetinea2). A summary of objec- 
tive polysomnographic variables is given in Table 
3, and correlations between subjective and objec- 
tive measures are shown in Table 4. Fig. 1 shows 
the diary ratings of sleep. Patients in the paroxetine 
group rated their sleep as worse on the polysom- 
nography nights compared with the nights before 
and after polysomnography. 
3.1. Sleep initiation and maintenance 
There was a significant correlation between 
patients' estimate of their TST and actual TST. 
This was maintained at all time points during 
treatment. More patients underestimated than over- 
estimated their sleep (Fig. 2) at baseline. There 
was no obvious alteration in the under- or over- 
estimation of sleep during the course of the study. 






Baseline Day 3 Day 10 Week 8 
Paroxetine 
Mean±S. D. 
Baseline Day 3 Day 10 Week 8 
Sleep onset 31±32 33±29 35±46 20±9 33±32 55±48 36±25 41±35 
latency (min) 
Total sleep 383±48 409±67 389±40 396±53 370±63 334±76 352±61 388±70 
time (min) 
Number of 13±8 13±6 10±6 14±9 17±8 16±9 18±8 24±13 
awakenings 
WASO (min) 55±42 35±41 40±40 53±60 67±58 74±54 74±52 63±37 
Sleep efficiency 81±9 85±10 84±12 84±11 78±11 71±13 77±9 78±8 
(%) 
Stage I sleep 40±26 38±21 27±18 28±20 42±36 46±31 45±27 57±33 
(min) 
Stage 2 sleep 182±57 204±49 178±44 197±55 171±8 184±3 186±4 182±12 
(min) 
Stage 3 sleep 30±17 36±8 40±26 47±32 32±19 34±9 33±21 34± 17 
(min) 
Stage 4 sleep 31±8 27±24 25±6 27±25 39±9 37±41 36±9 36±8 
(min) 
REM sleep 87±30 102±35 105±43 98±28 87±34 33±38 49±27 79±33 
(min) 
REM onset 78±36 59±28 61±42 62±34 73±45 278±113 227±120 173±52 
latency 
There was also a significant correlation between 
subjective SOL and SOL derived from EEG at 
nights 3 and 10. This correlation was near signif- 
icance at baseline but absent at week 8. At day 3, 
there were negative correlations between SOL and 
morning clear-headedness and `hangover' feeling; 
the shorter the sleep latency, the more hangover 
the patients experienced the following morning. 
There was very little correlation between sub- 
jective and objective measures of awakening. The 
objective and subjective number of awakenings 
only correlated at week 8. The former also corre- 
lated negatively with subjective sleep time at week 
8, while the latter correlated with wake after sleep 
onset at day 10. 
3.2. Sleep architecture 
There was a negative correlation between sleep 
satisfaction and Stage 1 sleep at baseline. Other- 
wise, Stage 1 and Stage 2 sleep did not correlate 
with any subjective sleep measures at any other 
time point. 
There was a good correlation between several 
subjective measures of sleep quality and amount 
of SWS at day 10. We investigated this further by 
combining (adding the scores) `depth of sleep', 
`how well slept' and 'how satisfied with sleep' of 
the SMHSQ. This composite index of sleep quality 
correlated strongly (for both drugs) with increase 
in SWS from baseline (see Fig. 3). 
Few correlations of REM with subjective aspects 
of sleep emerged. REM sleep was correlated with 
subjective sleep time on day 3. REM onset latency 
was negatively correlated with awakenings and 
worse sleep on HAM-D at baseline. However, 
inspection of the individual data indicated that this 
correlation was mainly based on three outliers who 
had extremely short REM latencies and a high 
number of awakenings. 
There were no significant differences on any of 
the correlations according to gender. Fig. 4 shows 
the relationship between subjective sleep quality 
and objective time spent awake during the night 
according to gender. It can be seen that there are 
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Table 4 




WASO No of Sleep Stagel 
wakes efficiency 
Stage 2 SWS REM ROL 
SMHSQ 
Subjective sleep 3 10 
latency 
Depth 10 
Number of 10 8w 10- 
awakenings 
Sleep satisfaction 8w 13- 10 
Subjective sleep B3 10 8w- 3 
time 8w 
Sleep quality 10 
Morning clear- 3-* 
headedness 
Awakenings B- 
HAM-D sleep B- 3- 
items 
LSEQ 
Getting to sleep 3- 10- 10- 
(worse) 




All patients: B=baseline, 3=day 3,10=day 10,8w =week 8 (- is negative correlation, * is confined to the nefazodone group). 
SMHSQ: St Mary's Hospital Sleep Questionnaire; HAM-D: Hamilton Depression Rating Scale; LSEQ: Leeds Sleep Evaluation 
Questionnaire; TST: Total sleep time; SOL: Sleep onset latency; WASO: Wake after sleep onset; SWS: Slow wave sleep; REM: 
Rapid eye movement sleep, ROL: REM onset latency. 
a few men who spent long periods awake but rated 
their sleep no worse than others with less disturbed 
sleep. 
4. Discussion 
In measures of sleep initiation and maintenance, 
our sample produced a mixed picture of correspon- 
dence of objective and subjective measures. We 
found that despite a tendency to underestimate 
their sleep, there was a good objective/subjective 
correlation of TST, both before and during treat- 
ment. Further, self-assessment of SOL was signif- 
icantly correlated with the EEG measure at nights 
3 and 10, and almost significantly so at baseline. 
The absence of correlation at week 8 could be 
explained by the effect, the outcome of treatment 
on the patients. Those taking nefazodone were all 
clustered at low SOL scores, while the ones taking 
paroxetine were spread out, so there was not 
enough overall variance of the data for a signifi- 
cant correlation to emerge. At baseline, our results 
are in accordance with those of Armitage et at. 
(1997), who also found a good correlation of 
objective and subjective TST and SOL before 
treatment, but not with those of Rotenberg et al. 
(2000), who found no such correlation. It should 
be noted here that our study was based on home 
recordings while the other two used laboratory 
recordings. The main difference between the two 
methods in the context of the above measurements 
is that laboratory recordings normally start meas- 
uring time in bed when lights go out, while in 
home recordings the starting point is when the 
subject closes his/her eyes. 
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However, the number of wakes only correlated 
after 8 weeks of treatment. At baseline, neither 
Armitage et al. (1997) nor Rotenberg et al. (2000) 
found a correlation between subjective and objec- 
tive number of awakenings. Other studies have 
come to the same conclusion (Monk et at., 1994, 
Mayers et al., 2003). So, it can be said with some 
certainty that depressed patients are not accurate 
in judging the number of times they wake up at 
night. One possible explanation is that the appre- 
ciation of this particular aspect of sleep is disturbed 
by acute illness and returns to normal following 
treatment, as evidenced by the con-elation found 
after 8 weeks of treatment in our sample. Another 
parameter to be taken into account here is the 
length of what constitutes a polysomnographic 
`wake'. This measure differs from study to study 
and it is perhaps set arbitrarily. For example, it 
was > 16 s in our study and > 30 s in the Armitage 
et at. (1997) study. It could be that this level is 
too short to be perceptible and that in the future 
one should ideally control for different durations 
to find out what the best discriminatory level 
between illness and normality is. It is also known 
that depressed patients sometimes report that they 



























Fig. 2. Subjective and objective estimates of %leep time at hair 
line. Each symbol is an individual patient. 
dence to the opposite. As Rotenheig el al. (2(N)0) 
commented, if one does not realise his or her 
previous sleep, one is then also unable to realise 
day 
Fig. 1. Mean sleep diary ratings for quality of sleep and number of awakenings. Patients rated how well they slept the night before 
(range: I =very badly to 6=very well) and estimated the number of times they woke up (range: O= none at all to 7- more than 
six times). Ratings are worse on recording nights in the paroxetine group. 
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the awakening that may have taken place in the 
meantime. 
Some further correlations that emerged in the 
area of sleep initiation and maintenance are prob- 
ably artefacts of other parameters of the study. The 
negative association between SOL and clear-head- 
edness/hangover effect at night 3 was only present 
in the nefazodone group, and it is most likely to 
reflect the well-described effect of this medication 
of facilitating putting patients to sleep more quick- 
ly (hence reducing SOL) and the side effect of 
producing a morning hangover. The negative cor- 
relation of sleep efficiency and the difficulty get- 
ting to sleep, as measured by the LSEQ, could 
also be explained by the fact that polysomnograph- 
ic sleep efficiency effectively includes SOL. 
The main correlation in the area of sleep archi- 
tecture was that of sleep quality measures and 
SWS at day 10, particularly as shown by change 
from baseline. This further strengthens the view 
that normal sleepers do not perceive changes in 
SWS while the poor sleepers may (Viola et al., 
2002). Our results here are not at odds with 
Rotenberg et al. (2000), where SWS did not 
correlate with sleep depth or sleep quality at 
baseline, while Armitage et al. (1997) found that 
sleep quality was correlated with increased SWS 
and fewer awakenings in controls but not in 
patients. Overall, however, this last study found 
less than 10% overlap in the variance between 
sleep quality and objective sleep measures, there- 
fore raising the question of the ultimate usefulness 
of sleep recordings for this parameter. 
The negative correlation of Stage 1 sleep with 
sleep satisfaction at baseline is an interesting one. 
Stage 1 sleep is light and usually associated with 
fragmented sleep, so this finding should be expect- 
ed: the more Stage 1 sleep one gets, the less 
satisfied one is likely to be. However, it did not 
extend to the other time points beyond baseline 
and this may be because the two different antide- 
pressants had opposite effects on Stage 1 sleep. 
Nevertheless, our finding is in agreement with data 
from healthy subjects. Riedel and Lichstein (1998) 
showed that the best polysomnographic predictor 
of subjective sleep satisfaction in a group of 47 
older healthy adults was the depth of sleep, 
expressed as decreased Stage I and increased 
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Stages 3 and 4. The suggestion of Bonnet (1993) 
that sleep depth might be more related to total 
time spent awake at night rather than SWS was 
not borne out here (Table 4). 
Keklund and Akerstedt (1997), in a study of a 
normal population, wrested a composite factor 
from the total of the Karolinska Sleep Diary items 
(Akerstedt et al., 1994), which they labelled the 
sleep quality index (SQI). This included: ease of 
falling asleep; sleep quality; calm sleep; sleeping 
throughout the night; and premature awakenings. 
therefore representing the processes of initiating 
and maintaining sleep or sleep continuity. The SQI 
correlated significantly with SWS, sleep efficiency 
and TST. It appears then that subjectively good 
sleep in normals, as measured by the SQI, relates 
both to the continuity (sleep efficiency) and the 
depth (SWS) of sleep in EEG. Sleep quality may, 
therefore, be a matter of more than one subjective 
parameter, that is, the ease of initiation and main- 
tenance of sleep, and it may arise out of a 
combination of objective parameters, being a mat- 
ter of SWS and sleep continuity as seen on the 
EEG. Our post hoc combination of the subjective 
scores of 'depth of sleep', 'how well slept' and 
'how satisfied with sleep' from the SMHSQ arrives 
at an index of sleep quality similar to the SQl, 
which we observed to correlate strongly with 
change in SWS from baseline. From the opposite 
direction, i. e. from the objective sleep measures to 
the subjective ones, Buysse et al. (1998) identified 
a sleep continuity factor consisting of sleep effi- 
ciency, sleep onset latency, minutes of wakeful- 
ness, time spent asleep, number of REM periods 
and REM latency. They found that this factor 
correlated with subjective sleep quality in 
depressed women. This factorial approach, tested 
both ways, may unravel the complexity of com- 
binations of related measures. 
Of the significant correlations with aspects of 
REM, the one with subjective sleep time at day 3 
appears to be a spurious association. Both were 
decreased in the paroxetine group, notably at the 
onset of treatment. The significant negative corre- 
lation of REM onset latency with awakenings 
could be partly explained by the fact that both 
increased wakefulness and decreased REM latency 
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commonly occur in depression, and indeed this 
was the case in our study. 
What is the meaning of the (partial) discrepancy 
between objective and subjective measures of 
sleep? Traditionally, sleep disturbance is consid- 
ered as one of the `vegetative' symptoms of 
depression that is thought to have a strong biolog- 
ical underpinning. However, if it were not entirely 
biological in its element, one would not expect it 
to be accurately measured through EEG alone. 
Sleep disturbance may be a combination of biolog- 
ical and cognitive elements, the latter being an 
aspect of the well-known pervasive `gloom' sce- 
nario of depression (Lee et al., 1993). Indeed, 
these authors provided further evidence supporting 
this idea. In their sample, improvement in subjec- 
tive sleep quality was reported after remission, 
even in the absence of changes in polysomnogra- 
phy, showing that objective and subjective meas- 
ures do not change in parallel and therefore may 
represent different elements. Such an outcome also 
argues for the need to use both subjective and 
objective methods in the assessment of sleep in 
depression. Subjective measures may be more 
valuable markers for the short-term clinical eval- 
uation of the condition while EEG measures may 
have significance in understanding the long-term 
picture of the biological recovery of the patient. 
The composition of the samples may offer some 
explanation with regards to the discrepant results 
between the various studies. Depression is a syn- 
drome that encompasses many different symptoms 
and various degrees of severity. Are the samples 
in our study and the studies mentioned above 
typical in their sleep profile of the findings in 
depression (Benca et al., 1992)? In the Armitage 
et al. (1997) study, patients did not differ at 
baseline from controls on REM latency or %SWS. 
Only sleep efficiency differentiated between the 
two groups. This indicates that their sample was 
not very typical of depression, at least in sleep 
profile. It also argues for the inclusion of a proper 
control group in these studies. The same applied 
to the Lee et al. (1993) study, where patients at 
baseline only differed from controls in one meas- 
ure: SOL. This in turn could explain why there is 
no difference between pre- and post- treatment 
polysomnography in this study, while subjective 
measures of sleep changed: the underlying sleep 
was not at the pathological end of the spectrum. 
In contrast, the patients in the Rotenberg et al. 
(2000) study, the one that showed the least corre- 
lation between subjective and objective measures 
so far, had a sleep profile that resembled more 
closely the typical one of depression. however, 
good correlation cannot be explained by these 
baseline characteristics of the sample alone, since 
our patients (before treatment) had low sleep 
efficiency and high waking after sleep onset com- 
pared with normal subjects. 
Some limitations of our approach have been 
highlighted earlier in the text, notably the absence 
of a control group. The pre-planned inclusion of 
patients with a typical depression sleep profile may 
be desirable but it is not feasible, since recruitment 
is based on clinical presentation rather than poly- 
somnographic findings. Further, if only patients 
with a specific sleep profile were included, varia- 
bility of the data would have been much reduced 
and the sample would have been biased. 
Subjectively the paroxetine-treated patients rated 
their sleep as worse on the EEG nights, but the 
nefazodone group appeared to notice no difference. 
which implies a protective role for nefazodone. 
This may have affected the correlations in that the 
EEG nights may not have been typical. however, 
the differences were small and unlikely to obscure 
large correlations. Finally, in this study we did not 
control for sleep apnoea, periodic leg movement 
or bruxism, although there was no evidence of 
these in the recordings. 
At the heart of the comparison of subjective and 
objective sleep estimates lie the questions, suc- 
cinctly articulated by Rotenberg et al. (2000): Is 
subjective estimation of sleep directly related to 
any corresponding or non-corresponding objective 
sleep variables? And is it possible to predict 
specific alterations of sleep structure from the 
subjective sleep complaints? It is not inconceivable 
that objective and subjective assessments of sleep 
quality, despite the fact that they often carry labels 
that imply direct relationship or equivalence, may 
relate to different parameters (Armitage ct al., 
1997). On balance, it appears that some measures 
of sleep continuity, such as TST and SOL correlate 
well between subjective and objective assessments 
S. V Argyropoulos et al. / Psychiatry Research 120 (2003) 179--190 
in depressed patients, therefore indicating a direct 
relationship. A notable exception here is the num- 
ber of awakenings, which the patients appear 
unable to estimate accurately. The picture with 
respect to sleep quality and sleep architecture is 
somewhat more complicated. It seems likely that 
sleep quality is represented by a combination of 
more than one subjective sleep parameter, those of 
initiation and maintenance of sleep, which proba- 
bly correspond to a combination of objective 
parameters, namely SWS and sleep continuity. 
Treatment and change of clinical status did not 
appear to have a huge influence in the relationship 
between subjective and objective measures, indi- 
cating that in our group they mostly co-vary. 
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